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SUMMARY
This thesis describes the analysis of various aspects of 
engraftment and chimerism in patients undergoing 
allogeneic bone marrow transplantation (BMT)• The first 
section discusses the background to allogeneic BMT and 
deals in particular with the advantages and disadvantages 
of the T-cell depletion procedure. The concept of 
haemopoietic chimerism is introduced and the available 
methods for monitoring host and donor cell populations in 
the post-transplant period are reviewed. The next section 
deals firstly, with the development of a panel of probes 
suitable for the analysis of engraftment and haemopoietic 
chimerism and secondly, with a detailed clinical study 
into the effects of radiation dose on the development of 
mixed haemopoietic chimerism (MXC) and the implications of 
this phenomenon. The final section explores the 
application of novel techniques, utilizing the polymerase 
chain reaction (PCR), to the examination of engraftment 
and chimerism following allogeneic transplantation.
EFFECT OF RADIATION DOSE ON THE DEVELOPMENT OF 
HAEMOPOIETIC CHIMERISM FOLLOWING T-CELL DEPLETED 
ALLOGENEIC BMT.
Allogeneic BMT is an important therapeutic modality in the 
treatment of a number of haematological conditions
12
including the acute leukaemias and chronic myeloid 
leukaemia (CML). Its success in this area is largely 
limited by the immunologically mediated complication of 
graft-versus-host disease (GVHD) and by leukaemic relapse.
T-cell depletion is a highly effective method for the 
prevention of GVHD. Donor T lymphocytes, however, play an 
important role in the facilitation of engraftment and also 
contribute to the graft-versus-leukaemia (GVL) effect. 
Perhaps not surprisingly therefore, the initial use of 
this technique was associated with an increase in graft 
rejection, mixed haemopoietic chimerism (MXC) and 
leukaemic relapse, indicating an immunological advantage 
in the host-versus-graft (HVG) direction. Having 
demonstrated previously, in a group of 102 patients 
undergoing T-cell depleted BMT in Glasgow, that 
intensification of the conditioning regimen, by increasing 
the TBI dose, is capable of overcoming the problems of 
graft rejection, it has been possible to go on and look at 
the effect of high dose TBI regimens on the development of 
MXC and to examine in detail the nature and consequences 
of this form of post-transplant haemopoiesis.
The presence of MXC was evaluated in 48 consecutive 
patients with haematological malignancies undergoing 
T-cell depleted BMT in Glasgow. Chimeric status was 
documented by both cytogenetic and Southern blot analysis. 
Southern blotting was carried out using a panel of probes 
established at the onset of the study. The dose of TBI
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prescribed to all patients, 14.4 Gy, was calculated to 
compensate for the absence of T-cells in the graft. The 
actual average midline dose of TBI received, however, 
differed significantly depending on the method of TBI 
administration. Thus 35 adult patients received an average 
midline dose of 14.3 Gy, while 13 children received a 
significantly lower dose of 13 Gy.
The incidence of MXC in the adult group, who had received 
very close to 14.4 Gy to the midline, was 34% (12/35),
which is lower than in most reported T-cell depleted 
series. During the period of follow-up (median 16 months) 
chimeric status remained relatively stable with time but 
was noted to vary between individual haemopoietic 
lineages. With regard to transplant outcome, MXC was not 
predictive of leukaemic relapse and there was no 
statistically significant relationship with overall 
leukaemia-free survival.
MXC in the 13 children who had received a lower midline 
TBI dose (13.0 Gy), was significantly higher at 69% 
(9/13), (p < 0.05) and increased to 90% (9/10) if patients 
receiving additional chemotherapy in their conditioning 
were excluded from the analysis, (p = 0.001). These
results suggest that, in terms of marrow ablation, 
relatively small changes in the dose of TBI may be 
biologically significant, at least at this dose range. 
Again, in the lower TBI group MXC was not predictive of 
leukaemic relapse.
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Potential variables associated with the development of 
MXC, other than the TBI dose, are presented and discussed 
for both groups of patients. In addition, possible reasons 
underlying the absence of any relationship between MXC 
and subsequent leukaemic relapse are discussed.
INVESTIGATION OF ENGRAFTMENT AND CHIMERISM USING THE 
POLYMERASE CHAIN REACTION.
Up until recently, monitoring of individual host and donor 
cell populations during the early post-transplant period 
has been limited due to the lack of a suitable assay 
system. One of the major problems has been the low cell 
numbers available for analysis at this time. This has 
therefore tended to preclude the detailed analysis of 
engraftment and rejection episodes.
Using the PCR technique to amplify a highly polymorphic 
sequence 3' to the apolipoprotein gene on chromosome 2, it 
has been possible to overcome these problems and to 
effectively monitor individual cell populations during 
periods of profound pancytopenia, in the early 
post-transplant period. Details of the general 
applications of this technique are presented together with 
the successful study of delayed engraftment and graft 
rejection in 6 clinical cases.
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One of the major advantages of the PCR technique has been 
its extreme sensitivity, enabling the detection of minute 
quantities of a specific marker DNA sequence. By applying 
this technology to the analysis of MXC following 
allogeneic BMT, it has been possible to develop an assay 
system which is many times more sensitive than more 
conventional forms of analysis.
This PCR based system involves the amplification of a 
highly repetitive Y-specific sequence, in male recipients 
of female marrow. In artificial mixing experiments used to 
establish the sensitivity of the technique, it has been 
found to be capable of the detection of a minor cell 
population in the order of 10"5 - 10"6 cells. Twelve male 
BMT recipients were analysed at various times 
post-transplant using this technique. The results of the 
analysis demonstrated residual host cells in a much higher 
percentage of patients than would have been predicted by 
alternative methods. The potential significance of these 
findings are discussed in detail.
16
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CHAPTER 1
ALLOGENEIC BONE MARROW TRANSPLANTATION
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1.1 BACKGROUND TO BONE MARROW TRANSPLANTATION
1.1.1. THE DISCOVERY OF THE "RADIATION CHIMERA".
In 1956 the term "radiation chimera" was introduced to 
describe an animal with a foreign haemopoietic system, 
which had been created following the administration of a 
lethal dose of radiation with subsequent transplantation 
of haemopoietic cells from another animal (1). Much of the 
initial research which eventually led to the discovery of 
the "radiation chimera", and later to the development of 
clinical allogeneic bone marrow transplantation (BMT), was 
conducted in an effort to understand the haemopoietic 
syndrome which occurred following exposure to the atomic 
bombs in Hiroshima and Nagasaki, at the end of the second 
world war.
In order to understand the mechanisms of radiation 
sickness, animals were exposed to various different 
schemes of high dose/lethal irradiation (2,3). These 
experiments led to the recognition of three distinct 
syndromes of radiation induced injury, which appeared to 
be dose dependent. Thus in animals exposed to the highest 
doses of radiation, death occurred rapidly, often within 
hours, and was due to central nervous system damage. At 
lower doses the animals survived slightly longer, up to 
4-5 days post-exposure, and died of irreversible damage to 
the gastro-intestinal tract. Animals exposed to still
30
lower doses within this apparently lethal range, developed 
a pancytopenia caused by destruction of the haemopoietic 
system and died of the infective and haemorrhagic 
consequences of this, usually between 10 and 14 days
following irradiation. This latter form of radiation death 
was originally termed the "bone marrow syndrome", and 
reflects the extreme radiosensitivity of haemopoietic 
tissues.
Jacobson was the first to report a decrease in the 
mortality of mice exposed to lethal doses of irradiation, 
provided that the spleen, a haemopoietic organ in the 
mouse, was effectively shielded during the irradiation 
procedure (4). This decrease in mortality was only 
apparent within the dose range associated with death due 
to haemopoietic cell damage. Later experiments 
demonstrated that a similar protective effect was possible 
in lethally irradiated mice which had, following 
irradiation, been given either splenic implants (5)
(autologous or syngeneic) or injections of cell
suspensions containing splenic or bone marrow cells (6). 
It soon became well established that these techniques were 
able to overcome the lethal effects of whole body 
irradiation at this particular dose range, by the
induction of haemopoietic recovery in the host animal.
There then followed considerable debate as to the nature 
of the protective effect of transplanted haemopoietic 
cells in lethally irradiated animals. A number of groups
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postulated that the transplanted cells were producing a 
humoral factor, which was in some way responsible for the 
stimulation of residual host haemopoietic cells which had 
survived irradiation, leading to increased proliferative 
activity and subsequent repopulation (7). However, in 
1956, three separate groups of investigators, utilizing a 
variety of different methods to demonstrate the presence 
of donor cells, were able to provide convincing evidence 
of engraftment of transplanted haemopoietic cells in 
irradiated recipient animals (1,8,9). A number of these 
techniques utilized cytogenetic, histochemical and 
serological differences between mouse and rat cells, in 
experiments on irradiated mice treated with rat bone 
marrow, the so called rat-mouse chimera. Donor cells were 
identified not only in the peripheral blood and bone 
marrow, but also in cells from the spleen, lymph nodes and 
thymus, thus confirming that complete replacement of the 
haemopoietic and immune systems was achieved in these 
experiments.
At the same time as it was recognized that animals could 
be protected from the lethal effects of irradiation by the 
infusion of haemopoietic cells, it was also noted that 
despite haemopoietic recovery, these animals subsequently 
developed a frequently lethal syndrome consisting of 
weight loss, diarrhoea, shin changes and liver 
abnormalities (10) . This syndrome was originally termed 
"secondary disease" to distinguish it from "primary
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disease" which referred to the initial radiation induced 
"bone marrow syndrome". Subsequently, with a greater 
understanding of its immunological basis, "secondary 
disease" was renamed graft-versus-host disease (GVHD).
One of the most fascinating and potentially important 
features of the GVHD syndrome described by Barnes in 1956, 
followed a series of experiments in leukaemic mice. In 
addition to describing the morbidity and mortality 
associated with GVHD, he also noted an association between 
the development of GVHD and a reduction in leukaemic 
recurrences in allogeneic BMT recipients as compared with 
animals receiving syngeneic marrow (11). He went on to 
record the apparent cure of some leukaemic mice following 
lethal irradiation and reconstitution with allogeneic 
marrow. At this point he was able to postulate that a 
significant contribution to the elimination of the 
leukaemic cell load was being mediated by the colonizing 
allogeneic cells in association with the development of 
the GVHD syndrome. This was the earliest description of 
what has in recent years been termed the graft-versus 
leukaemia (GVL) effect.
1.1.2 EARLY CLINICAL RESULTS OF BONE MARROW 
TRANSPLANTATION.
These initial experiments, carried out predominantly in 
murine models, and those which followed in larger species,
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were to pave the way for the development of clinical 
allogeneic BMT. The therapeutic potential of this 
technique was quickly recognized as it became apparent 
that a number of disease states, arising from disordered 
haemopoiesis or immune function, might be potentially 
curable by the replacement of a diseased haemopoietic 
system with that of a normal donor. These diseases 
included aplastic anaemia, leukaemia and several 
hereditary diseases of the haemopoietic and immune 
systems. In addition, there was considerable interest in 
the possibility of inducing the apparent direct 
anti-leukaemic effect of the allograft, as described by 
Barnes•
Despite early optimism, this therapeutic potential was 
however, slow to be realized. Early attempts at 
transplantation in humans were disappointing, partly due 
to a failure to fully understand and deal with all the 
complex immunological interactions involved in the 
technique. In the absence of any HLA matching, many of 
these transplants were inevitably mismatched and patients 
frequently died of either failure of engraftment or from 
the development of GVHD (12).
The 1960s saw significant advances in a number of 
important areas relevant to BMT. These included 
developments in histocompatibility testing, prevention and 
management of GVHD and supportive management in the 
context of bone marrow aplasia. Much of this information
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was again derived from experiments in animal models and 
these advances were to lead to renewed interest in 
clinical BMT.
As with any new therapeutic modality in the treatment of 
leukaemia, allogeneic BMT was initially used in patients 
in whom conventional treatment was deemed to have failed. 
Thus the early experience of transplantation in leukaemia 
was in patients with relapsed and refractory disease, who 
were, not surprisingly, often in poor clinical condition. 
Nevertheless, in the initial studies utilizing BMT to 
treat patients with refractory acute leukaemia it was 
possible to demonstrate that a small but significant 
percentage of these otherwise incurable patients became 
long term survivors and were therefore presumably cured of 
their disease (13-15).
It was also noted during these initial trials, that 
patients who were in reasonable or good clinical condition 
at the time of transplant had significantly longer 
survival times than patients in poor condition. These 
observations and the apparent efficacy of the procedure, 
even in patients with advanced disease, provided the 
rationale for applying this form of treatment to patients 
at an earlier stage in their disease.
Initial results, published in 1979, based on the work of 
Thomas et al., in patients with acute myeloid leukaemia 
(AML) transplanted in first complete remission (CR), 
showed that the probability of cure could be increased to
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approximately 50% in this group of good prognosis patients 
(16,17). These survival figures compared favourably with 
the best reported results following conventional 
chemotherapy in AML. Subsequent studies were able to 
demonstrate a similar outcome in patients with in acute 
lymphoblastic leukaemia (ALL) (18,19).
In chronic myeloid leukaemia (CML), initial attempts at 
BMT were again in patients with advanced, poor prognosis 
disease and the majority were either in accelerated phase 
or blast crisis. Although overall survival in these 
patients was disappointing, analogous to the situation in 
acute leukaemia, a small percentage did appear to be cured 
of their disease. These results led to further studies in 
patients with early stage, chronic phase disease, and as 
in patients with acute leukaemia in first CR as opposed 
to relapse, patients in chronic phase had significantly 
improved long term survival (20,21). This was an important 
therapeutic advance in a disease which appeared incurable 
with conventional forms of chemotherapy.
These studies therefore established allogeneic BMT as a 
useful therapeutic modality in the treatment of leukaemia 
and suggested that optimal results were achieved when 
patients were transplanted at an early stage, although a 
minority of patients, with more advanced disease, could 
undoubtedly still be salvaged later in the course of 
their disease.
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1.1.3 INCREASING UTILIZATION OF BONE HARROW 
TRANSPLANTATION.
Most of these early clinical trials of allogeneic BMT were 
carried out in the late 1970s and early 1980s. Despite 
considerable procedural morbidity and mortality, the
apparently favourable results, in terms of disease free 
survival, were to lead to a rapid expansion in the use of 
allogeneic BMT for the treatment of leukaemia. The
International Bone Marrow Transplant Registry (IBMTR), 
which is the organization responsible for the collection 
and analysis of data on all allogeneic and syngeneic BMTs 
performed worldwide, continues to publish epidemiological 
data at regular intervals on the use of this technique 
(22,23). Their data documents the remarkable increase in 
the utilization of BMT during the 1980s, particularly in 
the latter half of the decade.
Data published on the years 1985-1987 inclusive, 
calculated an average increase of 11% per annum, and also
noted that more transplants were carried out during this
three year period than during the previous thirty years. 
It is also important to note that between 1985-1987 the 
vast majority of transplants (73%) were carried out for 
leukaemia, whereas prior to 1981 the majority were for 
non-malignant conditions, principally aplastic anaemia and 
the severe immune deficiency syndromes. Therefore, 
although the IBMTR records data on transplants carried out
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for all indications, most of the increase is the result of 
an expansion in transplantation for leukaemia. Not 
surprisingly, an increase in the number of institutions 
performing transplants has also been recorded, although a 
significant proportion are still performed in a relatively 
small number of large centres.
The enormous number of trials which have now been 
performed, have generated further data regarding the 
optimal timing for transplantation in the various types of 
leukaemia. For both adults and children the optimal timing 
for BMT in CML is in chronic phase and for AML is in first 
CR or early first relapse. For adults with ALL either 
first or second remission may be appropriate, however in 
children, unless poor prognostic factors exist at the time 
of diagnosis eg. high presenting white cell count, 
transplantation is usually reserved for those who have 
relapsed after conventional chemotherapy.
The outcome of BMT varies with the type of leukaemia 
being treated and the stage of the disease. For CML in 
chronic phase, and AML in first CR, the 5 year 
leukaemia-free survival is 45-55%, with an actuarial 
probability of relapse of 10-20% in CML (24) and 15-25% 
in AML (25,26) • In ALL in first CR, the 3-4 year 
leukaemia-free survival is about 40% for adults and 55% 
for high risk children (27) • The rate of relapse is 
approximately 30%, which appears therefore, to be higher 
than for either AML or CML.
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While allogeneic BMT currently provides the only 
prospect of cure for patients with CML, it should not be 
assumed that the case for transplantation in acute 
leukaemia is completely cut and dried. Although initial 
studies suggested a superior outcome following 
transplantation as compared with conventional 
chemotherapy, with changing patterns of chemotherapy and 
supportive care, considerable controversy exists as to 
whether this is truly the case for all groups of patients 
(28) • It is clear that BMT is more effective at 
eradicating residual leukaemia, but whether this is always 
translated into improved overall leukaemia-free survival 
is less clear. Variables such as age play an important 
part in determining the outcome of transplantation, with 
younger patients having significantly better survival, 
largely due to lower transplant related mortality. There 
seems little doubt that for some groups of patients, 
particularly young patients and those with poor prognosis 
disease, BMT will provide a better prospect of long term 
survival. However, this may not be true for other groups 
and indicates the need for continued analysis of the 
available data, taking into account all the possible 
biases which exist at each stage, in order to design the 
most appropriate treatment strategies for individual 
patients.
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1.1.4 MATCHED UNRELATED DONOR BONE MARROW TRANSPLANTATION.
Up to this point, allogeneic BMT has been considered only 
in the context of the patient who has a fully HLA 
compatible sibling donor. Unfortunately, not all patients 
have such a donor. It has been estimated in Europe and 
North America that only about 30% of patients for whom 
allogeneic BMT would be indicated actually have an HLA 
identical sibling donor (29) • This leaves approximately 
70% of patients for whom other forms of treatment must be 
found. A number of alternative transplant strategies are 
currently available or under investigation for this group 
of patients. These include the use of mismatched family 
donors or matched unrelated donors, autologous bone marrow 
transplantation (ABMT), and transplantation with fetal 
haemopoietic tissue or umbilical vein cells. The latter 
approach remains highly experimental at the present time, 
but is potentially of considerable interest.
Approximately 5-10% of patients will have a family donor 
mismatched at only one HLA antigen. Although in such 
transplants the risks of the major immunological 
complications of graft rejection and GVHD are both 
increased, overall mortality is not excessive and such 
donors are therefore acceptable for leukaemic patients 
(30). Transplants from family donors mismatched at more 
than one HLA antigen are associated with unacceptably high 
mortality due to graft failure and GVHD and cannot be
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recommended (23).
The development of unrelated donor registries, both in 
Europe and North America, has permitted considerable
expansion in BMT using phenotypically matched unrelated 
donors as a source of marrow. A number of factors 
influence the likelihood of being able to identify a 
potential donor for any individual patient. These factors 
include the size of the registry, the frequency of the 
patient's haplotype within the donor pool and closely
associated with this, the patients ethnic background (31). 
It has been estimated that a registry of around 100 000
individuals is required to identify a serologically 
matched donor for 30-50% of patients, with much larger 
numbers being required if the individual patient has an 
uncommon haplotype (32). Estimates from 1990 suggest that 
around 300 000 potential bone marrow donors are available 
worldwide, however one of the major problems at the
present time remains the time taken to search the 
registries in order to identify suitable donors for 
individual patients.
Apart from severe aplastic anaemia, most of the 
experience in matched unrelated BMT currently comes from 
patients transplanted for CML. Although the risks of graft 
failure, GVHD and early transplant related mortality are 
considerably increased (33,34), some of the preliminary 
data now emerging are reasonably encouraging, with 
actuarial survival figures at > 2 years of 40-50% in
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patients with CML transplanted in chronic phase (35,36). 
There seems little doubt that with further expansion of 
the registries, the use of more sophisticated methods for 
HLA matching and continued improvements in supportive 
care, this mode of treatment will be increasingly utilized 
in the coming years for those patients who lack an HLA 
identical sibling.
1.2 PRE-TRANSPLANT CONDITIONING.
1.2.1 REQUIREMENTS OF THE CONDITIONING REGIMEN.
In the immediate period prior to allogeneic BMT, patients 
are generally "conditioned" with either high dose 
chemoradiotherapy or in a smaller number of cases, with 
high dose chemotherapy alone. This regimen is crucial to 
the successful outcome of the transplant procedure. 
Although the exact requirements of the conditioning 
regimen vary somewhat with the indication for 
transplantation, in the context of treating leukaemia and 
other haematological malignancies, the chosen regimen 
should fulfill three basic criteria:
1. It should literally create adequate "space" within the 
marrow cavity to facilitate engraftment of transplanted 
haemopoietic stem cells.
2. It should provide an adequate level of host
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immunosuppression in order to prevent immunologically 
mediated graft rejection.
3. It should contribute a significant direct anti-tumour 
effect.
The last point is relevant even in patients who are 
apparently in CR at the time of transplantation since 
they will still have a significant level of clinically and 
morphologically undetectable disease at this time. This is 
generally termed minimal residual disease (MRD). In 
fulfilling these requirements it is also important that, 
as far as possible, toxicity to non-haemopoietic tissues 
is minimized.
Most regularly used chemotherapeutic agents, as well as 
moderate doses of TBI, are capable of creating adequate 
"space" within the marrow cavity to facilitate engraftment 
and historically this has not been a particular problem 
(37,38). Most attention has therefore focused on the more 
difficult tasks of achieving adequate host 
immunosuppression and adequate levels of anti-tumour or 
more specifically anti-leukaemic activity.
1.2.2 CYCLOPHOSPHAMIDE - TBI
In clinical practice, the most commonly used conditioning 
regimen consists of a combination of the alkylating agent 
cyclophosphamide and a "supralethal" dose of total body
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irradiation (TBI). The effectiveness of this combination 
was first established by Thomas, during the early stages 
of transplantation (39). The original regimen used by 
Thomas in Seattle, consisted of cyclophosphamide 60 mg/kg 
administered on 2 consecutive days followed by TBI, as a 
single fraction of 10 Gy. This CY/TBI combination has
stood the test of time and is generally considered as the
"gold standard" against which new regimens should be
compared. Although many alternative regimens have since 
been developed, none have been notably superior, although 
a number can undoubtedly provide an equivalent effect.
Bearing in mind the basic requirements of the 
conditioning regimen, TBI has a number of advantages over 
other agents. Firstly, TBI is probably the most
immunosuppressive agent currently available and in keeping 
with this, has a good record in consistently achieving 
engraftment both in animal models and clinical studies. 
Secondly, TBI is able to contribute significant leukaemia 
cell kill, including the ability to mediate an effect on 
cells which are outside S-phase and cells in sanctuary 
sites eg. testis and CNS. In addition, since the vast 
majority of patients with leukaemia will not have had 
prior radiation exposure (with the exception of local CNS 
prophylaxis in ALL), therapy induced resistance should not 
be a problem.
With regard to the use of this TBI containing regimen it 
is apparent that its anti-leukaemic effect is dependent on
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its administration at an appropriate stage of the disease. 
Early on in the development of allogeneic BMT, it was 
realized that a TBI dose of 10 Gy would be unlikely to be 
curative in relapsed disease. This was known from patients 
with relapsed leukaemia who had been treated with even 
higher doses of TBI, in whom cure had not been achieved 
(40,41). A major intention of the initial studies in 
relapsed leukaemia carried out by Thomas in the early 
1970s, was therefore to use sufficient conditioning to 
secure engraftment and to rely on the postulated GVL 
effect to eradicate the residual leukaemia cell load. As 
previously noted only a few such patients actually 
survived and this approach to relapsed disease largely 
failed to achieve its aims. In patients transplanted in 
remission, in whom a relatively high percentage were 
eventually cured, the overall anti-leukaemic effect was 
apparently much more successful. The relative contribution 
of a GVL effect in remission disease, over and above the 
anti-leukaemic effect achieved by the conditioning regimen 
itself, is still debated and will be considered further in 
a subsequent section.
1.2.3 RADIOSENSITIVITY OF NORMAL HAEMOPOIETIC CELLS AND 
LEUKAEMIC CELLS.
Historically, the transplant procedure has been intended 
to achieve the complete ablation of all host haemopoiesis,
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both normal and abnormal and to replace this with healthy 
haemopoietic cells of donor origin. One of the underlying 
concepts associated with the use of TBI prior to BMT, has 
been its capability to achieve the desired ablation of 
both normal and abnormal ie. residual leukaemic 
haemopoiesis as simultaneous events. Thus the eradication 
of normal haemopoiesis should be synonymous with 
eradication of residual leukaemic cells and vice versa. 
Much of the evidence for this is based on information 
regarding the radiobiological characteristics of normal 
haemopoietic cells and leukaemic cells.
In general, it has been found that the radiosensitivity, 
repair and repopulation characteristics of normal and 
leukaemic cells are quite similar. There is considerable 
in vitro radiation response data to show that normal 
haemopoietic cells and leukaemic cells are both highly 
radiosensitive with only a limited capacity to recover 
following radiation damage (42). On a radiation survival 
curve this will be indicated by a steep dose response, in 
association with minimal shouldering (Figure l.l).
The shouldering effect (Dq) reflects the capacity of the 
irradiated cells to recover following exposure. Two 
different mechanisms - cellular repair and repopulation 
contribute to the overall tissue recovery. The importance 
of each of these mechanism varies between individual 
tissues.
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RADIATION DOSE RESPONSE CURVE
The steep slope of the dose response curve, representing 
radiosensitivity, will be mirrored by a relatively small 
D0 value (D0 = the radiation dose required to destroy 63% 
of the total cell number)•
The finding of little radiobiological difference between 
the characteristics of normal haemopoietic stem cells and 
leukaemic cells thus implies that an appropriate dose of 
TBI should indeed be equally capable of ablating both 
normal and abnormal haemopoiesis. In the context of
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clinical allogeneic BMT, although this concept apparently 
reflects the actual outcome in a significant number of 
cases, it undoubtedly to some extent represents an 
oversimplification.
A number of groups looking at the radiobiological 
characteristics of leukaemic cells, have now been able to 
demonstrate that although leukaemic cells undoubtedly 
possess the same qualitative radiation response as normal 
haemopoietic cells, ie. steep slopes with negligible 
shoulders, quite marked inter-patient variation occurs in 
terms of the actual D0 values obtained (43,44). Although 
many of these leukaemic cell D0 values will overlap with 
the those of normal haemopoietic stem cells, a significant 
percentage fall outside this range and D0 values both 
higher and lower than those seen for normal cells have 
been recorded. This implies that leukaemic cell 
populations may possess both greater or lesser degrees of 
radiosensitivity when compared to normal cells. Such in 
vitro studies are difficult to perform and may not always 
reflect the situation in vivo, however, they do suggest 
that the radiobiological characteristics of leukaemic 
cells may be more complex than previously thought.
1.2.4 FRACTIONATED TBI.
The initial conditioning regimen utilised by Thomas et 
al., involved the administration of single fraction TBI.
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The dose eventually used was 10 Gy, since earlier trials 
using lower doses (eg. 800 cGy) were unable to 
consistently achieve engraftment. The choice of single 
fraction TBI was at this time partly dictated by reasons 
of convenience. As already noted most of these early 
transplant patients with advanced disease, were in poor 
clinical condition and it was therefore advantageous to be 
able to administer the whole conditioning regimen 
including TBI, over a relatively short period of time. 
This argument became less important once it was 
established that patients transplanted at an earlier stage 
of their disease, who were thus in better clinical 
condition, had an improved outcome. At this point it was 
therefore possible to consider the radiobiological factors 
in favour of using a more prolonged, fractionated TBI 
regimen.
The rationale behind fractionation in the context of BMT, 
is that it allows relative sparing of non-haemopoietic 
tissues without sparing of either normal haemopoiesis or 
leukaemic haemopoiesis, provided that an equivalent 
fractionated dose of TBI is administered (45). This 
sparing effect reflects the different radiobiological 
characteristics of haemopoietic and a number of 
non-haemopoietic tissues. As already discussed, normal 
haemopoietic cells and leukaemic cells share generally 
similar radiobiological characteristics, with relatively 
high radiosensitivity and only a limited capacity for
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recovery. A number of non-haemopoietic tissues eg. lung, 
gastro-intestinal tract, have quite different survival 
characteristics following irradiation.
If one considers lung tissue, it is apparent that lung 
parenchymal cells are significantly less radiosensitive 
than haemopoietic cells and also have a greater capacity 
for recovery after radiation. On a radiation dose-response 
curve, compared to haemopoietic cells, the slope of the 
curve will be less steep, with a correspondingly higher D0 
value and there will be a much greater degree of 
shouldering (Dg)• The degree of shouldering on the 
radiation survival curve is crucial to the question of 
fractionation since it reflects the potential tissue 
recovery which may occur between each fraction of 
radiation and correlates with the sparing effect. Thus in 
the case of haemopoietic tissue (and leukaemic cells) 
little recovery would be anticipated between fractions, 
whereas for lung, significant recovery between fractions 
appears to be possible. The ability to spare 
non-haemopoietic tissues, particularly lung, the dose 
limiting tissue for TBI, without loss of effect to 
haemopoietic cells, obviously has considerable therapeutic 
importance and theoretically the use of fractionated 
regimens should permit the exploitation of this beneficial 
therapeutic ratio.
In clinical practice the sparing effect of fractionated 
TBI regimens has been clearly demonstrated. Lung, liver,
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lens, growing cartilage and possibly also the pre-pubertal 
ovary are all significantly spared (46-49)• In particular, 
the reduction in lung toxicity secondary to interstitial 
pneumonitis has been consistent in a number of studies. In 
general therefore, there has been a trend towards better 
survival and less toxicity with fractionated regimens.
In order to ensure that there is indeed no loss of effect 
on leukaemic cells using fractionated TBI, it is necessary 
to look at the incidence of leukaemic relapse. Clinical 
studies have addressed this question and in trials 
comparing single fraction versus fractionated TBI using 
relapse as the end point, the majority of studies have not 
found any significant loss in terms of cell killing with 
fractionation. Recently, however, data conflicting with 
this has been published by the IBMTR. This data, generated 
from a large number of patients undergoing T-cell depleted 
BHT, suggests that both in terms of ablation of normal 
marrow and anti-leukaemic potential, single fraction 
regimens might actually have some advantage, at least in 
the context of T-cell depletion (50)•
1.2.5 OTHER RADIATION SCHEMES.
In the context of pre-BMT conditioning, the available 
permutations of TBI administration do not end with single 
fraction versus fractionated regimens. Additional
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variations include the use of different doses, dose rates 
and fraction sizes as well as the addition of shielding 
and less frequently the use of extra fields. The number of 
different TBI regimens resulting from these permutations 
is quite considerable and this has generated a large 
number of clinical studies aimed a defining which, if any, 
of these regimens offers a definite advantage. For a 
number of reasons this has not been an easy question to 
answer. The virtual absence in the literature of adequate 
data concerning TBI dosimetry, together with the 
considerable variation in the actual methods of TBI 
administration, make comparisons of different sets of data 
difficult and possibly invalid.
A number of conclusions can, nevertheless, be drawn from 
the plethora of data. Firstly, there is almost certainly a 
dose effect in terms of the anti-leukaemic potential of 
TBI. This has been quite convincingly demonstrated by a 
clinical study comparing 12 Gy versus 15.75 Gy TBI (51).
In this study, however, the higher dose regimen was
associated with excess GVHD and consequently there was no
overall survival advantage. Secondly, in the context of
unmanipulated BMT, it seems likely that there is some 
benefit in terms of survival, from the use of fractionated 
regimens provided an equivalent dose of TBI is 
administered. This advantage, however, may well be lost or 
even reversed following T-cell depleted BMT. Otherwise it 
is probably fair to say that there is little convincing
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evidence to support the superiority of one TBI regimen 
compared to another.
1.2.6 BUSULPHAN - CYCLOPHOSPHAMIDE.
For a number of reasons there has been considerable 
interest in the development of a non-TBI containing 
conditioning regimen for the treatment of patients with 
leukaemia. This has been of particular concern in 
paediatric transplantation, where the long term effects of 
TBI on growth and development have been a serious problem 
(52)• The most successful regimen to date, BuCy2, consists 
of a combination of intravenous cyclophosphamide 120 mg/kg 
administered over 2 days and oral busulphan 16 mg/kg 
administered over 4 days (53). Although there was initial 
doubt regarding the efficacy of radiation-free 
conditioning, busulphan appears to provide adequate 
immunosuppression to facilitate engraftment and the 
combination seems to mediate an equivalent anti-leukaemic 
effect to that seen with TBI and cyclophosphamide.
Although follow-up with this particular combination is 
limited at the present time, toxicity, at least in short 
term follow-up, is currently acceptable. There is however, 
probably a need to develop and utilize specific assay 
systems for monitoring busulphan therapy since there 
appears to be considerable patient to patient variation 
in the absorption and elimination of this drug which has
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been shown to correlate with the development of 
veno-occlusive disease (VOD) (54).
1.2.7 OTHER CONDITIONING REGIMENS.
Following allogeneic BMT for leukaemia, relapse remains a 
significant problem. Although the agents currently used in 
the conditioning regimen provide significant anti- 
leukaemic potential they would not normally be the agents 
of choice for the treatment of patients with leukaemia 
and tend to be selected instead for other properties eg. 
immunosuppression. This has generated interest in the 
possibility of substituting or adding other agents, known 
to have good anti-leukaemic potential to the established 
conditioning regimens. Thus trials are currently underway 
using the drugs etoposide and cytosine as well as the 
newer agent thiotepa, in combination with either 
cyclophosphamide-TBI or BuCy2. While preliminary data 
suggests that these regimens may be useful, definitive 
results after an adequate period of follow-up are still 
awaited.
1.3 CAUSES OF TREATMENT FAILURE FOLLOWING ALLOGENEIC BONE 
MARROW TRANSPLANTATION.
There are a number of different reasons for treatment 
failure following allogeneic BMT (55). Broadly speaking
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these can be classified under two major headings:
1. Treatment failure secondary to recurrence of the 
primary disease.
2. Treatment failure secondary to transplant related 
complications, unrelated to the primary disease.
Following allogeneic BHT for the treatment of early stage 
leukaemia, the risk of leukaemic relapse is around 20%. 
Overall survival in such patients is, however, only 50%, 
which indicates an approximate patient loss of 30%, 
secondary to a number of other transplant related 
complications (Figure 1.2).
In patients who receive unmanipulated bone marrow grafts, 
the most important causes of mortality, unrelated to 
relapse, are graft failure, infection/interstitial 
pneumonitis and GVHD (which may occur in both acute and 
chronic forms). The latter two complications, GVHD and 
interstitial pneumonitis, are often, to a greater or 
lesser extent, interrelated events and may involve 
infections with agents such as cytomegalovirus (CMV) 
(56,57).
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Figure 1.2
CAUSES OF TREATMENT FAILURE AFTER UNMANIPULATED BMT
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1.4 GRAFT-VERSUS-HOST DISEASE.
1.4.1 RECOGNITION OF GRAFT-VERSUS-HOST DISEASE.
There is little doubt that GVHD has been the most serious 
complication related to the allogeneic BMT procedure. 
Despite considerable progress in the understanding of its 
complex pathogenesis it remains today a major cause of
both morbidity and mortality in the post-transplant period 
(58). The syndrome was originally recognized in animal 
models by Barnes and Loutit in 1954 who termed it 
"secondary disease" (10). They were able to demonstrate 
that lethally irradiated CBA mice transplanted from an 
allogeneic mouse strain were able to survive the radiation 
induced aplasia or "primary disease", but that despite
haemopoietic recovery the animals went on to develop a 
lethal multi-organ syndrome involving the skin,
gastro-intestinal tract and liver. It was some time 
however, before the immunological nature of this syndrome
was fully recognized.
In 1966 Binningham (59) defined the essential 
requirements for the development of GVHD:
" i. The graft must contain immunologically competent 
cells; ii. The host must possess important
transplantation isoantigens that are lacking in the 
graft donor, so that the host appears foreign to it, and
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is, therefore, capable of stimulating it antigenically; 
iii. The host must be incapable of mounting an effective 
immunologic reaction against the graft."
1.4.2 PATHOPHYSIOLOGY OF GRAFT-VERSUS-HOST DISEASE.
It is now well established that GVHD is an immunological 
reaction largely mediated by mature T lymphocytes. These 
cells have either been transferred with the graft or have 
developed from grafted precursor cells, but have failed to 
become tolerant to the host. The syndrome has been divided 
into acute and chronic forms which have a number of 
distinct features.
The pathophysiology of acute GVHD involves two principal 
phases, an afferent phase in which recipient cells 
stimulate activation of donor T lymphocytes and an 
efferent phase which involves the release of various 
cytokines and activation of secondary effector cells with 
subsequent tissue damage (60,61). Recognition of foreign 
MHC antigens and minor antigens, is presumed to be 
responsible for the initiation of GVHD; minor antigens are 
probably responsible for the development of GVHD in HLA 
identical sibling transplants. Recently, however, it has 
been recognized that GVHD may also develop following 
syngeneic (62) and autologous transplants (63) where 
foreign host antigens are obviously lacking. GVHD in these 
situations usually follows treatment with the
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immunosuppressive agent cyclosporin (CSA). The discovery 
of GVHD in this context, suggests that although 
histocompatibility differences between host and donor are 
obviously extremely important in this syndrome, other
factors possibly arising from disordered immunity may also 
contribute.
In syngeneic GVHD autoreactive lymphocytes directed 
against Class II MHC molecules are thought to develop as a 
consequence of thymic dysfunction with loss of the normal 
mechanisms of self tolerance (64)• These mechanisms 
involving thymic dysfunction are also thought to be
important in the pathogenesis of chronic GVHD, with thymic 
damage arising in this situation not only from the 
conditioning regimen, but also from any prior acute GVHD.
1.4.3 CLINICAL SPECTRUM OF GRAFT-VERSUS-HOST DISEASE.
The principal target organs in both acute and chronic GVHD 
include skin, intestine, liver and the immune system. The 
latter is associated with a profound state of 
immunoincompetence which predisposes to a variety of 
opportunistic infections which characterize the syndrome 
and are responsible for much of the mortality.
Acute GVHD occurs early in the post-transplant period, by 
definition within the first 100 days. Its exact incidence
following HLA-matched sibling BMT is difficult to define
since patients will virtually always receive some sort of
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prophylaxis, usually in the form of post-BMT 
immunosuppression. Some indication of the significance of 
the problem can, however, be gained from examining the 
results of the original methotrexate (MTX) series. In this 
group of patients, all of whom received post-BMT 
immunosuppression with MTX, the incidence of GVHD was 50% 
and half of the patients who developed GVHD subsequently 
died of this complication (39,65).
A number of factors have been noted to affect the
incidence and severity of GVHD. These include the degree 
of histocompatibility, the number of T cells in the 
graft, and the method of GVHD prophylaxis. The degree of 
histocompatibility is particularly important and it is 
perhaps not surprising that, in recipients of HLA 
non-identical transplants, the incidence of GVHD varies 
from 40% up to greater than 80% (66) .
The most common feature of acute GVHD is a diffuse
erythematous maculo-papular rash. In more severe cases 
this rash may become extensive with ulceration and
desquamation. At this stage skin changes are often 
accompanied by hepatic involvement with abnormal liver 
function tests and diarrhoea, which is the primary 
manifestation of gut GVHD. Grading criteria are generally 
used in order to assess the severity of acute GVHD. The 
original grading system introduced by the Seattle team has 
been the most frequently used and has provided a
considerable amount of information (67). It does however,
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have a number of disadvantages including a failure to 
recognize all target systems and some atypical disease 
patterns.
Chronic GVHD, by definition occurs more than 100 days 
post-transplant and has an incidence ranging from 30 to 
50% (68)• It may follow the acute form or in a minority of 
cases develop de novo at this time. Chronic GVHD has many 
features in common with the autoimmune/collagen vascular 
diseases. It is dominated by its cutaneous manifestations 
and advanced disease may resemble scleroderma. It is also 
associated with a profound state of immune deficiency and 
like acute GVHD, much of the mortality is secondary to 
opportunistic infection.
1.4.4 RISK FACTORS ASSOCIATED WITH GRAFT-VERSUS-HOST 
DISEASE AND PREDICTIVE MODELS.
Retrospective analyses have identified a number of risk 
factors for the development of both acute and chronic GVHD 
(69,70). The most important of these is the degree of MHC 
disparity, but other risk factors including increasing 
age, sex-mismatched transplants, female donors and parity 
have been identified. In addition to analysing risk 
factors a number of groups have developed predictive 
models for GVHD; the most successful models to date are 
the skin explant model (71), and the mixed epidermal 
lymphocyte reaction (72). With the appropriate use of risk
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factor analysis with or without the addition of predictive 
models it may be possible to make some estimation of the 
GVHD risk in order to make the most effective use of the 
available prophylactic regimens for each individual 
patient.
1.5 GVHD PROPHYLAXIS: IMMUNOSUPPRESSIVE TREATMENT.
1.5.1 BACKGROUND TO IMMUNOSUPPRESSION.
As indicated in the previous section, GVHD is one of the 
major determinants of outcome following BMT. It is not 
surprising therefore, that a considerable amount of effort 
has gone into the investigation of methods designed to 
prevent, or at least limit, this complication. Based on 
the immunological nature of the syndrome, the most 
commonly used method for the prevention of GVHD is the 
administration, during the post-transplant period, of one 
or more immunosuppressive agents. Treatment for 3-6 months 
post-transplant is an adequate duration for the majority 
of patients. In general these agents act by blocking 
different stages of the afferent phase of GVHD ie. those 
stages involved with T-cell activation and subsequent 
proliferation.
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1.5.2 IMMUNOSUPPRESSION WITH METHOTREXATE.
It was initially demonstrated in controlled experiments in 
canine models, that the antimetabolite drug MTX,
administered following transplantation, was capable of
reducing the incidence and severity of acute GVHD (73) •
MTX is a cytotoxic agent and is thought to act by
preventing the clonal proliferation which would normally 
follow T-cell activation. Based on these animal 
experiments, MTX was routinely included in transplant
protocols for the prevention of GVHD from an early stage
in the development of clinical bone marrow 
transplantation•
The question of whether this routine prophylaxis was 
necessary in all patients or indeed was clinically
effective in humans, was not addressed until sometime 
later. One non-randomized study which looked at the 
effect of MTX versus no MTX in a small group of patients, 
found no difference in the incidence of acute GVHD between 
the two groups (74). However, in this small study the 
overall incidence of GVHD was very high in both groups of 
patients, particularly in view of the young median age, 
and this may explain the lack of any difference. A 
subsequent pilot study carried out in Seattle again 
deleting MTX, noted the development of a hyperacute GVHD 
syndrome in all patients who did not receive the drug 
(75) . Following the results in this pilot group, a fully
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randomized study was not felt to be justified.
1.5.3 IMMUNOSUPPRESSION WITH CYCLOSPORIN.
Even using optimal treatment with MTX, the incidence of 
acute GVHD is estimated to be somewhere between 30-50% and 
this has prompted the search for additional agents. 
Another drug which was found to be effective in reducing 
GVHD, again with preliminary results coming from animal 
experiments, was CSA (76). The mechanism of action of CSA 
is incompletely understood at the present time, but 
probably involves a reduction in the synthesis of the 
interleukin-2, which is known to be important during 
T-cell activation (77)• A number of controlled trials have 
compared the efficacy of CSA with that of MTX and have 
concluded that these agents are equally effective (78,79). 
It should be noted however, that the risk of GVHD appears 
to correlate with the serum level of CSA (80) and as most 
of these studies did not titrate the dose of CSA to a 
serum level, it is therefore conceivable that CSA 
treatment may have been at times suboptimal.
1.5.4 IMMUNOSUPPRESSION WITH COMBINATION REGIMENS.
Since MTX and CSA appear to act by different mechanisms 
to prevent GVHD, there would seem to be some rationale for 
the use of these two agents in combination. A number of
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trials have used this approach and have now demonstrated a 
superior effect in terms of GVHD prevention using 
combinations of CSA and MTX as opposed to monotherapy with 
either drug (81). Another effective combination appears to 
be that of CSA plus methylprednisolone (82), with the 
latter drug probably acting predominately via a 
lympholytic action. Regimens utilizing combinations with 
other agents eg. MTX plus anti-thymocyte globulin with or 
without the addition of prednisolone have not shown any 
advantage•
Although trials utilizing a combination of CSA and MTX 
demonstrate a reduction in the incidence of GVHD, it is 
important to examine all the available end points in such 
studies. If overall leukaemia-free survival is taken as 
the most important end point, it is apparent that although 
the preliminary studies of combination therapy were able 
to show that the reduction in GVHD was associated with 
improved survival, longer follow up of these patients 
reveals an increased relapse rate and no overall survival 
advantage (83). This apparent increase in the incidence of 
relapse seems to be most marked in patients transplanted 
for AML but has also been observed in patients with ALL 
and CML (84)• The rather unfortunate conclusion of these 
studies may therefore be that the most effective 
prophylactic regimen may not in the long term improve 
overall leukaemia-free survival thus negating any real 
benefit to the patient.
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CHAPTER 2
T-CELL DEPLETED BONE MARROW TRANSPLANTATION
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2.1 PROPHYLAXIS GRAFT-VERSUS-HOST DISEASE: T-CELL
DEPLETION.
2.1.1 BACKGROUND TO T-CELL DEPLETION.
From the evidence presented in previous sections, it is 
clearly established that donor T lymphocytes are crucially 
involved in the mediation of both acute and chronic GHVD. 
It was also demonstrated at an early stage in the 
development of allogeneic BMT, both in mice and dogs, that 
the addition to the bone marrow inoculum of graded numbers 
of lymphoid cells, derived from either splenic or thymic 
tissue, was associated with an increase in both the 
incidence and severity of GVHD in the post-transplant 
period (85)• It therefore seemed a logical progression 
that the removal of T lymphocytes from the marrow inoculum 
might conversely lead to a reduction in GVHD. Experiments 
in animal models confirmed this as a feasible approach to 
GVHD prophylaxis. In mice it was demonstrated that the 
elimination of T lymphocytes was able to prevent GVHD 
across both major an minor histocompatibility barriers 
(86-88).
2.1.2 RESULTS OF T-CELL DEPLETION.
Numerous clinical trials utilizing T-cell depletion were 
to follow these experimental studies (89-91) and the data
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clearly indicate that extensive ex-vivo T-cell depletion 
is a highly effective method for GVHD prophylaxis. The 
overall incidence of GVHD is reduced to less than 10% in 
the context of HLA-matched related transplants with the 
virtual elimination of severe GVHD.
The removal of mature T lymphocytes from the marrow prior 
to infusion renders the graft relatively immunoincompetent 
and it is therefore unable to mediate an immune reaction 
against the host. It is thought that the T cells which 
subsequently mature from engrafted stem cells in the new 
environment are tolerant to the host and are therefore 
unlikely to initiate GVHD. The precise mechanisms of 
tolerance induction following allogeneic BMT, and the 
effects of prior T-cell depletion on this process are at 
present incompletely understood. From work in animals it 
seems likely that more than one mechanism may contribute 
to the development of tolerance and evidence exists for 
the involvement of the central mechanism of clonal 
deletion as well as the peripheral mechanisms of clonal 
suppression and clonal anergy (92) •
The question of the degree of T-cell depletion required 
to prevent clinically significant GVHD has also been the 
subject of considerable investigation. In murine models it 
has been shown that contamination of the marrow inoculum 
with as few as 0.3% T lymphocytes, equivalent to 3 x 104 T 
cells in a total dose of 107 cells, can induce lethal GVHD 
(93) . Although in humans the number of T cells required to
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induce GVHD is not well defined and even in the context of 
fully matched transplants probably varies from case to 
case, it appears that patients who receive less than 105 
clonable T cells per kg are unlikely to develop 
significant GVHD (93) • In general this is equivalent to a 
3-4 log depletion of clonable T lymphocytes which should 
be achieved without significant reduction in other 
haemopoietic progenitors.
2.2 PRACTICAL ASPECTS OF T-CELL DEPLETION.
2.2.1 METHODS OF EX-VIVO T-CELL DEPLETION.
The initial methodology for ex-vivo T-cell depletion was 
developed in mice (94) and was based on physical 
separation by centrifugation on albumin density gradients, 
thereby taking advantage of the specific-density/cell size 
characteristics of mature lymphoid cells. This methodology 
was rapidly adapted to the processing of human marrow, 
thus facilitating the introduction of the technique to 
clinical practice (95).
Subsequently a number of different techniques have been 
utilized for T-cell depletion. Physical methods of 
separation have been expanded and now include counterflow 
centrifugation (96), soybean lectin agglutination and 
E-rosette formation (97). The majority of trials have, 
however, used immune techniques involving one or more
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monoclonal antibodies. The most commonly used monoclonal 
antibodies have pan-T activity and include Campath-1 
(98,99), anti-CD2 (91) and anti-CD3 (90). Combinations of 
up to eight monoclonal antibodies have been used by some 
groups.
Initially donor bone marrow was simply incubated with 
these monoclonal antibodies prior to infusion into the 
recipient. However, murine monoclonal antibodies fix human 
complement poorly and this fact combined with the 
defective host immune response following cytoreduction 
lead to a failure of effective T-cell reduction and GVHD 
was therefore not prevented (100)• Subsequently this 
problem was overcome by adding rabbit complement which was 
able to facilitate in vitro complement mediated T cell 
lysis prior to marrow infusion. Unfortunately the use of 
rabbit complement has a number of practical disadvantages 
and alternatives to complement mediated lysis are 
currently being investigated, these include the use of 
monoclonal antibodies bound to ricin and other so-called 
immunotoxins (101).
2.2.2 MONITORING T-CELL DEPLETION.
All of the T-cell depletion methods outlined above, when 
functioning optimally, are capable of achieving a 2-4 log 
reduction in the number of T cells in the graft. 
Monitoring of the T-cell depletion procedure is important
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for two reasons. Firstly, to assess the number of T cells 
before and after depletion, ie. the efficacy of the T cell 
depletion procedure and secondly, to ensure that there has 
not been any significant or excessive decrease in the 
number of haemopoietic stem cells in the graft. The 
avoidance of stem cell loss is a crucial point, as this 
could impair subsequent haematological reconstitution. The 
choice of method for detecting residual T cells after 
T-cell depletion is at present controversial.
A number of investigators have suggested that a valid 
assessment of residual T cells in the marrow inoculum 
requires the use of a functional assay eg. a limiting 
dilution analysis (102). Although this may well represent 
the ideal system for monitoring the presence of viable T 
cells, in practice, few groups regularly use such assays, 
which tend to be time consuming and labour intensive. The 
majority instead prefer to employ phenotypic analysis, 
using a variety of pan-T and other T cell monoclonal 
antibodies. This lack of uniformity adds further to the 
difficulties of comparing data from different transplant 
groups using diverse methods of depletion.
2.3 OVERALL CONSEQUENCES OF T-CELL DEPLETION.
T-cell depletion has undoubtedly provided the most 
effective method of GVHD prophylaxis so far developed. 
Regardless of the particular technique used, provided that
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effective T-cell depletion is achieved (> 3 logs of
T-cells), the overall incidence of both acute and chronic 
GVHD is dramatically reduced. The incidence of acute GVHD 
falls to 5-20% and clinically even this is usually 
restricted to only mild to moderate cutaneous involvement. 
More significant acute GVHD, ie. > grade II, occurs in 
under 10% of cases and in most studies mortality secondary 
to GVHD is largely absent.
T-cell depletion thus facilitates the virtual 
elimination of GVHD as a clinical entity. In view of the 
significant mortality associated with moderate to severe 
GVHD, it would have been anticipated that this would 
confer a significant survival advantage. A large number of 
studies have, however, clearly demonstrated that survival 
is no better in recipients of T-cell depleted marrow and 
in fact in some studies overall survival has been 
decreased. Once again therefore the need to analyse all 
transplant endpoints with particular attention to overall 
leukaemia-free survival is apparent.
The explanation for the failure to translate this 
potentially advantageous situation into improved overall 
patient survival lies in the substitution of one cause of 
treatment failure - GVHD, with an increase in the 
incidence of two equally serious problems - graft failure 
and leukaemic relapse. Thus the early experience of T-cell 
depletion, using "standard" conditioning regimens (ie. the 
same schedules as used for unmanipulated BMT), was
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associated with a high rate of graft rejection and an 
increased incidence of leukaemic relapse. The latter 
problem of leukaemic relapse, for reasons which are not 
completely understood, was particularly evident in 
patients transplanted for CHL.
In addition to an increased incidence of leukaemic 
relapse and graft rejection, another phenomenon which 
became strikingly apparent following T-cell depleted BMT, 
was the presence of mixed haemopoietic chimerism (MXC). 
MXC is the term used to describe the co-existence, as 
defined by polymorphic markers, of both host and donor 
haemopoietic cells in the post-transplant period. Its 
presence implies a failure of the transplant procedure to 
completely eliminate host haemopoiesis. This form of 
haemopoietic reconstitution had previously been considered 
a relatively rare event, but was noted to occur frequently 
following T-cell depletion, even in those patients who did 
not subsequently reject their grafts.
The increased incidence of these three phenomena - graft 
rejection, MXC and leukaemic relapse, in the context of 
T-cell depleted BMT, were all to a certain extent largely 
predictable from animal models and from a knowledge of the 
immune events which occur in the post-transplant period. 
Following allogeneic BMT, it is generally accepted that a 
complex immunological balance exists between host and 
donor cells. Immunologically active mature T-cells, of 
both host and donor origin, appear to play the crucial
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role in the maintenance of this balance, although other 
cell types eg. natural killer (NK) cells undoubtedly 
contribute. In certain circumstances, this balance may be 
shifted in one direction or the other. A shift in favour 
of the donor immune system is likely to result in clinical 
manifestations of GVHD; on the other hand a shift in the 
opposite direction, in favour of the host, may lead to 
graft rejection.
After unmanipulated BMT, the immunological balance in the 
post-transplant period tends to favour the donor. In the 
majority of cases this permits the establishment of full 
donor haemopoietic chimerism and leads to some degree of 
clinically apparent GVHD in around 50% of patients. With 
the removal of the immunologically active component of the 
graft ie. mature T-cells, it would be anticipated that the 
host would obtain the immune advantage and the balance 
would shift in that direction. This indeed appears to be 
the case and all three events, graft rejection, MXC and 
leukaemic relapse can be seen as reflections of this 
uncompensated shift in favour of the host.
2.4 CONSEQUENCES OF T-CELL DEPLETION: GRAFT FAILURE.
2.4.1 CATEGORIES OF GRAFT FAILURE.
Graft failure is a relatively uncommon but frequently 
fatal complication of allogeneic BMT. Two broad categories
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of graft failure have been recognized and these should be 
defined to avoid confusion in terminology. The first 
category, which is probably best termed graft rejection, 
is associated with the regrowth of immunocompetent host 
cells and simultaneous loss of donor cells. In this 
situation an immunologically mediated host-versus-graft 
reaction is responsible for the failure of the graft. The 
second category of graft failure does not involve regrowth 
of host cells, but the graft itself does not function 
adequately and this results in various combinations of 
cytopenias.
Graft failure without actual host mediated rejection of 
donor cells has been estimated to occur in as many as 9% 
of HLA matched allogeneic transplants carried out for 
haematological malignancies (30). It is also recognized in 
a similar number of patients following autologous BMT 
(103). The underlying mechanisms of this form of graft 
failure are not well defined, but probably include low 
stem cell numbers in the marrow inoculum, post-transplant 
infections especially with cytomegalovirus and drug 
toxicity. Damage to the marrow microenvironment may well 
be responsible in some of these cases.
Actual immune mediated graft rejection in patients 
undergoing unmanipulated BMT for haematological 
malignancies, using marrow from HLA matched sibling 
donors, occurs in around 2% of cases. The incidence is, 
however, significantly increased in recipients of HLA
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non-identical transplants (104), in patients undergoing 
BMT for aplastic anaemia (105) and as already discussed, 
in patients who receive T-cell depleted marrow following a 
"standard" conditioning regimen. In aplastic patients, 
those sensitized by prior use of blood products seem to 
fall into a particularly high risk category.
2.4.2 PATHOPHYSIOLOGY OF GRAFT REJECTION.
Graft rejection characteristically occurs in the early 
post-transplant period. It may be associated with 
non-engraftment or a peripheral blood pancytopenia may 
supervene following a brief period of initial partial or 
complete engraftment. Graft rejection is recognized as an 
immune phenomenon, however, the mechanisms involved are 
incompletely understood.
The effector cells which mediate the reaction are host 
derived and must by definition have survived the 
"ablative" conditioning regimen. In clinical studies it 
has been shown that functionally viable T lymphocytes can 
indeed survive pre-transplant cytoreduction (106) • Their 
survival is predictable from radiobiology models and does 
not necessarily imply inherent radioresistance. In cases 
of graft rejection it is often possible to observe a 
peripheral lymphocytosis of host origin at the time of the 
rejection and immunophenotypic analysis of these cells has 
shown T cell associated markers. It has also been possible
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to demonstrate in cytotoxicity assays that these 
circulating host T cells are able to mediate specific 
lysis of donor cells, although the target antigens remain 
unknown at the present time (107).
The other potential effector cell in graft rejection is 
the NK cell. Whether or not host NK cells are capable of 
mediating graft rejection in humans is at present 
controversial. However, NK cells are also known to be able 
to survive intensive conditioning and NK cell mediated 
graft rejection does occur in lethally irradiated mice 
(108,109) .
2.4.3 MANAGEMENT OF GRAFT REJECTION.
Treatment of graft rejection usually involves either 
supportive management alone or a second transplant with or 
without further pre-transplant conditioning. Overall the 
outcome is poor whichever form of treatment is used. The 
success of supportive management depends on the eventual 
regeneration of autologous bone marrow, however, even with 
the administration of haemopoietic growth factors, this is 
a slow process and patients frequently die of infective 
complications during the prolonged period of neutropenia. 
The long term survival of patients with haematological 
malignancies undergoing second transplants following 
initial graft rejection is also poor with overall survival 
documented at less than 20% (110,111).
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2.4.4 GRAFT REJECTION, T-CELL DEPLETION AND THE ROLE OF T 
CELLS IN ENGRAFTMENT.
Following transplantation with T-cell depleted bone 
marrow, early studies using "standard" conditioning 
regimens reported increased rates of graft rejection as 
high as 30-60%. Although it has been suggested that a 
reduction in the number of viable stem cells in the marrow 
inoculum may occur during the process of T-cell depletion 
and that this may contribute to graft rejection, in vitro 
studies of haemopoietic progenitors do not support this 
concept. Most of the available evidence favours the 
reduced number of T cells in the graft as being the 
crucial factor. This observation has logically led to 
considerable interest in the role of T cells in the 
process of engraftment.
Clinical data support the concept that donor T cells play 
an important role in the facilitation of engraftment and a 
number of potential mechanisms have been proposed largely 
based on work in experimental models (112). One suggestion 
is that donor T lymphocytes exert "veto activity" in order 
to prevent an immune response when they are recognized as 
foreign by residual host T cells (113). Alternatively 
donor T cells might mediate a selective GVH effect against 
host lymphoid cells without necessarily initiating the 
clinical manifestations of GVHD. A third suggestion is 
that donor T cells are responsible for the secretion of
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various lymphokines and cytokines which facilitate the 
growth and proliferation of stem cells in their new 
environment (114).
Although at present the mechanisms are poorly defined, 
donor T cells appear to mediate a graft enhancing effect 
which probably involves the elimination or inactivation of 
residual immunocompetent host T cells which have survived 
the pre-transplant conditioning regimen. The removal of 
donor T cells from the marrow inoculum thus eliminates 
this effect and potentially allows the proliferation of 
residual T cells which may under certain circumstances be 
capable of mounting an immunological reaction against the 
graft resulting in graft rejection.
2.5 CONSEQUENCES OF T-CELL DEPLETION: RELAPSE.
2.5.1 CURE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION: 
THE GRAFT-VERSUS-LEUKAEMIA EFFECT.
Allogeneic BMT permits the delivery of "supralethal" doses 
of chemoradiotherapy which have considerable antileukaemic 
potential. Despite this, there are several lines of 
evidence which suggest that the efficacy of allogeneic BMT 
is not limited to the conditioning regimen and that a 
significant proportion of the beneficial effect may 
relate to an additional immunological component (115,116). 
It is thought that in the post-transplant period,
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immunocompetent donor cells are capable of mediating an 
immunological reaction against residual host leukaemic 
cells which have not been ablated by the cytoreductive 
conditioning. This has been termed the
graft-versus-leukaemia (GVL) effect and it is postulated 
that it is the loss of this immunological reaction which 
is responsible for the increased incidence of leukaemic 
relapse in the context of T-cell depleted BMT (117,118).
Data supporting the concept of a GVL effect comes both 
from experimental animal models and from clinical studies. 
As discussed in Chapter 1, as early as 1956, it was 
demonstrated in a murine leukaemia model that animals 
dying of "secondary disease" ie. GVHD, had a marked 
reduction in their leukaemic cell load at the time of 
death (11). Although the nature of this phenomenon was not 
understood at the time, it was suggested that it might be 
due to a direct anti-leukaemic effect of GVHD. Indeed much 
of the initial interest in allogeneic BMT was aimed, not 
just at the ablation of host haemopoiesis by "supralethal" 
chemoradiotherapy, but at the possible induction of this 
anti-leukaemia effect. Subsequently, the occurrence of a 
GVL effect has been confirmed and further defined in a 
number of different rodent leukaemia models (119-121).
The most compelling evidence for the existence of an 
immunological GVL effect in man comes firstly, from 
analysis of the results of syngeneic versus allogeneic BMT 
and secondly, from analysis of the effect of GVHD on the
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incidence of leukaemic relapse. It is apparent that 
patients with AML, either in first CR or with more 
advanced stage disease, who undergo transplantation from 
an identical twin have a higher incidence of leukaemic 
relapse than those who receive marrow from an 
HLA-identical sibling (122,123). This would be in keeping 
with an additional anti-leukaemic component of the 
allograft. Similar results exist for ALL, at least in 
patients beyond first CR (124)• This difference in 
outcome, between syngeneic and allogeneic transplants, 
seems to be less marked in CML patients (116). However, 
part of the reason for this may be found in the relatively 
small number of twin transplants available for analysis.
A number of large studies have now documented the lower 
incidence of leukaemic relapse in patients who have 
clinical manifestations of GVHD (125)• Chronic GVHD exerts 
a greater anti-leukaemic effect than acute GVHD, which 
perhaps indicates a separate mechanism of action. The 
anti-leukaemic effect is, however, maximal when both 
acute and chronic GVHD have been present. Despite the 
significant benefit in terms of leukaemic relapse, overall 
survival is only improved in patients who have had chronic 
GVHD alone (126) • This is undoubtedly due to the 
relatively high mortality associated with acute GVHD. The 
anti-leukaemic effect of GVHD occurs in all types of 
leukaemia, although the degree to which it exists has been 
reported to vary. It is therefore perhaps not surprising
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that the most effective immunosuppressive regimen for the 
prevention of GVHD, ie. combined CSA and MTX, has been 
associated with an increased incidence of relapse in long 
term follow-up studies (127).
The anti-leukaemic effect of GVHD in allogeneic BMT is 
clearly very important. It should, however, also be noted 
that, in syngeneic BMT, the incidence of relapse is still 
greater than in allografted patients who do not develop 
GVHD (128). This would seem to imply that there is an 
anti-leukaemic effect associated with allografting which 
is independent of the occurrence of GVHD. The concept that 
GVHD and GVL may, at least to some extent, occur 
independently has led to considerable interest in the 
therapeutic potential of modifying the immune response to 
allow amplification of the GVL effect without increasing 
GVHD (129). While some success has been achieved in the 
separation of GVHD and GVL in vitro and in animal models 
(130,131), the data in humans is unconvincing at the 
present time.
2.5.2 MECHANISMS INVOLVED IN THE GRAFT-VERSUS-LEUKAEMIA 
RESPONSE.
Despite the considerable body of evidence in support of a 
GVL effect following allogeneic BMT, the actual immune 
mechanisms involved in this response are not well-defined. 
Experimental evidence exists in support of a number of
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different groups of effector cells and target antigen 
structures (128,132).
These include i. alloreactive donor T-cells recognizing 
MHC antigens on both normal and tumour cells of host 
origin, ii. non-MHC restricted natural killer (NK) and 
lymphokine activated (LAK) cells and iii. donor T-cells 
recognizing antigens unique to or selective to host tumour 
cells (133-136). There is also evidence that some of the 
GVL effect may be mediated indirectly, via cytokines which 
are secreted in the post-transplant period and possess 
anti-tumour activity (137).
2.5.3 REDUCTION OF THE GRAFT-VERSUS-LEUKAEMIA EFFECT WITH 
T-CELL DEPLETION.
In the context of T-cell depletion, leukaemic relapse 
appears to be significantly increased. This has been noted 
in all types of leukaemia, however, a number of groups 
have noted a more marked increase in CML. The impact of 
T-cell depletion on overall leukaemia-free survival, as 
already discussed, remains controversial. Recent data 
published by the IBHTR noted that in first remission acute 
leukaemia and chronic phase CML, leukaemic relapse was 
2.75 times more likely following T-cell depleted BMT 
(131). It should, however, be noted that this data applies 
to transplants performed prior to 1988, when a large 
proportion of patients would still have received a
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"standard" conditioning regimen. In AML and ALL the 
increase in relapse seems to be completely attributable to 
the reduction in GVHD. In CML, however, this has not been 
the case and it appears that the incidence of relapse 
remains increased even after correction for the occurrence 
of GVHD. This suggests that in CML there may be an 
additional anti-leukaemic T-cell effect, which is 
independent of the occurrence of GVHD and is absent in 
other types of leukaemia.
The magnitude of the GVL effect in the context of 
allogeneic BMT for leukaemia has been difficult to 
measure. From studies aimed at defining this problem in a 
rat model for human AML, the Brown Norway acute monocytic 
leukaemia (BNML) model, it has been possible to make a 
number of theoretical calculations (138). It has been 
estimated that at diagnosis leukaemic patients have a 
tumour burden in the order of 1012 cells which is reduced 
to around 108 cells following successful remission 
induction and consolidation. This latter figure will 
therefore represent the tumour burden present in patients 
with leukaemia who are transplanted in remission. 
Cytoreductive conditioning using chemoradiotherapy, has 
been found to add a further 8 log cell kill (LCK) to that 
already achieved, leaving only few malignant cells 
(Figure 2.1).
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MECHANISM OF CURE AFTER ALLOGENEIC BMT
It has further been calculated that the occurrence of 
GVHD, which presumably accounts for a very significant 
proportion of the GVL effect, will only add a further 1 
LCK on top of this figure (139). It appears, however, that 
this additional 1 LCK may be crucial in terms of eventual 
cure of leukaemia, and this may go some way towards 
explaining the increase in leukaemic relapse following 
T-cell depleted BMT.
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2.6 CONSEQUENCES OF T-CELL DEPLETION: MIXED HAEMOPOIETIC 
CHIMERISM.
2.6.1 DEFINITION OF MIXED HAEMOPOIETIC CHIMERISM.
The terminology applied to describe the chimeric status of 
haemopoiesis following allogeneic BMT is not standardized 
and will therefore be clarified at this point to avoid 
confusion. The accepted scientific definition of a chimera 
is "an organism whose cells derive from two or more 
zygotic lineages" (140). It follows therefore that any 
recipient of a successful allogeneic BMT, by virtue of a 
possessing a foreign haemopoietic system, will fulfill 
this definition. Further terminology is therefore required 
to define chimerism within the haemopoietic compartment 
itself.
Recipient haemopoiesis following transplantation may 
either consist solely of donor cells or may be a mixture 
of donor cells and surviving/regenerating host cells. For 
the purposes of the discussion in this thesis the latter 
situation will be referred to as mixed haemopoietic 
chimerism (MXC) and the former as full chimerism (FC). It 
should be pointed out that this does not take account of 
marrow stromal cells, certain subtypes of which eg. bone 
marrow derived fibroblastic stromal cells, are probably 
always host derived following transplantation and do not 
appear transplantable using current techniques (141,142).
86
The term "split chimerism" refers to a different situation 
altogether in which individual lineages are derived from 
either host or donor cells but not from a mixture of both. 
In humans this has been most frequently observed in 
children transplanted for severe combined immune 
deficiency (SCID), where post-transplant T lymphocytes are 
of donor origin whereas B lymphocytes, myeloid and 
erythroid cells remain of host origin (143). This occurs 
in fully HLA-matched recipients who do not require 
conditioning prior to BHT and appear to engraft only the 
deficient lineage. Occasionally, depending on the exact 
nature of the underlying immune deficiency syndrome, B 
lymphocytes may also engraft.
Following allogeneic BMT, residual normal host 
haemopoietic cells may consist of surviving mature cells 
and/or regenerating cells derived from surviving 
haemopoietic stem cells. Surviving mature cells represent 
long lived lymphoid cells, whereas surviving stem cells 
can give rise to cells of all lineages. Although not 
actually defined as such, MXC has generally been 
considered to involve active host cell repopulation, thus 
implying the survival of host stem cells. In practice, 
however, the nature of the surviving host cell population 
has not always been well documented in the literature. 
Although it has been argued that some cases of so-called 
MXC are simply due to minor populations of surviving long 
lived lymphoid cells (144), in the majority of cases it
87
appears more likely that active regeneration of host cells 
has in fact occurred. This implies that despite the 
presence of donor haemopoietic cells, host derived stem 
cells are capable of continued proliferation and
differentiation.
2.6.2 OCCURRENCE OF MIXED HAEMOPOIETIC CHIMERISM USING
UNMANIPULATED MARROW.
The overall intention of allogeneic BMT is the replacement 
of host haemopoiesis with a new self-maintaining 
haemopoietic system of donor origin. While the intention 
has always been that this replacement should be complete, 
it has been recognized for many years that this is not 
always the case. Thus in certain situations host 
haemopoiesis seems to be capable of at least some degree 
of regeneration in the post-transplant period and on 
occasions this leads to the co-existence of host and donor 
haemopoiesis ie. MXC.
In animal models, MXC has been observed in a number of 
different species including mice, rats, pigs, dogs and 
rhesus monkeys following conditioning regimens utilizing 
only total lymphoid irradiation (TLI) (145). MXC also
occurs frequently in dogs conditioned with 
cyclophosphamide or dimethyl myleran alone, but is
infrequent when TBI is used in doses adequate to achieve 
consistent engraftment (146,147).
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In clinical practice, prior to the introduction of T-cell 
depletion as a method of GVHD prophylaxis, MXC appeared to 
be a relatively uncommon event in patients transplanted 
for haematological malignancies with TBI containing 
regimens. Originally the administration of > 10 Gy single 
fraction TBI was thought to be completely ablative and 
thus preclude the survival of host haemopoiesis. Closer 
examination has demonstrated that host haemopoietic 
elements can in fact survive this dose of TBI (106). The 
potential relevance of surviving host lymphoid cells in 
cases of graft rejection has already been discussed in a 
previous section. In recent years with the development of 
more sensitive methods for the analysis of engraftment and 
chimerism, minor populations of residual host cells have 
been observed in a significant proportion of patients 
following unmanipulated BMT. Pooling data from a number of 
studies the overall incidence has however, usually been 
less than 30% (148-150).
The relatively low incidence of MXC in patients 
transplanted for haematological malignancies contrasts 
with that seen following BMT for aplastic anaemia. In this 
situation MXC occurs quite frequently, although it is 
usually only a transient event (151). The reason for the 
higher incidence of MXC in patients with aplastic anaemia 
once again seems to reflect the conditioning regimen 
employed prior to transplantation. Patients with aplastic 
anaemia have generally been conditioned with a non-TBI
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containing regimen, most commonly cyclophosphamide alone 
with CSA administered for GVHD prophylaxis. Thus the 
situation in aplastic patients seems to be analogous to 
that seen in experimental animal models where less 
intensively conditioned animals ie. animals receiving 
chemotherapy or TLI alone, are quite frequently mixed 
chimeras, whereas animals conditioned with TBI are usually 
full chimeras. The transient nature of MXC in patients 
transplanted for aplastic anaemia is thought to reflect 
the underlying defect in host haemopoiesis which probably 
limits continued proliferation in this situation.
2.6.3 OCCURRENCE OF MIXED HAEMOPOIETIC CHIMERISM USING 
T-CELL DEPLETED MARROW.
Following the introduction of T-cell depletion as a method 
of GVHD prophylaxis in patients undergoing allogeneic BMT 
for haematological malignancies, it soon became apparent 
that even in those patients where graft rejection did not 
occur, engraftment was frequently incomplete ie. MXC was 
present. Whereas in recipients of unmanipulated bone 
marrow MXC appears relatively uncommon, with an overall 
incidence of < 30%, in recipients of T-cell depleted bone 
marrow the overall incidence was initially found to be 
>50% and in one study MXC was documented in 100% of cases 
(148). In addition to the high incidence of MXC, it was 
also observed that in contrast to patients transplanted
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for aplastic anaemia where MXC was usually transient, 
following T-cell depleted transplants MXC appeared to be 
of a persistent nature.
Not surprisingly, the biological significance and 
clinical implications of this apparent failure to 
eradicate normal host haemopoiesis following T-cell 
depleted BMT were of immediate concern, particularly in 
view of the increased incidence of graft rejection and 
leukaemic relapse.
2.6.4 CONCLUSIONS REGARDING THE OCCURRENCE OF MIXED 
HAEMOPOIETIC CHIMERISM.
If the outcome of allogeneic BMT, in terms of the chimeric 
status of haemopoiesis, is viewed as the end result of 
competing HVG and GVH immune mediated reactions, then it 
is perhaps not surprising that MXC occurs more frequently 
in two particular situations:
1. Following cytoreduction where one of the less intensive 
(usually non-TBI containing) conditioning regimens has 
been utilized.
2. Following the use of T-cell depleted donor marrow as 
the method of GVHD prophylaxis.
In both of these situations the post-transplant 
immunological balance is shifted to confer a degree of
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advantage to the host which thus permits some host cell 
repopulation to occur. Why in the context of T-cell 
depletion this host advantage sometimes terminates in 
graft failure and at other times results in engraftment 
with persistent MXC is incompletely understood at the 
present time.
2.7 STRATEGIES FOR OVERCOMING THE PROBLEMS OF T-CELL 
DEPLETION.
2.7.1 THE REQUIREMENT FOR NEW STRATEGIES.
As discussed in the preceding sections T-cell depletion is 
a highly effective method for the prevention of GVHD but 
has serious clinical disadvantages in terms of rejection 
and leukaemic relapse, which, at least initially, have 
probably prevented any significant benefit in terms of 
overall patient survival. These problems have led many 
transplant groups to abandon the procedure altogether or 
at least to restrict its use to those patients who are at 
particularly high risk of GVHD eg. patients undergoing BMT 
from matched unrelated donors. Others have been more 
reluctant to give up the obvious advantages of T-cell 
depletion, particularly as the other available methods for 
GVHD prophylaxis are clearly less effective and the 
treatment of GVHD, once it is established, is difficult 
and unsatisfactory.
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This has led to the development of a number of strategies 
aimed at overcoming the adverse effects of rejection and 
relapse while retaining effective GVHD prevention 
(152-154)• Many of these strategies for so-called "third 
generation" or "intelligent" T-cell depletion aim to 
redress the balance between host and donor cells which 
appears to have been shifted in favour of the host by this 
procedure.
2.7.2 INTENSIFICATION OF THE CONDITIONING REGIMEN.
In terms of engraftment, it has been shown in murine 
models that the incidence of graft rejection can be 
reduced by either increasing the cell dose in the marrow 
inoculum or by intensifying pre-transplant recipient 
immunosuppression (155). Similar experiments in monkeys 
and dogs have demonstrated that an increased dose of TBI 
in the preparative regimen is required in order to 
facilitate engraftment of T-cell depleted bone marrow 
(156).
In humans it has not been possible to significantly 
increase the cell dose in the marrow inoculum and efforts 
have therefore concentrated on increasing the intensity of 
the pre-transplant conditioning regimen so as to provide 
greater host immunosuppression and hopefully more 
effective ablation of the host marrow. This has most 
frequently be achieved by increasing the dose of TBI and a
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number of groups have now been able to demonstrate a 
beneficial effect on engraftment (90,157-159). Thus 
intensification of the conditioning regimen by increasing 
the dose of TBI seems to result in a high rate of 
engraftment.
It has been of some importance, particularly with regard 
to the avoidance excess toxicity, to establish the 
magnitude of the required increase in the dose of TBI. 
Based on calculations made in a mouse model, it has been 
estimated that, in the context of T-cell depletion, an
extra dose of 2-3 D0 will be required to secure
engraftment. This is the equivalent of an extra 1.5 - 2 Gy 
using single fraction TBI or an extra 2 - 2.5 Gy if the 
regimen is fractionated (160).
As previously discussed the contribution of the GVL 
effect to the overall anti-leukaemic potential of
unmanipulated BMT has been estimated at around 1 LCK 
(139) . Since the addition of 2 Gy to the conditioning 
regimen is thought to represent an extra 1-2 log leukaemic 
cell kill, it follows that the degree of intensification 
required to secure engraftment should also be capable of 
supplying the additional anti-leukaemic potential required 
to overcome loss of the GVL effect. The concept that TBI 
regimens optimized in this way can overcome the problems 
of graft rejection without excess toxicity is now 
accepted, however, the outcome in terms of leukaemic 
relapse currently awaits the results of ongoing studies.
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Other methods of increasing the immunosuppressive effect 
of the conditioning regimen have also been shown to be 
effective in reducing the incidence of graft rejection or 
are currently under investigation. These include the use 
of additional chemotherapeutic agents, TLI, and monoclonal 
antibodies against lymphoid tissues eg. anti-LFA-l. It 
should however be emphasised, that while these regimens 
may be able to facilitate engraftment, the use of TLI and 
monoclonal antibodies are unlikely to contribute any 
significant anti-leukaemic effect and therefore cannot be 
expected to be able the influence the incidence of 
leukaemic relapse.
2.7.3 QUALITATIVE AND QUANTITATIVE T-CELL DEPLETION.
Alternative strategies for overcoming the problems of 
T-cell depletion include both quantitative and qualitative 
approaches to the actual depletion procedure. 
Quantitative, or complete versus partial, T-cell depletion 
is based on the concept that GVHD and GVL reactions may 
well be mediated by similar or identical groups of T-cells 
and that while the two reactions may therefore not be
separable it may be possible to utilize a dose effect to
minimize GVHD while retaining some GVL (161,162). 
Qualitative or selective T-cell depletion, on the other 
hand, pre-supposes that GVHD and GVL are mediated by
different groups of T-cells and that it may therefore be
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possible to selectively remove the subsets responsible for 
GVHD, while retaining those capable of inducing GVL 
effects (163-165). A number of studies have been based on 
these approaches, however to date neither has produced 
convincingly favourable results.
2.7.4 EXPERIMENTAL STRATEGIES.
More experimental methods of overcoming the problems of 
T-cell depletion include the use of cytokines eg. IL-2 to 
modify T-cell function in the post-BMT period and the 
so-called mixed allogeneic BMT, aimed at the induction of 
specific transplant tolerance with the retention of an 
anti-leukaemic effect. The place of these latter 
techniques remains to be established and at the present 
time the use of augmented conditioning regimens is 
undoubtedly the most feasible approach to retaining T-cell 
depletion in clinical practice.
2.8 T-CELL DEPLETION - GLASGOW EXPERIENCE.
2.8.1 GRAFT REJECTION.
The introduction of T-cell depletion in Glasgow using a 
"standard" conditioning regimen was typical of many 
centres, with an unacceptably high incidence of graft 
failure. The conditioning regimen which was initially used
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consisted of cyclophosphamide 120 mg/kg administered over 
2 days and fractionated TBI - 12 Gy administered in 6 
fractions of 200 cGy, over a period of 3 days. This was
the same regimen as had been used previously in patients
receiving unmanipulated marrow and in this context its use 
had not been associated with engraftment problems.
Ex-vivo T-cell depletion was achieved using CD6 and CD8 
monoclonal antibodies with complement mediated lysis. Of 
the 8 patients who received this conditioning regimen 
followed by T-cell depleted marrow, 5 had engraftment 
problems. In 4 patients there was evidence of transient 
engraftment only, and in one patient there was no evidence
of engraftment at any stage.
In an attempt to compensate for the adverse effect of 
T-cell depletion on the engraftment process, host 
immunosuppression was increased by using a higher dose of 
TBI as part of the conditioning regimen. The dose of TBI 
was thus increased from 12 Gy to 14.4 Gy. This regimen 
was administered in 8 fractions of 180 cGy, over a period 
of 4 days. This increase in the TBI dose by almost 2.5 Gy 
would be predicted, on theoretical grounds, to compensate 
for both the loss of the graft enhancing effect of T-cells 
and the absence of a GVL effect. It would therefore be 
anticipated to be capable of overcoming the problems of 
both graft rejection and leukaemic relapse.
Using this intensified conditioning regimen, the 
incidence of graft failure in Glasgow currently stands at
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less than 2% (Table 2.1). This figure is comparable to 
transplantation using unmanipulated marrow. In addition, 
the increased dose of TBI has been administered without 
any apparent increase in toxicity. These results confirm 
therefore the ability of an intensified conditioning 
regimen, aimed at enhanced host immunosuppression, to 
secure engraftment and overcome the problems of graft 
rejection associated with T-cell depleted BMT (157).
Table 2.1. T-Cell depletion - Glasgow experience
TBI DOSE 12 Gy 14.4 Gy
GRAFT FAILURE 5/8 (62%) 2/102 (<2%)
2.8.2 BACKGROUND TO THE PRESENT STUDY.
As already discussed, a high incidence of post-transplant 
MXC has been noted in two independent situations. Firstly, 
following the use of one of the less intensive (usually 
non-TBI containing) conditioning regimens and secondly, 
following T-cell depleted BMT. In both of these settings 
an association between reduced or inadequate host 
immunosuppression/ablation appears to exist, ie. an 
immunological advantage in the HVG direction. MXC can
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therefore be seen as an indicator of this immunological 
advantage.
Following T-cell depleted allogeneic BMT, in patients who 
achieve stable engraftment, increased MXC occurs in the 
context of a reduced incidence of GVHD and an increased 
incidence of leukaemic relapse. Again this apparently 
reflects an overall host advantage. The precise 
relationship between MXC, GVHD and leukaemic relapse in 
the individual patient, is not, however, well defined.
Although the reduction in GVHD is presumably largely due 
to a direct effect of the T-cell depletion procedure, 
there is also evidence to suggest that as an additional 
indirect effect, MXC, resulting from inadequate host 
conditioning, may itself mitigate against GVHD. A negative 
association between MXC and the development of GVHD would 
therefore be anticipated.
The relationship between MXC and leukaemic relapse is 
also of considerable interest since it raises important 
issues regarding the adequacy of the ablative protocol in 
the face of a reduced or absent GVL effect. It is also of 
considerable importance to know whether MXC, in a given 
situation, can be used as a predictor of relapse or 
whether failure to eliminate normal haemopoiesis occurs 
independently of the elimination of leukaemic 
haemopoiesis.
Returning once again to the Glasgow experience of T-cell 
depleted BMT, having intensified the conditioning regimen
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and having demonstrated that this regimen is capable of 
securing engraftment in a high percentage of patients, it 
seems reasonable to postulate that if graft rejection is 
not excessive, then the conditioning regimen must be
providing an adequate degree of host immunosuppression/ 
ablation. Following on from this, it could also be
postulated that if this is true, MXC should also be
reduced, possibly to the levels seen using unmanipulated 
marrow ie. usually < 30%.
The main area of clinical study presented in this thesis 
centres around this question of the relationship between 
haemopoietic chimerism and the intensity of the
pre-transplant conditioning regimen. The work undertaken 
also attempts to better define the nature of MXC and its 
implications, particularly in relation to transplant 
outcome, in terms of the occurrence of GVHD, leukaemic 
relapse and overall patient survival.
2.9 METHODS OF MONITORING HOST/DONOR CELL POPULATIONS 
FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION.
2.9.1 POLYMORPHIC MARKERS
Up until this point little mention has been made of the 
methodology involved in defining haemopoietic chimerism in 
the post-transplant period. There is an obvious 
requirement to be able to clearly and unequivocally
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distinguish host and donor cell populations from each 
other and various markers can be employed for this 
purpose. The currently available techniques will now be 
reviewed.
There are a number of reasons for wanting to be able to 
examine host and donor cell populations following 
allogeneic BMT. These include the need to monitor i. 
engraftment and rejection, ii. chimerism and iii. disease 
relapse. The ability to analyse these events depends upon 
assays designed to examine genetic differences between 
host and donor cells. It should be noted that in the 
context of disease relapse these are markers of host cells 
and are not, in general, markers of disease. A number of 
different marker systems are shown in Table 2.2.
Table 2.2. Polymorphic markers
RBC antigen systems.
RBC and WBC isoenzymes. 
Immunoglobulin allotypes. 
HLA differences. 
Cytogenetic markers. 
Molecular markers.
The ideal marker system for monitoring host and donor cell 
populations following allogeneic BMT should fulfill a
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number of different criteria. Firstly, it should be able 
to provide informative markers for all donor/recipient 
pairs and will therefore require to be highly polymorphic 
within the population. Secondly, it should be capable of 
analysing all haemopoietic cells and should not be 
restricted to a single lineage or a particular stage of 
cell development. Thirdly, it should not be subject to 
interference from "third party" haemopoietic components 
eg. transfused blood products. Fourthly, particularly if 
chimerism is to be analysed, the method should be 
sensitive enough to detect the presence of a minor cell 
population in a mixture and for the purposes of 
monitoring, should also preferably be at least 
semi-quantitative. Finally, it in order to facilitate the 
analysis of samples in the early post-transplant period, 
it should be capable of being performed on a limited 
amount of material. In addition it would be desirable to 
have a method which was rapid, easy to perform, and in the 
current financial climate, cost effective.
The analysis of cytogenetic (166-168), molecular 
(148,169-172) and red cell antigen (173,174) markers have 
been the most commonly used techniques to monitor 
engraftment. In the context of HLA-identical BMT the use 
of HLA antigens as polymorphic markers is obviously 
extremely limited. Immunoglobulin allotyping (175-177) has 
also been infrequently used, mainly due to a limited 
degree of polymorphism and interference from transfused
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blood products. The analysis of red and white cell 
isoenzyme differences has been employed more frequently 
(178-180), however, the methodology is relatively 
insensitive for detecting minor cell populations and 
several enzyme systems require to be analysed in order to 
provide an adequate range of polymorphic markers. Again 
this technique is subject to interference from transfused 
cells.
2.9.2 RED CELL ANTIGEN SYSTEMS.
The red cell antigen system provides a useful source of 
highly polymorphic markers within the population. If 
patients and their respective donors are phenotyped for a 
variable number of red cell antigens, including the minor 
antigens, informative markers can be found for the 
majority of transplant pairs. Post-transplant analysis of 
erythrocyte antigens can then be carried out either using 
conventional agglutination techniques or more recently by 
using fluorescent microspheres coated with anti-human IgG 
(181,182). This latter technique has enhanced the
sensitivity of RBC antigen analysis, allowing the
detection of a minor cell population as low as 0.01%.
Red cell antigen analysis, however, has two major 
limitations. The first is that the analysis is limited to 
a single cell lineage and may not therefore be
representative of the haemopoietic system overall.
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Secondly, it is subject to interference from "third party" 
transfused red cells. Even patients who engraft promptly 
may remain transfusion dependent for a variable period of 
time and since the average red cell life span is around 
120 days this considerably limits the use of the technique 
during the first 6 months post-transplant.
The problem has to some extent been overcome in some 
centres by the use of a so called "adapted transfusion 
policy" (183). This involves the identification of marker 
antigens for both donor and recipient cells prior to 
transplantation. Red cell transfusions thereafter are 
screened to exclude the presence of these marker antigens. 
This policy however, involves considerable screening of 
blood products, which can be cumbersome particularly if 
CMV screening is also being used. Many groups have 
therefore reserved RBC analysis for use once the patient 
is deemed to be free of transfused cells, ie probably 
beyond 6 months post-BMT.
2.9.3 CYTOGENETIC MARKERS.
Cytogenetic markers have been extensively used in various 
studies of engraftment and chimerism following allogeneic 
BMT. In general the technique utilizes the analysis of sex 
chromosome markers and has therefore been restricted to 
sex-mismatched transplants. While it is possible to extend 
the technique to sex-matched pairs by examining autosomal
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polymorphisms, this usually requires additional chromosome 
banding techniques which are time consuming to perform.
Cytogenetic monitoring of post-transplant cell 
populations, unlike the analysis of red cell antigens, is 
not restricted to any individual cell lineage. It can be 
applied to erythroid and myeloid progenitors in bone 
marrow as well as peripheral blood lymphocytes. The nature 
of the technique does, however, restrict its use to the 
analysis of mitotic cells. Potentially therefore it could 
fail to detect a cell population which was quiescent and 
not actively dividing. The other disadvantage of 
cytogenetic analysis is its relative insensitivity unless 
relatively large numbers of metaphases are examined. 
Predictive tables exist in order to determine the number 
of cells which require to be examined in order to exclude 
a minor cell population of a given size (184)• Thus to 
exclude a minor cell population of 5% with 95% 
confidence, between 60 and 70 cells should be examined 
(Table 2.3).
Few studies of chimerism published in the literature have 
examined such large cell numbers and they will therefore 
have been relatively insensitive to the presence of these 
minor cell populations. On the other hand, cytogenetic 
analysis has the advantage of potentially providing 
information regarding the normality of the cell population 
which has been detected. Thus unlike other markers, in the 
presence of an underlying chromosomal abnormality, this
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technique can simultaneously operate as a marker of 
host/donor cells and as a marker of disease. This has been 
particularly useful in monitoring patients with CML 
following transplantation (185,186).
Table 2.3. Confidence intervals for the exclusion of 
mosaicism
Number 
of cells
90%
Confidence
95%
Confidence
99%
Confidence
5 38% - -
10 21% 26% 37%
20 11% 14% 21%
30 8% 10% 15%
50-55 5% 6% 9%
99-112 3% 3% 5%
459 1% 1% 1%
2.9.4 MOLECULAR MARKERS.
Molecular markers are derived either from polymorphic 
sequences, which are present to a greater or lesser extent 
on all chromosomes or from male specific sequences which 
are present only on the Y-chromosome.
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BASIS OF VNTR POLYMORPHISM
Many of these polymorphic markers are based on variable 
number of tandem repeat (VNTR) sequences, which make up 
large segments of non-coding DNA throughout the human 
genome (187). The extensive polymorphism of these 
sequences is based on variation in the repeat unit copy 
number within the population (Figure 2.2). This variation 
is often expressed as a heterozygosity index or as the 
polymorphism information content (PIC). For any given
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sequence, the higher the heterozygosity index or PIC 
value, the greater the degree of polymorphism. While male 
specific markers are only informative in sex mismatched 
pairs, polymorphic markers can be applied to all 
transplants regardless of sex matching.
Most studies of engraftment and chimerism to date have 
utilized Southern blotting in order to facilitate analysis 
of these markers. However, Y-specific sequences can also 
be detected by in-situ hybridisation (188,189) and the 
current expansion in the use of the polymerase chain 
reaction (PCR) now provides an alternative method for the 
analysis of an increasing number of DNA sequences (190).
One of the advantages of using molecular markers in 
post-BMT monitoring is that they are extremely polymorphic 
within the population and can be used to analyse 
nucleated haemopoietic cells, regardless of lineage and 
cell cycling characteristics, in all donor/recipient 
pairs. In addition, the methods involved offer a high 
degree of sensitivity together with the ability to 
quantify the individual populations detected. The major 
disadvantage of Southern blotting has been the fact that 
it is a somewhat time consuming procedure, involving the 
use of radioactivity and this has restricted its use to 
the research laboratory.
The PCR technique, originally described in 1985 (190),
has made an enormous impact on molecular analysis in a 
number of different areas of research and development.
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THE POLYMERASE CHAIN REACTION
Using this technique, a specific DNA (or cDNA) sequence 
may be amplified in vitro many millions of times. The 
procedure is rapid and following amplification the 
specific sequence of interest can often be analysed 
directly. The amplification process is carried out using 
two specific oligonucleotide primers, which flank the 
sequence of interest (Figure 2.3). Binding of the primers
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is achieved by first denaturing the DNA at 90 - 95°C for 
about 1 min and then allowing binding, or annealing to 
take place at 45 - 55°C. Addition of a DNA polymerase 
enzyme then acts on the single stranded DNA, in the 
presence of an excess of deoxynucleotide triphosphates 
(dNTPs), to facilitate synthesis of a complementary strand 
of DNA by primer extension. Repetition of this cycle of 
denaturation, annealing and primer extension is then 
carried out by varying the incubation temperatures to 
allow continued synthesis of the DNA sequence of interest. 
Automation of the technique has been facilitated by the 
use of the thermostable enzyme, Taq polymerase.
The application of this technique to the analysis of 
polymorphic or male specific markers offers the 
possibility of an even greater level of sensitivity and 
also has the advantage of requiring only minimal starting 
material. These features together with the ability to 
perform rapid, automated analyses have made its 
application in this area seem very attractive.
2.9.5 CONCLUSIONS ON THE CURRENTLY AVAILABLE TECHNOLOGY.
When it comes to assessing engraftment and chimerism, each 
of the methods discussed in this section have obvious 
advantages and disadvantages. It appears however, that the 
expansion in molecular biology during the last few years 
has generated the most useful techniques for the analysis
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of genetic markers in the context of transplant 
monitoring. As developments in this area continue it seems 
likely that in the next few years molecular techniques 
will become part of the routine monitoring of all 
transplant patients.
2.9.6 METHODS TO BE USED IN THIS STUDY.
For the purposes of the main clinical studies described in 
this thesis, chimerism has been examined by both 
cytogenetic and restriction fragment length polymorphism 
(RFLP) analysis. In order to facilitate the RFLP analysis, 
a panel of informative DNA probes was first established. 
The usefulness of this panel for monitoring engraftment 
and chimerism in the post-transplant period was verified 
initially in a large group of donor/recipient pairs. This 
work is fully described in Chapter 3.
In addition, during the courses of the main clinical 
study, it was possible to investigate in smaller subgroups 
of patients, novel methods for the analysis of engraftment 
and chimerism utilizing the recently established PCR 
technology. The development and utilization of these PCR 
based methods is described in Chapters 5 and 6.
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2.10 SUMMARY OF THE AIMS OF THE STUDY.
1. To establish a panel of RFLP probes, suitable for 
monitoring engraftment and chimeric status by Southern 
blot analysis following allogeneic BMT and to assess i.
the usefulness of this panel in a group of 60
donor/recipient pairs and ii. the sensitivity of these 
probes in terms of their ability to detect a minor cell 
population. (Chapter 3)
2. To document the chimeric status of haemopoiesis, as 
assessed by cytogenetic and RFLP analysis, and its 
clinical implications, in a group of 48 matched sibling 
transplants, who were prescribed one of two high dose TBI 
schedules in an attempt to compensate for the effects of 
T-cell depletion. (Chapter 4)
3. To document in the same group of patients as described 
above, the natural history of haemopoietic chimerism and 
where possible to examine chimerism within individual 
haemopoietic lineages. (Chapter 4)
4. To examine in smaller subgroups of patients, novel 
methods, utilizing the recently developed PCR technology 
in order to examine i. engraftment in the early
post-transplant period and ii. the chimeric status of
haemopoiesis following engraftment. (Chapters 5 and 6)
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CHAPTER 3
THE DEVELOPMENT OF A PANEL OF PROBES FOR MONITORING 
ENGRAFTMENT AND CHIMERISM FOLLOWING ALLOGENEIC BONE MARROW
TRANSPLANTATION
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3.1 INTRODUCTION.
As discussed in Chapter 2, examination of host and donor 
cell populations by molecular analysis, appears to offer a 
number of advantages over the other available techniques. 
In order to monitor engraftment and chimeric status 
following allogeneic BMT by Southern blot analysis, a 
panel of informative probes was first established. The 
panel consisted of five highly polymorphic, single locus, 
RFLP probes from different chromosomes and one male 
(Y-chromosome) specific probe.
The RFLP probes all detect highly repetitive sequences, 
which show extensive allelic variation in the repeat unit 
copy number within the population ie. VNTR sequences. The 
Y-specific probe detects a similar highly repetitive 
region on the short arm of the Y-chromosome. Although 
Y-specific markers can provide information on engraftment 
in all sex-mismatched pairs, in the context of looking for 
mixed chimerism, they are essentially only of value for 
the detection of residual male cells in those cases where 
a male patient is the recipient of a transplant from a 
female donor.
Before any selected panel of probes can be used to 
monitor engraftment, it must be demonstrated that these 
probes can provide informative markers, capable of clearly 
distinguishing individual donor and recipient cell 
populations, in the majority of transplant pairs. In the
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present study this was determined by analysing DNA from a 
total of 60 pre-transplant patients and their respective 
sibling donors. The sensitivity of Southern blot analysis, 
in terms of the ability to identify a minor cell 
population, was also established for both the RFLP and 
Y-specific probes, in a series of mixing experiments using 
artificially prepared cell mixtures.
3.2 MATERIALS AND METHODS.
3.2.1 MATERIALS.
Peripheral blood and bone marrow samples were used as the 
source of DNA in the majority of donor/recipient pairs. 
Recipient samples were collected prior to cytoreductive 
treatment and donor marrow was collected at the time of 
marrow harvesting. In a small number of cases where 
pre-transplant recipient DNA was not obtained, 
constitutional DNA was later extracted from either buccal 
epithelial cells (191) or cultured skin fibroblasts (192).
Bone marrow and peripheral blood samples were collected 
in anticoagulant, either EDTA (Ethylenediaminetetraacetic 
acid) or lithium heparin. In order to facilitate the 
collection of buccal epithelial cells, patients were 
required to rinse their mouths with 15 ml of 0.9% 
weight/volume (w/v) saline for about 15 s. Alternatively 
buccal epithelial cells were removed by gently scrapping
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the inside of the patient's cheek with a wooden spatula. 
The cells thus obtained were removed by rinsing the 
spatula in 15ml of 0.9% (w/v) saline.
Skin fibroblasts were cultured from skin biopsy samples 
under standard conditions (192). Once the cells had formed 
a confluent adherent monolayer they were detached from the 
flasks using a trypsin-EDTA solution (Gibco, Scotland). 
The cells were incubated with trypsin-EDTA at room 
temperature for 1-2 min, excess liquid was then removed 
and the flasks left at room temperature for a further 5-10 
min. Once detachment was almost complete, the cells were 
resuspended in 10 ml of phosphate buffered saline (PBS).
3.2.2 ISOLATION OF MONONUCLEAR CELLS.
Isolation of mononuclear cells (MNCs) was achieved by
centrifugation of peripheral blood and bone marrow samples 
on a density gradient. This technique is based on the 
knowledge that MNCs (lymphocytes and monocytes) have a 
lower density than either red blood cells or granulocytes.
Samples were first diluted 1:1 with a balanced salt 
solution, either RPMI 1640 (Life Technologies, Paisley, 
UK) or PBS. Using a Pasteur pipette, 8 ml of the diluted 
cells were then carefully layered onto 4 ml of Lymphoprep 
(Nycomed, Oslo, Norway) in a 15 ml tube. Lymphoprep
separation fluid has a density of 1.077 g/ml and
centrifugation at 800g for 15 min facilitates the
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formation of a distinct band of MNCs, close to the top of 
the tube. Following centrifugation mononuclear cell bands 
were harvested with a pipette and washed twice in PBS to 
remove excess separation fluid.
3.2.3 PREPARATION OF MONONUCLEAR CELL MIXTURES.
In order to establish the sensitivity of Southern blotting 
it was first necessary to create a set of known cell 
mixtures. MNCs from unrelated individuals, known to be 
informative with several of the RFLP probes, were used to 
make mixtures in various ratios. Mononuclear cell 
suspensions were made from each of the informative 
individuals and their final cell concentration adjusted to 
107 cells/ml. A set of 10 mixtures was then made in the 
following proportions - 50%:50%; 75%:25%; 90%:10%; 95%:5%; 
99%:1%; 99.5%:0.5%; 99.8%:0.2%; 99.9%:0.1%, 99.95%:0.05%.
A second set of mixtures was made using male and female 
cells, with the male cells added in the minor proportion.
3.2.4 PREPARATION OF HIGH MOLECULAR WEIGHT DNA.
The method used for the preparation of high molecular 
weight DNA was based on that originally described by 
Gross-Bellard (193). This involves initial digestion of 
white cells with the proteolytic enzyme, proteinase K, in 
the presence of sodium dodecyl sulphate (SDS), followed by
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deproteinization by phenol/chloroform extraction.
In order to prepare high molecular weight DNA from 10 ml 
of peripheral blood, the red cells were first lysed with 
30 ml of red cell lysis buffer (l55mM ammonium chloride,
O.lmM EDTA, pH 7.4, lOmM potassium hydrogen carbonate) in 
a 50 ml polypropylene tube. A white cell pellet was 
obtained after centrifugation at 3000gr for 10 min. The 
pellet was washed with PBS in order to remove residual 
lysis buffer. Similar cell pellets were obtained from the 
buccal epithelial and fibroblast cell suspensions by 
centrifugation at 3000g for 10 min.
The resulting cell pellet was then thoroughly resuspended 
in 5-10 ml (depending on the size of the pellet) of 0.2M 
sodium acetate, pH 7.0. SDS was added to 0.5% (w/v) and 
proteinase K to a final concentration of 10 mg/ml. After 
mixing the solution was incubated at either 56°C for 1 h 
or 37°C overnight.
Following this incubation, phenol-chloroform extraction 
was performed by adding an equal volume of tris-saturated 
phenol-chloroform and allowing this to mix completely by 
rotating on a tumbler for 20-30 min. The mixture was then 
centrifuged at 3000g for 2 min to separate the aqueous and 
phenol phases. Using a wide bore pipette, the aqueous 
phase containing the DNA, was transferred to a second 
tube, the DNA was then precipitated by adding two volumes 
of absolute alcohol. The DNA strands were then looped out 
using a hooked pipette and the DNA was further dehydrated
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by rinsing first in 95% ethanol, and then in chloroform. 
The DNA was allowed to air dry briefly prior to 
resuspension in an appropriate volume of sterile TE (lOmM 
Tris-HCl, pH 7.6, ImM EDTA).
Where no obvious strands of DNA were precipitated 
following the addition of absolute alcohol, the solution 
was cooled at -20°C for 1 h and then centrifuged at 3000gr 
for 10 min. The resulting pellet, containing both DNA and 
RNA, was resuspended in 500 /xl of distilled H20. DNA was 
then reprecipitated by the addition of 0.1 volume of 3 M 
sodium acetate and 2.5 volumes of absolute alcohol. Any 
precipitated DNA was looped out, dried and resuspended as 
previously described.
In the case of samples known initially to have a very low 
cell count, all volumes were scaled down to allow the 
whole extraction procedure to be performed in a 1 ml 
Eppendorf tube. The use of these small volumes minimises 
unnecessary loss of DNA during the procedure.
3.2.5 DNA PROBES.
The following six probes were used to construct a panel of 
informative markers. Details of location, heterozygosity 
and informative restriction enzymes are shown in Table 
3.1.
1.GMGY7: 4.5 kb Hindlll fragment of the cDNA clone GMGY7, 
in the vector Charon 21A (194).
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2.3'HVR: 4.0 kb Hinfl fragment of pSEAI, subcloned into
the Hinc II site of pSP64 (195).
3.pYNH24: 2.0 kb MspI fragment of cosmid YNH24, subcloned 
into the AccI site of pUCl8 (196)•
4.pYNZ22: 1.7 kb BamHI fragment of cosmid YNZ22, subcloned 
into the BamHI site of pBR322 (197)•
5.M27B: 2.3 kb EcoRI fragment of genomic clone M27, 
subcloned into pAT153 (198).
6.MSI: 4.6 kb Sau3A fragment of clone MSI, subcloned into 
the BamHI site of pAT153 (199).
Table 3.1. Probes used for Southern blot analysis
Probe Location Heterozygosity Enzyme
GMGY7 Yp (DYS58) NA TaqI
a-globin 3'HVR 16p(16S85) > 90% PvuII
pYNH24 2p (D2S44) 97% TaqI,PvuII
pYNZ22 17p(D17S30) 86% TaqI
M2 78 Xp (DXS255) > 90% TaqI,EcoRI
MSI lp (D1S7) > 99% Hinfl
Five of the probes were supplied as gifts from the 
following sources: pYNH24, pYNZ22 (Y. Nakamura); a-globin 
3'HVR (D. Higgs); M27B (N.J. Fraser); GMGY7 (G. Lanyon). 
MSI was supplied under licence from Cellmark Diagnostics, 
UK.
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3.2.6 PREPARATION OF PROBES.
The DNA probes were supplied either as stab cultures or 
plasmid DNA. Probes supplied as stab cultures were 
suitable for immediate large scale isolation of plasmid 
DNA, whereas those obtained as plasmid DNA required 
initial transformation into a host strain of competent E. 
Coli.
3.2.7 PREPARATION OF STERILE AGAR PLATES.
Sterile agar plates were required in order to prepare 
single colonies of host bacteria both before and after 
plasmid transformation.
Initially a 1.5% (w/v) solution of agar in L-Broth (pH 
7.5) was prepared using L-broth containing 1% (w/v) sodium 
chloride, 0.5% (w/v) yeast extract and 1% (w/v) tryptic
soy broth. The agar/L-broth mix was sterilized by 
autoclaving for 15 min at a pressure of 10 lb/in2, 
and then allowed to cool. If required, once the agar/broth 
mix had reached a temperature of 40-50°C, ampicillin was 
added to a final concentration of 100 /tig/ml. The solution 
was then poured into an appropriate number of 90mm 
diameter Sterilin plastic petri dishes to a depth of 5mm. 
The plates were covered but not completely sealed and 
allowed to cool on a flat surface. Prepared agar plates 
could either be used immediately or stored for up to 1
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month at 4°C for later use.
3.2.8 PREPARATION OF COMPETENT E. COLI.
Competent E. Coli for subsequent plasmid transformations, 
were prepared from the host strain JM83. The method used 
is based on the observation that bacterial cell uptake of 
both bacteriophage DNA and plasmid DNA is enhanced by 
prior treatment of the bacterial cells with calcium 
chloride (200,201).
A single bacterial colony, which had been grown overnight 
on a 1.5% (w/v) agar plate without ampicillin, was used 
to inoculate a 10ml starter culture of L-broth. Following 
overnight incubation at 37°C, 1ml of this starter culture 
was diluted in a further 100ml of L-broth and reincubated 
at 37°C with vigorous shaking. Incubation was continued 
until the ODgoonm reading of the bacterial suspension 
reached 0.2-0.4, this usually took around 2-3h. After 
cooling briefly on ice, the bacteria were pelleted by 
centrifugation at 3000g for 10 min at 4°C. The bacterial 
pellet was then gently resuspended in 50 ml of sterile ice 
cold lOmM magnesium sulphate and left on ice for 2 0 min. 
The bacteria was then re-pelleted by repeat 
centrifugation, resuspended in 20 ml of sterile, ice cold 
50mM calcium chloride and left on ice for 30 min. The 
bacteria was then pelleted once again and resuspended in 
1 ml of sterile ice cold calcium chloride and left for a
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further 30 min on ice.
The competent bacterial cells could then be used 
immediately. If however, the cells are left on ice for a 
further 12-24 h the efficiency of transformation increases 
by 4-6 fold. The cells were therefore usually left on ice 
overnight prior to use. It is important that after the 
initial centrifugation the cells are kept cool and are 
handled fairly gently as they tend to become fragile 
during the procedure.
3.2.9 TRANSFORMATION OF COMPETENT E. COLI.
5 ng of an appropriate plasmid DNA, at a concentration of 
1 ng/pl, was diluted in 100 pi of transformation buffer 
(lOmM Tris, pH 8, lOmM calcium chloride, lOmM magnesium 
chloride) • This was then added to 100 fil of an overnight 
sample of competent E. Coli and the mixture was left on 
ice for 20 min prior to being heat shocked at 42°C for 2 
min. The mixture was then left to stand at room 
temperature for 10 min. Following this, 2.5 ml of L-broth 
was added to the transformation reaction which was then 
allowed to incubate at 37°C in a shaking incubator for 90 
min. Thereafter, 100 n 1 of this reaction mixture was 
plated out on 1.5% (w/v) agar plates containing
ampicillin, and incubated overnight at 37°C. The 
antibiotic growth conditions select for the ampicillin 
resistant plasmid containing E. Coli and the resulting
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colonies can then be used for plasmid DNA isolation.
3.2.10 LARGE SCALE ISOLATION OF PLASMID DNA.
Large scale isolation of plasmid DNA was carried out by 
the method of Birnboim and Doly (202) • The method is based 
on differential precipitation of plasmid DNA from 
bacterial DNA following treatment with alkali. The alkali 
treatment leads to selective denaturation of bacterial DNA 
which upon renaturation forms an insoluble aggregate. The 
covalently closed circular plasmid DNA can then be
recovered from the supernatant.
Single plasmid containing bacterial colonies were 
obtained either from transformation cultures or by 
streaking out the appropriate stab culture onto a 1.5% 
(w/v) agar plate in the presence of ampicillin and
incubating overnight at 37°C. A single colony was used to 
inoculate a 10 ml starter culture of L-broth containing
ampicillin at a concentration of 100 /xg/ml. After
overnight incubation at 37 °C in an orbital shaking 
incubator, the starter culture was added to 500 ml of 
L-broth containing ampicillin. This was allowed to 
incubate under the same conditions for a further 15-20 h.
In order to harvest the bacterial cells, the culture was 
transferred to a 500 ml polypropylene bottle and 
centrifuged at 4000g for 10 min at 4°C. To facilitate 
partial lysis of the bacterial cell wall, the cell pellet
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was resupended in 10 ml of a sterile lysis solution (50mM 
glucose, 25mM Tris-HCl, pH 8.0, lOmM EDTA) containing 
lysozyme 5 mg/ml, the powdered lysozyme should be 
dissolved just before use. To ensure adequate lysis the 
solution was left to stand at room temperature for 5 min. 
This was followed by the addition of 20 ml of freshly 
prepared sterile alkaline SDS (0.2M NaOH, 1% (w/v) SDS). 
The solution was gently inverted until it became clear and 
left on ice for 10 min. This process results in the 
irreversible denaturation of bacterial DNA which can be 
precipitated by the addition of 15 ml of ice cold sterile 
5M potassium acetate (pH 4.8).
The precipitated DNA can then be pelleted together with 
the bacterial debris by centrifugation at 16000g for 10 
min at 4°C. Following centrifugation the supernatant was 
transferred to a fresh tube and the plasmid DNA was 
precipitated by adding 0.6 volumes of isopropanol and 
allowing the solution to remain at -20°C for 30 min. The 
precipitated plasmid DNA was recovered by centrifugation 
at 16000gr for 10 min at room temperature. The resulting 
DNA pellet was washed in 70% ethanol and allowed to air 
dry briefly prior to resuspension in 5 ml of TE (lOmM 
Tris-HCl, pH 8.0, lmM EDTA).
Further purification of plasmid DNA was then carried out 
by centrifugation to equilibrium in a cesium 
chloride-ethidium bromide gradient (203)• The principle of 
this technique is that supercoiled or closed circular
125
plasmid DNA binds less to the ethidium bromide than either 
nicked circular or linear DNA. This results in a discrete 
band of closed circular DNA further down the cesium 
chloride gradient.
Five grammes of solid cesium chloride was added to the 
5 ml of TE containing the resuspended plasmid DNA, this 
was mixed gently until the salt had fully dissolved. 0.5 
ml of ethidium bromide (10 mg/ml) was added and the 
concentration adjusted to obtain a density of 1.39 g/ml 
and a final concentration of ethidium bromide of around 
600 /xg/ml. The remainder of the tube was filled with 
liquid paraffin (this could be used to balance additional 
tubes) and the mixture was centrifuged at 40000 rpm for 
40 h, in a fixed angle rotor of a Centrikon T-20000 ultra 
centrifuge at 20°C. Two bands of DNA should be visible, if 
the bands are faint a U/V light source may be used. The 
lower band consists of closed circular plasmid DNA which 
can then be harvested with a #21 hypodermic needle. The 
excess ethidium bromide was removed by repeated 
extractions using equal volumes of 1-butanol saturated 
with water or isopropanol saturated with cesium chloride. 
Cesium chloride was removed by dialysing the plasmid DNA 
solution, in a colloidal bag, against several changes of 
O.lx TE over a 24 h period.
The purified DNA was then precipitated at -20°C for 1 h 
by the addition of 0.1 volume of 3H sodium acetate and 2.5 
volumes of ice cold absolute alcohol. The precipitated DNA
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was pelleted by centrifugation at I6000gr for 15 min at 
4°C, washed twice in 70% ethanol and after air drying 
briefly was resuspended in 1 ml of TE (pH 8.0). This 
plasmid DNA is quite stable and can be stored at -2 0°C 
until required.
3.2.11 ISOLATION OF PLASMID DNA.
The concentration of each of the plasmid DNA suspensions 
was estimated using a spectrophotometer (OD260nm)* The 
final concentration was then adjusted to 1.5 /xg//il. In 
order to excise insert DNA from whole plasmid DNA, 
endonuclease digestion was carried out with an appropriate 
restriction enzyme (see page 120). Digests were set up in 
1 ml Eppendorf tubes with 75 /ig of plasmid DNA, 15 /il of 
lOx reaction buffer (as supplied by the manufacturer), 
150 U of restriction endonuclease (NBL, Northumbria, 
England) and distilled H2 O to a final volume of 150 /il. 
Incubation was carried out at 37°C for a minimum period of 
4 h. In order to monitor the completeness of digestion, 2 
/il of each plasmid digest solution was removed and 
electrophoresed at 70 volts for 1 h on a 1% agarose 
minigel. The resulting fragments were inspected using a 
UV transilluminator (320 nm) . If digestion was incomplete, 
additional enzyme was added and the incubation continued 
for a further 3-4 h.
Once the plasmid DNA was fully digested, insert DNA was
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excised following electrophoresis using a 1.5% (w/v) low 
melting point (LMP) agarose gel. The gel was prepared by 
dissolving 1.5 g of LMP agarose in 100 ml of lx TBE buffer 
(89 mM Tris-borate, 89 mM boric acid, 2mM EDTA, pH 8.0) 
containing ethidium bromide (0.5 nq/ml). The gel was 
solubilized in a microwave oven and after cooling briefly, 
was poured into a gel mould containing a comb with a 
single slot. Once the gel had set adequately, the digested 
plasmid DNA was loaded into the slot and electrophoresed 
for 2-3 h at 50 volts in lx TBE buffer with 0.5 ng/m 1 
ethidium bromide. The DNA fragments were visualized with a 
UV transilluminator (320 nm) and the required insert band 
excised from the gel using a scalpel blade (Figure 3.1). 
The gel slice containing the insert DNA was transferred 
into an appropriate number of Eppendorf tubes which were 
stored at 4°C until required for use.
3.2.12 RESTRICTION ENDONUCLEASE DIGESTION OF DNA.
High molecular weight DNA was digested to completion with 
a restriction endonuclease. Appropriate enzymes were 
selected to permit the detection of the VNTR polymorphism 
for each probe (Table 3.1). A total of 4 enzymes were used 
in this study: Taql, PvuII, EcoRI and Hinfl (NBL,
Northumbria, England). Some of the enzymes were 
informative with more than one probe (Table 3.1).
Digests were set up in 1 ml Eppendorf tubes with 8 ng of
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Figure 3.1
PLASMID DNA FOLLOWING ENZYME DIGESTION.
3.4 kb
LMP agarose gel visualised with UV light (32 0 nm), showing 
plasmid DNA following enzyme digestion. The 3.4 kb band 
represents plasmid DNA (pAT153) ; the 2.3 kb band 
represents insert DNA (2.3 kb EcoRl fragment of the 
genomic clone M27).
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DNA, 0.1 volume of lOx reaction buffer (as supplied by the 
manufacturer for each enzyme), 40 U of enzyme (5 U//Ltg of 
DNA) and distilled water to a final volume of 40 /xl. The 
digests were incubated for a minimum period of 6 h, at 
37°C for Pvull, EcoRI and Hinfl and at 65°C for Tagl. In 
the case of Taql digests, a small quantity of mineral oil 
was added to each tube to prevent evaporation.
Following incubation, in order to check that DNA 
digestion was complete, 2 /xl of each reaction mixture was 
loaded onto a 1% agarose minigel and electrophoresed at 70 
volts for lh. The digested DNA was visualized using a UV 
(32 0 nm) transilluminator• If the DNA was not completely 
digested, additional enzyme was added and the incubation 
continued for a further 6 h.
3.2.13 GEL ELECTROPHORESIS.
The 0.8% (w/v) agarose was prepared by dissolving 2.4 g of 
agarose in 300 ml of lx TBE buffer (89mM Tris-borate, 89 
mM boric acid, 2mM EDTA, pH 8.0). The agarose was 
solubilized by heating in a microwave oven and then left 
to cool to approximately 60°C. Ethidium bromide, 0.5 
Hq/ml, was added to the agarose solution prior to pouring 
into a 20 cm x 20 cm horizontal gel mould. Once the gel 
had become opaque it was transferred, on a glass plate, to 
an electrophoresis tank. The tank was filled with 
sufficient lx TBE buffer containing ethidium bromide (0.5
130
fig/ml), to cover the gel to a depth of 1 cm.
Following the addition of 0.1 volume of gel-loading 
buffer (lOmM Tris, pH 7.6, lOmM EDTA, 0.1% (w/v)
bromophenol blue, 30% (w/v) sucrose), the DNA digests were 
loaded onto the gel. Standard molecular weight markers of 
lambda DNA, digested with EcoRI and Hindlll, were run in 
the two outside lanes. The samples were then 
electrophoresed at 80 volts until the 2 kb marker was 
within 2 cm of the end of the gel or in the case of Hinfl 
digests until the 2 kb marker had electrophoresed off the 
gel. An ultraviolet transilluminator (320 nm) was used to 
visualize the molecular weight markers. Once the 
electrophoresis was completed, the UV illuminated gels 
were photographed using high speed (type 667) Polaroid 
film (Polaroid Corporation, Mass., USA.).
3.2.14 TRANSFER OF DNA FROM AGAROSE GELS.
Prior to transfer of the electrophoresed DNA from the 
agarose gel, the DNA was depurinated by washing the gel in 
500 ml of 0.25M HC1 for 15 min. This was followed by 
denaturation carried out by washing twice, for 2 0 min per 
wash, with 500 ml of 1.5M NaCl, 0.5M NaOH. Once these 
treatments were completed the DNA was transferred to a 
Biodyne B reinforced nylon membrane (Pall, UK) by 
capillary diffusion, according to the method of Southern 
(204).
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Briefly, a transfer system was set up in a plastic tray 
filled with 2Ox SBC, using a glass plate supported 2-3 cm 
above the SSC and covered by 2 layers of Whatman 3MM paper 
wicks. The gel was placed on top of the glass plate and 
the gap between the edge of the gel and the plate sealed 
with old X-ray film to ensure transfer of the SSC through 
the gel and not around the edges. A sheet of Biodyne B 
membrane, pre-soaked in 2Ox SSC was then laid over the 
surface of the gel. Care was taken to exclude any air 
bubbles. Two layers of similarly pre-soaked Whatman 3MM 
paper were laid over this and a stack of absorbent paper 
tissues placed on top. The stack was weighted (0.5 - 2 kg) 
and DNA transfer allowed to continue in the presence of 
2Ox SSC for a minimum period of 12 h.
Once the period of transfer was completed the Biodyne B 
membrane was removed from the gel. Cross-linking of the 
DNA to the membrane was carried out by baking the filter 
in a conventional oven, at 80°C for 15 min followed by 
rinsing in 2x SSC for 5 min. The membranes were then heat 
sealed in polythene bags which were stored at 4°C until 
required.
3.2.15 PREHYBRIDISATION.
Prior to hybridisation with an appropriate radiolabelled 
DNA probe, membranes were prehybridised in order to block 
non-specific binding sites. Each membrane was
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prehybridised in a heat sealed plastic bag, with 20 ml 
(4 ml/100 cm2 of membrane) of a solution containing 5x 
SSPE (SSPE = l80mM NaCl, lOmM sodium phosphate, lmM EDTA, 
pH 7.7), 5x Denhardt's solution (Denhardt's solutions 
0.02% (w/v) polyvinylpyrrolidone, 0.02% (w/v) ficoll,
0.02% (w/v) bovine serum albumin), 0.5% (w/v) SDS and 100 
Mg/ml of freshly denatured salmon sperm DNA.
Prehybridisation was carried out in a shaking water bath 
at 65°C for a minimum period of 4 h.
3.2.16 RADIOLABELLING OF DNA PROBES.
DNA probes were radiolabelled with [a-32P]-dCTP, by the 
random hexanucleotide priming method (205)• This was 
carried out to a specific activity of 106 cpm/ml.
Labelling reactions were set up in Eppendorf tubes with 10 
Ail of oligolabelling buffer (OLB) (206), 3 /il of 2% (w/v)
bovine serum albumin, 3 /il of [a-32P]-dCTP (Amersham PB 
10205, > 3000 Ci/mmol), 25 ng of denatured probe DNA, 1 /il 
(6.5 U//il) of DNA polymerase (Klenow fragment, IBI, 
Connecticut, USA) and distilled H2 O to a final volume of
50 /il. The reactions were incubated at 37°C for 1 h.
Following incubation, unincorporated isotope was removed 
by passing the reaction mixture through a Sephadex G-50 
Nick column (Pharmacia LKB, Sweden).
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3.2.17 HYBRIDISATION.
Hybridisation buffer was prepared as for prehybridisation. 
Radiolabelled probe DNA was boiled for 10 min and then 
cooled briefly on ice to ensure adequate denaturation. 
Denatured probe DNA was added, with 2 0 ml of hybridisation 
buffer, to a plastic bag containing the prehybridised 
membrane. The bag was heat sealed and hybridisation 
carried in a shaking water bath at 65°C for 16-2 0 h.
3.2.18 WASHING OF MEMBRANES.
On completion of hybridisation, the membranes were removed 
from the hybridisation buffer and placed in a plastic box. 
In order to remove non-specifically bound radioisotope, 
each membrane was washed several times under conditions of 
increasing stringency. Washing was carried out using a 
rotary platform mixer (for room temperature washes) and a 
shaking water bath (for 65°C washes). The first wash was 
in 2x SSC, 0.1% (w/v) SDS at room temperature for 15 min, 
followed by a 30 min wash in lx SSC, 0.1% (w/v) SDS at 
65°C. A final high stringency wash was carried out in O.lx 
SSC, 0.1% (w/v) SDS for 30 min again at 65°C.
3.2.19 AUTORADIOGRAPHY.
The washed membranes were air dried briefly prior to being
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heat sealed in plastic bags. These were then exposed to 
Kodak XAR-5 films with intensifying screens, at -80°C for 
24 h. Depending upon the intensity of the signal on the 
24 h autoradiograph, the membranes were re-exposed under 
the same conditions for a variable period of between 2 
and 8 days. For the purposes of quantification, 
autoradiographs were scanned using a scanning densitometer 
(Shimatzu, CS-9000)•
3.2.2 0 STRIPPING OF MEMBRANES (DEHYBRIDISATION).
After radiography, in order to facilitate rehybridisation 
with other DNA probes, membranes were strip-washed 
(dehybridised) • This was achieved by immersing each 
membrane in a solution of boiling 0.1% (w/v) SDS, which 
was then allowed to cool to room temperature. The stripped 
membranes were stored in sealed plastic bags at 4°C until 
required.
3.3 RESULTS.
3.3.1 ANALYSIS OF DONOR/RECIPIENT PAIRS.
In order to evaluate the usefulness of this panel of 
probes for monitoring engraftment and chimerism, a total 
of 60 patients and their respective sibling donors were 
screened for the presence of an informative marker probe.
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Where the Y-specific probe (GMGY7) was informative due to 
sex mismatching, an additional RFLP probe was also sought 
so as to provide a marker for both donor and recipient 
populations. Screening of donor recipient pairs was 
carried out sequentially in order to reduce the number of 
Southern blots required. All pairs were screened first 
with the probes a-globin 3'HVR and pYNH24, which utilize 
the same restriction enzyme (Figure 3.2). Pairs not 
informative with either of these probes were then screened 
with the probes pYNZ22 and M27B, and finally if still 
uninformative with the probe MSI.
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Figure 3.2
SOUTHERN BLOT ANALYSIS OF DONOR/RECIPIENT PAIRS
pYNH24.
1 2 3 7 8 9 10
Southern blot analysis of DNA from pre-BMT patients and 
their respective donors digested with the enzyme Taql and 
hybridised with the polymorphic probe pYNH2 4. Lanes 1 & 2, 
3 &4, 5 & 6 ,  7 & 8 =  informative recipient/donor pairs;
lanes 9 & 10 = an uninformative recipient/donor pair.
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In this group of 60 donor/recipient pairs, it was possible 
to demonstrate in all cases at least one informative 
marker for each cell population (Table 3.2).
Table 3.2. Informative probes.
Informative D/R1 pairs Number %
GMGY7 (M/F & F/M) 31/60 52%
GMGY7 (M/F) 17/60 28%
3'HVR, PYNH2 4 46/60 77%
PYNZ22, M276, MSI2 14/60 23%
All RFLP probes 60/60 100%
1Donor/recipient pairs.
2Cases uninformative with 3'HVR & PYNH24
A total of 31/60 (52%) of cases were informative with the 
Y-specific probe (6M6Y7) due to sex mismatching. In all of 
these pairs an additional RFLP probe was also identified. 
In 17/60 (28%) cases a male patient had a female donor and 
the Y-specific probe would therefore have been useful for 
the analysis of mixed chimerism. The results of sequential 
analysis with the RFLP probes indicated that 46/60 (77%)
of cases were informative with one or both of the first 
two probes used. The remaining 14 pairs were informative 
with at least one of the remaining 3 probes. Thus in the
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majority of cases only one set of digests (usually Tag l) 
would require to be prepared.
3.3.2 RESULTS OF MIXING EXPERIMENTS.
In a series of artificial mixing experiments, using 
prepared MNC mixtures, Southern blotting was capable of 
consistently detecting a minor cell population of 1% using 
the single locus RFLP probes and 0.25-0.5% using the 
highly repetitive Y-probe (Figures 3.3 and 3.4). The 
sensitivity was the same with each of the RFLP probes.
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Figure 3.3
ARTIFICIAL MIXING EXPERIMENT (PYNZ22)
pYNZ.
1 2  3 4
Southern blot analysis of an artificial mixing experiment 
using DNA digested with the enzyme TaqI and hybridised 
with the polymorphic probe pYNZ22. 1 = 100% recipient DNA; 
2 = 100% donor DNA; 3 = 1%:99% recipient: donor DNA; 4 =
0.1%:99.9% recipient:donor DNA. The minor proportion of 
DNA present in the mixture is detectable in lane 3 (1%)/
but undetectable in lane 4 (0.1%).
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Figure 3.4
ARTIFICIAL MIXING EXPERIMENT (GMGY7)
M
1
Southern blot analysis of an artificial mixing experiment 
using DNA digested with the enzyme TaqI and hybridised 
with the male specific probe GMGY7. 1 = 100% male DNA; 2 = 
0.5%:99.5% malerfemale DNA; 3 = 0.25%:99.75% malerfemale 
DNA; 4 = 0.1%:99.9% male:female DNA. The minor proportion 
of male DNA remains detectable in lanes 2 and 3 (0.5% and 
0.25%), but is undetectable in lane 4 (0.1%).
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3.4 DISCUSSION.
Southern blot analysis is an extremely useful technique 
for the examination of various aspects of engraftment 
following allogeneic BMT. The technique involves the
identification of informative markers, which are based on 
the high degree of polymorphism found in certain
non-coding areas of the human genome, as well as sex
differences between patient and donor.
In order to facilitate the use of Southern blotting in 
this study, a panel of probes was created consisting of 
five highly polymorphic RFLP probes and one male specific 
probe. The usefulness of the panel was verified by the 
examination of DNA from 60 pre-transplant patients and
their respective sibling donors. In this group, at least 
one informative probe (in addition to the Y-specific probe 
in sex-mismatched cases) was found for each
donor/recipient pair, thus indicating an adequate 
polymorphic content within the panel. The work involved in 
screening donor/recipient pairs with different probes was 
significantly reduced by screening in a sequential manner. 
Since the majority of pairs were found to be informative 
with one of the first two probes used, both of which 
utilize the same restriction enzyme, no further digests or 
filters were required for these pairs.
The sensitivity of the panel was also established in a 
series of mixing experiments using DNA extracted from
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artificially prepared cell mixtures. The results 
a high degree of sensitivity for both the RFLP 
Y-specific (<1%) probes and compare favourably 
sensitivity levels reported in the literature.
indicate 
(1%) and 
with the
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CHAPTER 4
THE EFFECT OF RADIATION DOSE ON THE DEVELOPMENT OF MIXED 
HAEMOPOIETIC CHIMERISM FOLLOWING T-CELL DEPLETED 
ALLOGENEIC BONE MARROW TRANSPLANTATION
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4.1 INTRODUCTION.
Allogeneic BMT provides an important therapeutic modality 
in the management of a variety of haematological 
malignancies and perhaps not surprisingly, the last two 
decades have seen a dramatic increase in the number of 
transplants being performed worldwide (23) . Following 
transplantation, donor T-lymphocytes play an important 
role in the facilitation of engraftment and establishment 
of full donor haemopoiesis (112) and also contribute to 
the anti-leukaemic or GVL effect (118,128). In addition, 
they are known to be the cells which mediate GVHD (60,61) 
which, despite post-transplant immunosuppressive therapy, 
remains a major source of both morbidity and mortality 
(78,81).
Extensive ex-vivo T-cell depletion provides a highly 
effective method for the prevention of GVHD (89-91)• The 
initial use of this technique was, however, associated 
with an increased incidence of graft rejection (117,207), 
MXC (148,208,209) and leukaemic relapse (50,210,211). The 
latter problem being most evident in patients with CML 
(24). These features reflect a shift in the complex 
immunological balance which exists in the post-transplant 
period between host and donor cells in favour of the host 
and demonstrate that in the context of T-cell depletion, 
"standard" conditioning regimens provide inadequate host 
immunosuppression. In order therefore to benefit from the
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potential reduction in GVHD, further modification of the 
preparative protocol is crucial (157).
In addition to a significant incidence of graft failure 
using "standard" TBI schedules, T-cell depletion has been 
associated with a high rate of MXC (148,208,209). The 
clinical and laboratory studies reported in this chapter 
document the chimeric status of haemopoiesis, as assessed 
by cytogenetic and molecular techniques, and its 
implications, in a group of matched sibling transplants 
who were prescribed high dose TBI, which was successful in 
achieving engraftment in 100 of 102 consecutive patients 
receiving this schedule.
4.2 PATIENTS AND METHODS.
4.2.1 PATIENTS.
A group of 55 consecutive patients undergoing allogeneic 
BMT in Glasgow were entered into this study. Only patients 
being transplanted for an underlying haematological 
malignancy, using bone marrow from an HLA matched/MLC 
non-reactive sibling donor were included. Overall 48 
patients were suitable for the analysis of chimeric status 
following engraftment. Seven patients were not evaluable; 
6 relapsed or died early in the post-transplant period 
(within one month) and one patient, who returned abroad, 
did not have adequate follow-up samples.
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Table 4.1. Patient Diagnoses
Adults AML = 15
ALL = 12 
CML = 6 
PMF = 2 
Children AML = 2
ALL = 11
PMF = primary myelofibrosis
Within this group 35 patients were adults and 13 were 
children under 15 years of age; their primary diseases are 
shown in Table 4.1. The distinction between adults and 
children is important with regard to the conditioning 
regimen and will be discussed further in the following 
section.
4.2.2 CONDITIONING REGIMENS.
All patients were conditioned with cyclophosphamide 60 
mg/kg on 2 consecutive days (days -6 and -5), followed by 
a prescribed TBI dose of 14.4 Gy. The TBI was administered 
from a Cobalt 60 source, in 8 fractions of 1.8 Gy over 4 
days (days -3, -2,-1,0), at an average dose rate of 
0.06-0.12 Gy/min. Donor bone marrow was returned to the 
patients on day 0, following the last dose of TBI.
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In 35 adult patients, TBI was prescribed to the midline 
with the reference dose of 14.4 Gy taken as an average 
between mediastinum, abdomen and pelvis. The lungs were 
shielded to reduce the corrected lung dose to 14.4 Gy. In 
13 children, TBI was prescribed to lung rather than to the 
midline, with the dose adjusted to deliver a maximum lung 
dose of 14.4 Gy, with no lung shielding. Additional
chemotherapy was administered in 7 of the adult patients 
(4 CML, 3 advanced AML) and 3 children (advanced ALL),
using either mitoxantrone (12 mg/m2, 3 doses) or busulphan 
(4mg/kg, 2 doses).
4.2.3 TBI DOSIMETRY.
The two different methods of TBI administration employed 
in this study, one prescribing to the midline and the
other to lung, were associated with quantitative 
differences in the actual average midline dose of TBI 
received. Dosimetry was utilized in order to objectively 
assess the actual average midline dose received by each 
patient. The dosimetry was performed using externally
positioned thermoluminescent dosimeters.
In the 35 adult patients, the average midline dose of TBI 
received was 14.3 Gy. In the 13 children, however, as 
would have been anticipated from calculations based on the 
prescribing method, the average midline dose received was 
significantly lower at 13.0 Gy.
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4.2.4 GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS.
The procedure for marrow processing was identical in both 
adults and children and was performed in the same 
laboratory. In all patients donor marrow was T-cell 
depleted as the sole method of GVHD prophylaxis. T-cell 
depletion was carried out using the monoclonal antibodies 
CD6 and CD8 with complement mediated lysis as previously 
described (157).
The efficiency of the T-depletion was assessed by 
quantification of the absolute number of T-cells remaining 
in the mononuclear concentrate using flow cytometry 
(Becton-Dickinson FACScan)• Ethidium bromide counter 
staining was used to corroborate cell death.
4.2.5 CYTOGENETIC ANALYSIS OF CHIMERISM.
Cytogenetic analysis of post-transplant peripheral blood 
and bone marrow samples was carried out using conventional 
banding techniques, by an experienced cytogeneticist 
working in the regional cytogenetics laboratory. The 
analysis was possible in sex-mismatched cases and those 
sex-matched cases where an informative autosomal 
polymorphism could be identified in pre-transplant 
samples. In this study, 21/35 of the adult group and 6/13 
of the children were informative due to sex-mismatching. 
In each group one additional case had an informative
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autosomal polymorphism using routine G-banding.
Cytogenetic analysis was performed on unstimulated bone 
marrow samples at 1, 3, 6 and 12 months post-transplant 
and thereafter at 6-12 month intervals. In addition where 
possible, unstimulated and PHA stimulated peripheral blood 
lymphocytes were analysed simultaneously with the bone 
marrow samples.
The sensitivity of cytogenetic analysis for the detection 
of a minor cell population is directly related to the 
number of metaphases examined (184). In all cases, a 
minimum of 20 cells were analysed from each sample. This 
however, only allows the exclusion of a minor cell 
population of 14% with 95% confidence (Table 2.3). In 
those cases where HXC was identified by the more sensitive 
RFLP analysis, up to 100 metaphases were examined. 
Analysis of this number of cells allows the exclusion of a 
minor cell population of 3% with 95% confidence.
4.2.6 SAMPLE COLLECTION FOR DNA EXTRACTION.
Prior to transplantation peripheral blood or bone marrow 
was collected from patients and their respective donors to 
permit the identification of an informative marker probe. 
Following transplantation, bone marrow samples were 
collected as for cytogenetic analysis. However, peripheral 
blood samples were collected more frequently in the 
majority of patients.
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4.2.7 ISOLATION OF SPECIFIC CELL FRACTIONS.
In order to facilitate the analysis of individual 
haemopoietic lineages, peripheral blood samples were first 
separated into granulocyte and mononuclear fractions. T 
and B lymphocytes were then isolated from the mononuclear 
fraction using antibody coated immunobeads, CD2 for T-cell 
selection and CD19 for B-cell selection. The majority of 
the cells remaining after these procedures were noted to 
be monocytes.
MNCs were prepared from anticoagulated whole blood samples 
using Lymphoprep (Nycorned, UK) as described in Chapter 2.
T and B lymphocyte fractions were isolated from the MNC 
suspension by an immunomagnetic cell isolation technique, 
using antibody coated magnetic beads i.e. Dynabeads 
(Dynal, Oslo, Norway)• Dynabeads coated with the pan-T 
monoclonal antibody CD2 were used for the positive 
selection of T lymphocytes, whereas the pan-B monoclonal 
antibody, CD19, was used for B lymphocyte isolation. Other 
than the use of different monoclonal antibodies, the 
actual isolation procedure was identical for both T and B 
cells. This was carried out sequentially, with T cells 
usually isolated first.
Prior to commencing the isolation procedure, the cells in 
the MNC suspension were counted and the number of
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Dynabeads required for positive selection, calculated 
according to the manufacturers instructions. The 
recommended bead to cell ratio for positive selection from 
a MNC suspension is 3:1.
Before adding the Dynabeads, the MNC suspension was 
cooled on ice. The cells were then kept at 2-4°C 
throughout the procedure, to prevent non-specific binding 
of phagocytic cells to the Dynabeads. The required volume 
of beads, which had been washed briefly in PBS, was added 
to the cooled cells and allowed to mix for 30 min using 
gentle rotation. Following this, the rosetted cells were 
collected by placing the tube containing the cells in a 
magnetic particle concentrator (Dynal MPC-l) for 2 min. 
The rosetted cells migrate to the wall of the tube 
adjacent to the magnetic concentrator. The unrosetted 
cells in the supernatant were then removed with a Pasteur 
pipette. The tube was taken out of the magnetic 
concentrator and the cells resuspended in 5 ml of PBS. A 
total of 4 washes were performed with PBS, using the 
magnetic concentrator to collect the cells between each 
wash.
The isolated cells can be detached from the Dynabeads 
following overnight incubation in RPMI or a similar 
culture medium at 37°C. This detachment procedure was, 
however, found to result in the loss of cells and was not 
in fact necessary if subsequent DNA extraction was carried 
out since the beads can be removed during phenol
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extraction and they do not appear to otherwise interfere 
with the DNA extraction process. Detachment was therefore 
only carried out if the purity of the fractions was to be 
checked, as the presence of the beads leads to 
interference during flow cytometry.
The purity of the fractions was intermittently checked 
using a Becton Dickinson FASCan and appropriate CD2 and 
CD19 monoclonal antibodies. The purity of the B cell 
fraction was > 80% and the purity of the T cell fraction 
> 90-95%. The residual cells left after the isolation of B 
and T cells were also checked and were usually > 90%
monocytes, although this varied to some extent from sample 
to sample.
4.2.8 RFLP ANALYSIS OF CHIMERISM.
High molecular weight DNA extraction and subsequent 
Southern blot analysis (204) was performed as described in 
Chapter 2.
4.2.9 STATISTICAL ANALYSIS.
Differences in a number of continuous and categorical 
variables were compared using the Student's t-test, the 
Mann-Whitney U-Test and the Fisher's exact test as 
appropriate. All tests were two-sided. Kaplan-Meier 
estimates and the log-rank test were used to evaluate
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relapse and overall survival.
4.3 RESULTS (14.3 GY TBI GROUP).
4.3.1 INCIDENCE OF MIXED CHIMERISM
The incidence of MXC in the 35 adult patients, who had 
received 14.3 Gy TBI to the midline, as assessed initially 
at one month post-BMT was 34% (12/35) . MXC was more
frequently detected by RFLP analysis (12/35, 34%), than by 
cytogenetic analysis (5/35, 14%)• The size of the residual 
host cell population, as assessed by scanning 
densitometry, varied between individual cases, but was 
always present in a minor proportion, < 20% in all cases.
All cytogenetic mixed chimeras were also detected by RFLP 
analysis and in two patients with CML cytogenetic analysis 
revealed the presence of triple chimerism (Figure 4.1). 
Additional, transient cytogenetic abnormalities, both 
clonal and non-clonal, were occasionally observed in 
residual host cells, presumably secondary to radiation 
damage•
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Figure 4.1
KARYOTYPE SHOWING TRIPLE CHIMERISM 
(Myeloid)
« •  • •  M
9 22 X 1
9 22 X
A  *
Y
22 i X 3
t !
9q+. 22q-
Karyotype showing triple chimerism in a patient with CML. 
The patient, a female recipient of marrow from a male 
donor. 1 = a normal female (ie. host) cell; 2 = a normal 
male (ie. donor) cell; 3 = an abnormal female (ie. host) 
cell containing the (9,22) translocation.
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4.3.2 EFFECT OF PATIENT AND GRAFT CHARACTERISTICS ON 
CHIMERISM.
A number of patient, disease and transplant variables were 
analysed for their effect on subsequent chimeric status in 
this group of 35 patients. No significant differences were 
found between MXC and FC patients in terms of age, sex, 
sex-matching or primary disease (Table 4.2). Nor was there 
any difference between the total mononuclear cell dose 
infused, total CFU-GM, CFU-GM/kg or in the T-cell dose, 
expressed as either an absolute number or per kg (Tables
4.3 and 4.4). The kinetics of neutrophil regeneration were 
also similar in MXC and FC patients (Table 4.5).
All patients with acute leukaemia who received additional 
chemotherapy in their conditioning became full chimeras, 
this was not, however, true for patients with CML (n=4), 
who were evenly split between FC and MXC.
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Table 4.2. Characteristics of adult patients.
MXC FC
Number 12 23
Patient age (median) 27 29
Patient age (range) (14-44) (17-46)
Donor age (median) 31 28
Donor age (range) (8-53) (16-49)
Patient sex (M:F) 9:3 10:13
Donor sex (M:F) 6:6 11:12
Sex-mismatched 7 14
Sex-matched 5 9
Disease/status 
AML CR1 6 7
AML Rel 0 2
ALL CR1 2 3
ALL CR2 1 5
ALL CR>2 0 1
CML CP 2 3
CML AP 1 0
PMF 0 2
CP, chronic phase; Rel, relapse; 
AP, accelerated phase.
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Table 4.3. Graft characteristics of adult patients.
MNC 
(X 108)
CFU-GM(Total) 
(X 105)
CFU-GM/kg 
(X 104)
MXC 0.46 170.3 26.1
(n=12) (±0.03) (±33.0) (±5.1)
FC 0.51 207.0 25.1
(n=23) (±0.05) (±25.1) (± 3.3)
P NS NS NS
Results as means ± SEM.
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Table 4.4. Graft characteristics: T cell doses
T-Cells (Total) 
(x 108)
T-Cells/kg 
(x 105)
MXC 0.1 1.3
(n=l2) (±0.01) (±0.3)
FC 0.08 1.1
(n=23) (±0.01) (±0.2)
P NS NS
Results as means ± SEM.
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Table 4.5. Neutrophil regeneration.
Neutrophils Neutrophils
0.5 x 109/1 l.o x io9/l
MXC 23 31
(±3) (±3)
FC 19 26
(±1) (±2)
P NS NS
Results in days, as means ± SEM.
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4.3.3 STABILITY OF CHIMERIC STATUS.
Following the initial documentation of chimeric status at 
one month post-BMT, patients were then followed up at 
regular intervals for a median of 16 months (range 2.5 
51 months). During this time, no MXC patients converted to 
FC. Nor, in the absence of leukaemic relapse, did any FC 
patients later develop detectable host cells.
In 9/12 MXC patients, followed up for a minimum of 9 
months (median 23, range 9 - 4 8  months), it was possible 
to examine the stability of the residual host cell 
population by RFLP analysis. In 2 patients the host cell 
population increased with time. In one patient with CML, 
this was due to an increasing number of Ph1 positive 
cells, rather than an increase in the residual normal cell 
population. This expansion of the malignant clone occurred 
over a period of 10 months prior to haematological 
relapse. In the other patient with AML, residual host 
cells were observed to increase gradually over 3% years, 
with no evidence of relapse. In 3 patients the proportions 
of host and donor cells remained relatively constant, 
while in another 3 patients, host cells, although still 
readily detectable, appeared to gradually decline. In one 
case, the host cell population fluctuated around the 1% 
level, but was consistently detectable with scanning 
densitometry (Figures 4.2 and 4.3).
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Figure 4.2
AUTORADIOGRAPH SHOWING MIXED CHIMERISM
R D 1 2 ‘ 3
R = recipient DNA pre-BMT; D = donor DNA; 1-3 = BM samples 
at 1, 3 & 6 months post-BMT. MXC is visible in the 1 & 6
month samples, but not in the 3 month sample.
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Figure 4.3
SCAN OF THE AUTORADIOGRAPH SHOWN IN FIGURE 4.2
0
n
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i i J  .  » • i- *
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1
Scans 1-3 correspond to lanes 1-3 in figure 4.2. Using 
scanning densitometry it is possile to detect a minor 
proportion of recipient cells in lane 2 (0.86 % of the 
total signal).
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4.3.4 MIXED CHIMERISM WITHIN HAEMOPOIETIC LINEAGES.
In no instance was there a discrepancy between the 
chimeric status of the bone marrow and that of the 
peripheral blood. However, in MXC patients, more detailed 
examination of individual haemopoietic lineages, by RFLP 
analysis of fractionated samples using scanning 
densitometry for quantitation, showed lineage disparity in 
7/8 patients examined (Figures 4.4 and 4.5). In these 
patients MXC was more frequently detected in myeloid and 
T-cells. The highest percentage of residual host cells was 
usually present in the T-cell fraction, while in the 
B-cell fraction host cells were present in low numbers or 
were absent altogether.
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Figure 4.4
ANALYSIS OF HAEMOPOIETIC LINEAGES (PYNH2 4)
PYNH.
Southern blot analysis of DNA digested with TaqI and 
hybridised with the polymorphic probe pYNH2 4. R = 
recipient; D = donor; G = granulocytes; B = B-lymphocytes; 
T = T-lymphocytes. MXC is present in the granulocyte and 
T-cell fractions, but is absent in the B-cell fraction.
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Figure 4.5
ANALYSIS OF HAEMOPOIETIC LINEAGES (GMGY7)
GMGY-7.
m
■
M
Southern blot analysis of DNA digested with PvuII and 
hybridised with the Y-specific probe GMGY7. All samples 
are from a male recipient of female marrow. G = 
granulocytes; T = T-lymphocytes; B = B-lymphocytes; M = 
monocytes. Residual male cells are present to some degree 
in all fractions. The male DNA content appears maximal in 
the T cell fraction and minimal in the B cell fraction.
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4.3.5 TRANSPLANT OUTCOME: GRAFT-VERSUS-HOST DISEASE.
The overall incidence of histologically proven acute GVHD 
was extremely low in this group of patients. Only 2/35 
patients had greater than grade I GVHD. Although both of 
these patients were in the FC group the numbers are too 
small to permit valid statistical analysis.
4.3.6 TRANSPLANT OUTCOME: RELAPSE.
Out of 35 patients followed-up for a median period of 16 
months (range 2.5-51), leukaemic relapse occurred in 6/23 
(26%) FC patients (AML CR1=2, AML Rel=l, ALL CR1=1, ALL 
CR2=2) and 3/12 (25%) MXC patients (CML CP=1, CML AP=1, 
AML CR1=1) • All but two relapses took place during the 
first year, with a single case of relapse beyond this time 
in each group. Kaplan-Meier estimates of the probability 
of relapse (Figure 4.6) indicate no significant difference 
(p=0 • 2) in the actuarial relapse risk between MXC and FC 
patients.
In all patients who relapsed post-transplant, it was 
possible to demonstrate that the relapse was of host cell 
origin. In 5/6 patients, where cytogenetic data was 
available from the time of diagnosis as well as at 
relapse, there was evidence of clonal evolution in relapse 
(Table 4.6).
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Figure 4.6
KAPLAN MEIER CURVE SHOWING THE PROBABILITY OF RELAP8E
RELAPSE
FC
MXC
6040200
MONTHS POST BMT
Kaplan-Meier estimates of the probability of relapse in 
MXC and FC patients. There was no significant difference 
in relapse in the two groups (p = 0.2).
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Table 4.6. Cytogenetic data on patients relapsing post-BMT
UPN Disease Karyotype Karyotype
at diagnosis at relapse
46 ,XY
46,XX,t(8,21)
46,XX,t(8,21),-4,?7q+,+mar 
46, XX
45-46,X,-1,-6,-8,-14,-21,-22, 
+mar
46,XX
46,t(9,22),-3,-6,-7,-10,-11 
-14,-16,-20,-21,+mar
47,Y,+abnormalities as above
46,XY,t(9,22) + non-clonal 
abnormalities •
105 CML 46,XY,t(9,12,12) 46-49,XY,t(9,12,12),15q-,
16p+,18q+,+7,?16q-,+mar
110 ALL 46,XY 46,XY
45,XY,-2,-4,-7,-8,-12,-21,mar
072 AML 46,XX,t(8,21)
073 AML 46,XY
090 ALL 46,XY,t(9,22)
094 CML 46,XY,t(9,22)
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In four of these cases extremely complex karyotypic 
abnormalities were noted in relapse samples. In one case 
(UPN 073) due to sex chromosome loss, it was not possible 
to identify the origin of relapse by cytogenetic analysis. 
However, this was successfully achieved by Southern 
blotting, using two RFLP probes from different chromosomes 
(Figure 4.7).
In 3 patients who relapsed post-BMT (all previously FC), 
it was possible to analyse residual normal haemopoiesis at 
the time of relapse. This was carried out by RFLP analysis 
of individual lineages, using fractionated marrow and 
peripheral blood samples. In these cases residual normal 
haemopoiesis remained of donor origin in relapse (Figure 
4.8). In one patient, reinduction of remission was 
associated with restoration of full donor chimerism.
4.3.7 TRANSPLANT OUTCOME: SURVIVAL.
Overall event free survival with the same median follow-up 
was 57%. In the MXC group 8/12 (67%) remained alive, with 
12/23 (52%) alive in the FC group. Again Kaplan-Meier
estimates of the probability of survival (Figure 4.9) 
failed to show any significant difference (p = 0.5)
between the 2 groups. There was, however, a tendency 
towards more infective deaths in the first 9 months 
post-transplant in FC patients, 0/3 infective deaths in 
MXC patients versus 5/8 in the FC group.
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Figure 4.7
SOUTHERN BLOT ANALYSIS OF RELAPSE
#  • <-4.0Kb 
•  •  • 
D P R
Southern blot analysis of DNA digested with PvuII and 
hybridised with the polymorphic probe PYNH2 4. D = donor 
DNA; P = patient DNA pre-BMT; R = patient DNA extracted 
from a BM sample at the time of relapse. The arrow 
indicates the patient specific band which has re-emerged 
in the relapse sample in keeping with recipient origin of 
the relapse.
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Figure 4.8
SOUTHERN BLOT ANALYSIS OF CELL FRACTIONS AT RELAPSE
PYNZ.
1 2 3 4 5 6  7 8 9
Southern blot analysis of DNA digested with Taql and 
hybridised with the polymorphic probe pYNZ22. 1 =
recipient pre-BMT; 2 = donor; 3-8 = samples at relapse, 
BM, PB, granulocytes, B-cells, T-cells & blasts 
respectively; 9 = BM following re-induction of remission. 
In relapse granulocytes and T-cells remain of donor 
origin. The blast cells (Calla positive) have 
cross-reacted with the monoclonal antibody used to select 
B cells, both therefore appear of recipient origin. 
Following re-induction of remission, FC is re-established.
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Figure 4.9
KAPLAN MEIER CURVE SHOWING THE PROBABILITY OF SURVIVAL
SURVIVAL
PROBABILITY
MXC
FC
60400 20
MONTHS POST TRANSPLANT
Kaplan-Meier estimates of the probability of survival in 
MXC and FC patients. There was no significant difference 
in survival in the two groups (p= 0.5)
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4.4 RESULTS (13.0 GY TBI GROUP).
When this group of 35 adults, who had received a midline 
dose of 14.3 Gy, was compared with the 13 children who had 
received a lower midline dose of TBI, 13 Gy, a significant 
difference in the incidence of MXC was observed. Using 
RFLP analysis, MXC was documented in 9/13 (69%) children 
compared with 12/35 (34%) adult patients (p < 0.05). The 
difference was even more marked if the analysis was 
restricted to patients who had received conditioning with 
CY/TBI alone, 9/10 (90%) compared with 8/28 (29%),
(p=0.00l)•
Comparing the graft characteristics in the 2 groups 
(Table 4.7), no significant difference was observed in the 
MNC dose per kg or in the T-cell dose per kg; however, the 
children did receive a higher dose of CFU-GM (p < 0.05).
since the majority of children were suffering from ALL, 
the incidence of MXC in ALL was considered in a separate 
analysis. In this ALL subgroup, MXC was present in 3/12 
(25%) adult patients compared with 10/11 (91%) children, 
(p=0•002)•
Again follow-up of this group of children did not show 
any significant difference in terms of relapse or overall 
event free survival between MXC and FC patients.
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Table 4.7. Graft characteristics: adults and children
MNC/kg 
(X 108)
CFU-GM/kg 
(X 104)
T-Cells/kg 
(x 105)
Children 0.59 48.3 1.7
<n=l3) (±0.08) (±8.2) (±0.36)
Adults 0.49 25.6 1.2
<n=35) (±0.03) (±2.8) (±0.15)
P NS 0.045 NS
Results as means ± 8EH.
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4.5 DISCUSSION.
4.5.1 MIXED CHIMERISM FOLLOWING T-CELL DEPLETED BONE 
MARROW TRANSPLANTATION USING HIGH DOSE TBI.
In this study the chimeric status of haemopoiesis was 
analysed in a total of 48 patients undergoing T-cell 
depleted BMT. All patients received an intensified 
conditioning regimen, utilizing a nominal prescribed TBI 
dose of 14.4 Gy, known to be capable of achieving a high 
rate of engraftment (100/102 patients have successfully 
engrafted with this regimen)• This represents an increase 
in TBI from the original dose of 12 Gy, aimed at 
compensating for the the absence of T-cells in the marrow 
inoculum. It has been estimated from calculations based on 
animal models that an increase in the dose of TBI in the
order of 2 - 2.5 Gy should be able to overcome the
problems, of both graft rejection and leukaemic relapse, 
which have been encountered in the context of T-cell 
depleted BMT using "standard" conditioning regimens.
In this study two different methods of TBI administration 
were employed. These were associated with a significant 
difference in the actual average midline dose of TBI 
received by each patient. Taking this into account, only
the group of 35 adult patients actually received an 
increase in TBI which exceeded 2 Gy, the remaining 13
children received a significantly lower dose of 13 Gy.
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These differences indicate the importance of knowing the 
precise details of the dosimetry involved in the TBI 
administration. Such details are unfortunately often 
inadequately documented in the literature.
In the 35 adult patients who received an average midline 
dose of 14.3 Gy the incidence of MXC, as determined by 
cytogenetic and/or RFLP analysis, was 34% (12/35)• It is 
also important to emphasise that chimerism in this series 
has been assessed in the context of a low incidence of 
graft failure, whereas in other T-cell depleted series 
only a proportion patients actually successfully engrafted 
and in the remainder it would not therefore have been 
possible to document a stable chimeric state.
Compared to previous studies of MXC in the context of 
T-cell depleted BMT, the incidence in this group, while 
still significant, is lower than might have been expected, 
which may reflect the effect of the increased dose of TBI. 
The incidence of MXC in other T-cell depleted series has 
usually been over 50% (208,209,212,213) and has been 
documented to be as high as 100% in one study (148). These 
results contrast with those seen in recipients of 
unmanipulated bone marrow, where MXC is observed less 
frequently. In one large study of non T-cell depleted BMT, 
MXC was documented by RFLP analysis in 29/172 (17%) of
cases (149) and in general the incidence has been found to 
be under 30% (148,150).
It should, however, be noted that it is difficult to
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compare the various studies which have examined MXC 
following BMT, largely due to the number of different 
techniques which have been used to assess chimerism, each 
of which, in terms of their ability to detect residual 
host cells, has a different level of sensitivity. Even 
when the comparison is restricted to groups using RFLP 
analysis, the quoted sensitivity levels vary from less 
than 1% up to 10%. Since in the majority of patients, 
residual host cells are present in a minor proportion, 
such differences in sensitivity may be crucial.
4.5.2 MIXED CHIMERISM: IMPORTANCE OF TBI DOSE.
The incidence of MXC in this adult cohort was also 
compared with a group of children who received a 
significantly lower midline dose of TBI. Despite an 
otherwise identical BMT procedure, the incidence of MXC in 
the lower TBI group was significantly higher, with the 
most marked difference seen in patients conditioned with 
CY/TBI alone. Although the comparison here has been made 
between adults and children, no published studies have 
indicated a correlation between age and the development of 
MXC, suggesting that age is unlikely to be the relevant 
factor influencing chimerism. Disease heterogeneity 
between the two groups also seems to be an unlikely 
explanation, since the difference in the incidence of MXC 
remains when the analysis is restricted to cases of ALL,
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which constitute the majority of the children. Instead the 
data support the potential importance of differing TBI 
schedules and the concept that in terms of marrow 
ablation, relatively small differences in the TBI dose may 
be biologically significant, at least at this dose range 
and in the context of T-cell depletion, where the graft 
promoting potential of donor T cells is reduced or absent.
4.5.3 NATURAL HISTORY OF CHIMERISM.
Although the incidence of MXC has been observed in a 
number of studies, its natural history is less well 
defined. Following transplantation for severe aplastic 
anaemia, MXC is quite frequent (151), but is usually 
transient and only a small number of cases of apparently 
stable long term MXC have been recorded (214) . The 
relatively rare occurrence of stable MXC in this context 
may well be due to a defect in the proliferative capacity 
of the residual host cells, reflecting the underlying 
aplastic process. The situation appears to be somewhat 
different following transplantation for leukaemia where 
long term MXC has been recognized more commonly. Less 
however, is known about the effect of time on the relative 
percentages of the co-existing host and donor cells. To 
date, this has only been adequately documented by RFLP 
analysis in one previous study (213).
In common with Roy et al. (213), it was apparent from the
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analysis in this study, that the overall chimeric status 
of haemopoiesis ie. MXC or FC, is established early in the 
post-transplant period and thereafter remains stable. 
However, unlike Roy et al. (213), a consistent increase in 
the relative proportion of host cells was not found and in 
fact host cells tended either to remain relatively 
constant or to gradually decline in the majority of 
patients.
4.5.4 MIXED CHIMERISM WITHIN INDIVIDUAL HAEMOPOIETIC 
LINEAGES.
Differences in chimeric status between different 
haemopoietic lineages have been noted previously (209). 
These differences have generally been attributed to the 
different sensitivities of the methods used to analyse 
individual cell types. Few studies with the exception of 
those looking at patients transplanted for SCID have 
analysed purified cell populations. In this study, 
despite the high sensitivity of RFLP analysis, which 
exceeded the purity of the cell fractions, it was possible 
to demonstrate differences in the relative proportions of 
host and donor cells within individual lineages. Host 
cells were present in the highest proportions in the 
myeloid and T-cell fractions. The observation that in 
patients with MXC, residual host cells were always present 
in the myeloid cell fraction, is against the concept that
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MXC is simply a reflection of surviving lymphoid cells and 
favours active repopulation. The reason for the low 
numbers of residual host cells in the B lymphocyte 
fraction is unknown, but might reflect differing 
radiosensitivities of progenitor cells or stromal cell 
damage affecting cellular differentiation.
4.5.5 HOST AND DONOR CELL POPULATIONS IN RELAPSE.
Although the development of donor cell leukaemia appears 
to be a rare event, it remains of interest, with regard to 
the basic pathophysiology of leukaemia, to be able to 
document whether recurrent leukaemia following allogeneic 
BMT is of host or donor origin. In the group of patients 
analysed here, relapse of host cell origin was found in 
all cases. The origin of leukaemic relapse can be 
documented by both cytogenetic and molecular analyses, 
however, discrepant results between these two techniques 
have been noted in a number of cases (215)• This may be at 
least partly due to the complex karyotypic abnormalities 
which are present in many relapse samples. These 
abnormalities necessitate the careful interpretation of 
both cytogenetic and molecular data in combination, 
preferably with the use of at least two probes, from 
different chromosomes, in order to avoid misleading 
results (216).
In this study, multiple additional cytogenetic
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abnormalities were noted at the time of relapse in a high 
proportion of cases, apparently reflecting clonal 
evolution within the original leukaemic population. 
Similar abnormalities have been documented in other 
studies (217,218). The available data would appear to 
suggest that the clonal evolution seen in relapse 
following allogeneic BMT, is both more frequent and more 
complex than that which occurs in relapse following 
treatment with chemotherapy alone. To date, however, no 
characteristic abnormalities have been noted in these 
cases. Since clonal evolution may to some extent reflect 
the effect of previous therapy, it seems probable that 
many of these cytogenetic defects are a consequence of 
radiation induced structural damage following TBI. This 
may also apply to the cytogenetic abnormalities found 
occasionally in residual host cells which are not part of 
a malignant clone, ie. normal haemopoietic cells in a 
mixed (or triple) chimeric population (219)•
In this analysis it was also possible to document in a 
small number of patients that residual normal haemopoiesis 
at the time of relapse, remains of donor origin. This 
confirms that leukaemic relapse per se, is not necessarily 
associated with graft failure. Knowledge of the origin of 
residual normal haemopoiesis in relapse, particularly with 
regard to residual immunocompetent T-cells may be of 
importance in designing treatment strategies aimed at the 
induction of an immunological, GVHD/GVL reaction, against
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leukaemic cells (220-222)•
4.5.6 MIXED CHIMERISM AND GRAFT-VERSUS-HOST DISEASE.
In terms of transplant outcome, it has been possible in 
this study, to examine the relationship of MXC to both the 
incidence of leukaemic relapse and overall patient 
survival. However, due to the extremely low incidence of 
GVHD, it has not been possible to draw any conclusion 
regarding the relationship of MXC to the development of 
GVHD. Other groups have, however, noted an inverse 
relationship between MXC and GVHD (149,150) and a number 
of theories have been put forward to account for this.
One possible explanation is that residual host cells are 
able to modify the GVHD response by the induction of 
immunological tolerance. Much of the evidence for this 
comes from experiments in animal models utilizing "mixed 
allogeneic BMT" (223,224). In this system, it is thought 
that the syngeneic component of the marrow inoculum, 
analogous to surviving host cells, is responsible for the 
low incidence of GVHD. In these models, lethally 
irradiated mice are inoculated with a mixture (1:3 ratio) 
of T-cell depleted syngeneic bone marrow and unmanipulated 
allogeneic bone marrow. The transplanted animals 
reconstitute initially as mixed chimeras, however 
elimination of host lymphohaemopoietic cells usually 
occurs by 4 weeks post-transplant. Thereafter the animals
183
remain as stable full donor chimeras. This contrasts with 
the situation in which the syngeneic and allogeneic 
components of the marrow inoculum are both T-cell 
depleted. In this latter situation stable MXC results. In 
both models, however, the mixed marrow inoculum appears to 
protect against the development of acute GVHD.
The anti-GVHD effect in this setting is thought to be 
largely mediated by natural suppressor activity, derived 
from the syngeneic marrow component. This activity can be 
demonstrated by in-vitro assays during the first week 
post-transplant. Other syngeneic marrow derived cell 
types, including LAK cells, may also play a part in this 
anti-GVHD effect, but their contribution is at present 
less well defined.
The other notable feature of this type of transplant is 
that they have been shown to retain GVL activity despite 
the absence of GVHD (225). In a clinical setting patients 
could therefore potentially retain the beneficial 
anti-leukaemic effects of the allograft without the 
morbidity and mortality associated with GVHD. To date 
there is little clinical experience of this approach to 
the induction of tolerance. A single case report in the 
literature documented a mixed syngeneic/allogeneic BMT 
carried out for chronic phase CML which had relapsed 
following an initial syngeneic transplant (226) . This 
patient engrafted successfully with allogeneic marrow, but 
subsequently developed severe acute GVHD and was therefore
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not effectively protected by anti-GVHD activity. It is 
therefore apparent that more work requires to be done in 
this highly experimental area to define the place, if any, 
of mixed allogeneic transplants in clinical practice.
A converse explanation for the relationship between MXC 
and GVHD might be that MXC is actually a consequence of 
low GVHD activity. In this context it has been suggested 
that MXC might reflect better donor/recipient matching at 
non-HLA minor histocompatibility loci (151). For this 
mechanism to apply the GVHD syndrome must presumably 
incorporate a GVH reaction against residual host cells, 
loss of which could permit the survival of residual host 
cells. Donor T cells are known to be involved in the 
engraftment process, however, this may be via mechanisms 
other than an active GVH response. In addition, it is not 
known whether T-cell subtypes involved in engraftment are 
the same as those which mediate GVHD. Nevertheless, if the 
development of full donor chimerism is a consequence of a 
GVH response it is important to note that it must in many 
cases be subclinical, since, as clearly demonstrated in 
this study and in others, patients who are full chimeras 
do not necessarily manifest clinical GVHD.
A third possibility is that decreased MXC and GVHD both 
reflect essentially independent consequences of inadequate 
pre-transplant host immunosuppression. This inadequate or 
at least reduced host immunosuppression could occur as a 
consequence of either the conditioning regimen or where
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T-cell depletion had been used as the method of GVHD 
prophylaxis. The resulting shift in the immunological 
balance in favour of the host could potentially lead to 
graft rejection, but alternatively, if the graft was 
retained, MXC and an absence of GVHD might be predicted.
4.5.7 MIXED CHIMERISM AND RELAPSE.
With regard to leukaemic relapse, while it was initially 
anticipated that patients with MXC would be at higher risk 
of leukaemic relapse, evidence is now accumulating that 
this is not in fact the case. In this series, as in other 
recently published studies (212,213), regardless of the 
dose of TBI received, MXC did not appear to be associated 
with an increased incidence of relapse. There are a number 
of possible explanations for the lack of correlation 
between the occurrence of MXC and leukaemic relapse.
Firstly, this might reflect differences in the 
radiosensitivity patterns of normal haemopoietic cells and 
leukaemic cells. As discussed at some length in Chapter 1, 
although these two groups of cells undoubtedly share 
similar qualitative responses to radiation, it is 
possible, at least in vitro, to demonstrate significant 
quantitative differences and overall the radiobiological 
characteristics of leukaemic cells are probably 
considerably more complex than was previously thought 
(43,44). Thus, in terms of overall cell kill, leukaemic
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cells may show a greater, lesser or equivalent response to 
"supralethal" doses of radiation, when compared with 
normal haemopoietic cells. This allows one to postulate 
that, where MXC is detected post-BMT but the patient does 
not relapse, leukaemic cells have been more radiosensitive 
than the normal haemopoietic cell population. Conversely, 
when MXC is not detected but the patient subsequently 
relapses, it follows that the leukaemic population has 
been less radiosensitive.
Alternatively, since the therapeutic potential of 
allogeneic BMT reflects both cytoreduction and an 
immunological component, the apparent lack of correlation 
between the eradication of normal and leukaemic cells may 
reflect a difference in the immune response. Thus a 
quantitative difference may exist in the relative GVH and 
GVL effects, which occur in the post-transplant period, 
even after T-cell depleted BMT. Intrinsic to these 
uncertainties is, however, a lack of precise knowledge 
regarding the tumour burden present in each individual 
patient prior to transplantation.
4.5.8 MIXED CHIMERISM AND SURVIVAL.
Finally, overall survival was also similar in MXC and FC 
patients. In the adult group, FC patients did nevertheless 
have a tendency towards more infective deaths in the early 
post-transplant period. There is some evidence to suggest
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that this could reflect improved immunocompetence in the 
MXC group which again has been noted to be a feature of 
mixed allogeneic transplants in animal models. In this 
situation, host accessory cells are able to interact more 
effectively with donor T cells and thus to improve the 
immune response. Confirmation of improved immunocompetence 
in the context of MXC in man would, however, require 
further functional studies of the immune response in the 
post-transplant period.
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CHAPTER 5
THE USE OF THE POLYMERASE CHAIN REACTION TO MONITOR 
ENGRAFTMENT FOLLOWING ALLOGENEIC BONE MARROW 
TRANSPLANTATION: AMPLIFICATION OF THE POLYMORPHIC 
APOLIPOPROTEIN B REGION
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5.1 INTRODUCTION.
In general, the established methods for monitoring host 
and donor cell populations following allogeneic BMT are of 
limited value during the very early stages of the 
engraftment process. Two main factors are responsible for 
this difficulty. The first is the transfusion dependence 
of patients at this time and the second, the profound 
haemopoietic hypoplasia which follows ablative 
conditioning and precedes engraftment.
As previously discussed, transfused blood products 
contribute "third party" components which interfere with a 
number of the available techniques. The haemopoietic 
hypoplasia, which persists for a variable period of time 
prior to engraftment, is associated with extremely low
cell counts in both bone marrow and peripheral blood 
samples. It can therefore be difficult to obtain adequate 
cell numbers for DNA extraction and subsequent RFLP 
analysis. It has also been noted that cytogenetic analysis 
is often unsuccessful during the early phase of
engraftment, or may yield insufficient metaphases for 
statistically representative karyotyping. These factors 
have thus prevented the detailed study of engraftment
kinetics during this early period.
The PCR technique, in which a specific DNA (or cDNA)
sequences of interest may be amplified in vitro many 
millions of times, is extremely useful for analysing
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ACP1
D2S1
2p25 ACP1: Acid phosphatase-1.
2p26 D2S1: DNA Segment, single copy.
* D2S10 2p24 D2S10: DNA segment, single copy.
* APOB 2p 24-p23 APOB: Apolipoproteln B.
* POMC 2p23 POMC: Proopiomelanocortin.
* D26S 2p23-p1S D2S6: DNA segment, single copy.
CD8A 2p12 CDS A: Antigen CD8A.
Ficrure 5.1
CHROMOSOME 2 (SHORT ARM) MAP
material from small numbers of cells. It thus potentially 
offers a method of overcoming the problems of hypocellular 
samples as it requires only minimal starting material. 
Many of the RFLP sequences currently used to monitor 
engraftment by Southern blot analysis are based on highly 
polymorphic VNTR regions which are scattered throughout 
the genome. Frequently these regions extend over many 
kilobases and are technically difficult to amplify
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efficiently, however, a number of smaller VNTR regions 
can now be successfully analysed using the PCR technique. 
One such polymorphic region lies 3' to the apolipoprotein 
B gene (Figure 5.1), on the short arm of chromosome 2
(227-229).
In this study amplification of the polymorphic 
apolipoprotein B VNTR region has been investigated 
firstly, in terms of its ability to provide an informative 
marker of donor/recipient cell populations and secondly, 
in order to assess its ability to monitor these 
populations in the early post-transplant period, 
particularly in the clinical context of delayed 
engraftment and graft rejection.
5.2 PATIENTS AND METHODS.
5.2.1 PATIENTS.
A group of 33 pre-BMT patients was examined in order to 
determine: i. the index of heterozygosity at this locus
in a group of 33 unrelated individuals and ii. the number 
of cases in which analysis of DNA from each of the pre-BMT 
patients and their respective donors would generate an 
informative marker at this locus, suitable for 
post-transplant monitoring of donor/recipient cell 
populations.
Mixing experiments were also carried out to determine the
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threshold level for detection of a minor cell population. 
Sets of known cell mixtures, informative at this locus, 
were used as in Chapter 2.
In addition, peripheral blood and bone marrow samples were 
analysed from 6 transplanted patients during the early 
stages post-transplant. The analysis was performed in 
order to document the presence or absence of engraftment 
using this technique. The clinical details of each of the 
individual cases examined are summarized briefly as 
follows:
Case 1.
In August 1989, a 10-year-old boy with secondary AML in 
relapse received an allogeneic BMT from his HLA matched/ 
MLC non-reactive brother. He was conditioned with 
cyclophosphamide, busulphan and TBI, 14.4 Gy in 8 
fractions. The donor marrow was T-cell depleted with CD6 
and CD8 monoclonal antibodies as the sole method of GVHD 
prophylaxis. He remained clinically well post-transplant, 
however, his peripheral blood counts were slow to 
regenerate (Table 5.1), his neutrophil count only 
exceeding 0.5 x 109/1 at day 36 post-transplant. His WBC 
gradually increased to normal and he remained well until 
December 1989 when his AML relapsed. He subsequently died 
of his relapsed leukaemia in January 1990.
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Case 2.
In May 1989, a 10-year-old girl with severe aplastic 
anaemia received an allogeneic BMT from her HLA 
matched/MLC non-reactive brother. She was considered to be 
at high risk of graft rejection due to prior sensitization 
from prolonged blood product support. She was initially 
conditioned with intravenous Campath-l immunoglobulin and 
cyclophosphamide. CSA was administered as GVHD 
prophylaxis. Following an initial transient regeneration, 
her WBC count fell (Table 5.1) in keeping with graft 
rejection. In July 1989, 46 days after her first graft, 
she received a second transplant from the same donor. On 
this occasion conditioning consisted of anti-lymphocyte 
immunoglobulin (ALG), cyclophosphamide and TLI, 600 cGy in 
3 fractions. CSA was again used as GVHD prophylaxis. 
Following her second transplant she successfully engrafted 
with a neutrophil count > 0.5 x 109/1 at day 15 post-BMT. 
She remains well, with stable trilineage engraftment, 29 
months after her second transplant.
Case 3.
In September 1989, a 20-year old man with Ph1 positive CML 
in chronic phase received an allogeneic BMT from his HLA 
matched/MLC non-reactive sister. He was conditioned with 
daunorubicin, cyclophosphamide and TBI, 14.4 Gy, 
administered in 8 fractions. The donor marrow was T-cell 
depleted with CD6 and CD8 monoclonal antibodies as GVHD
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prophylaxis. Post-transplant, his clinical condition 
remained satisfactory, however, his peripheral blood 
counts were slow to increase (Table 5.1), his neutrophil 
count only exceeding 0.5 x 109/1 at day 56 post-BMT. He 
went on to achieve complete engraftment and remained well 
until May 1990 when his disease relapsed. He is currently 
awaiting a second allogeneic transplant.
Table 5.1. Total white blood cell (WBC) and neutrophil (N) 
counts post-BMT, expressed x 109/1 (Cases 1-3)•
Day Case 1 Case 2 Case 2 Case 3
post (BMT1) (BMT2)
BMT WBC N WBC N WBC N WBC N
+7 0.1 0 0.1 0 0.1 0 0.1 0
+10 0.1 0 0.4 0.26 0.3 0 0.1 0
+14 0.2 0 0.2 0.02 0.9 0.36 0.3 0
+21 0.1 0 0.2 0 3.5 2.0 0.1 0
+28 0.4 0.1 0.4 0.02 7.1 5.0 0.1 0.06
+35 0.7 0.5 0.2 0 9.0 5.5 0.4 0.18
+42 1.2 0.7 0.1 0 7.3 2.6 0.4 0.2
+56 3.7 2.6 - - 6.9 3.6 0.8 0.5
+74 3.9 2.5 - - 7.1 3.8 1.4 1.0
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Case 4.
In February 1990, a 30 year-old-woman with AML in CR1 
received an allogeneic BMT from her HLA matched sister. 
Conditioning consisted of cyclophosphamide and TBI, 14.4 
Gy administered in 8 fractions. The donor marrow was 
T-cell depleted with CD6 and CD8 monoclonal antibodies as 
prophylaxis against GVHD. She initially appeared to 
engraft successfully, however, between day 28-35 
post-BMT, following a transient peripheral lymphocytosis, 
her WBC fell dramatically in keeping with graft rejection 
(Table 5.2). On day 38 post-BMT, without further 
conditioning, she received an autologous BMT, following 
which her WBC slowly regenerated. Despite this, she died 
45 days after receiving her autologous marrow, of a 
non-specific interstitial pneumonitis.
Case 5.
In September 1990, an 18-year-old girl with Ph1 positive 
CML in chronic phase received an allogeneic BMT from an 
HLA matched unrelated male donor. Conditioning consisted 
of cyclophosphamide, busulphan, TLI, 600 cGy in 3 
fractions and TBI, 14.4 Gy in 8 fractions. The donor 
marrow was T-cell depleted with CD6 and CD8 monoclonal 
antibodies as GVHD prophylaxis. Post-transplant her 
peripheral counts failed to regenerate (Table 5.2) in 
keeping with primary graft failure. On day 29 post-BMT, 
without further conditioning, she received an autologous
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transplant. Despite an increasing neutrophil count, she 
died 10 days later of a non-specific interstitial 
pneumonitis.
Table 5.2. Total white blood cell (WBC) and neutrophil 
(N) counts post-BMT, expressed x 109/1.
Day Case 4 Case 5 Case 6 Case 6
post (BMTl) (BMT2)
BMT WBC N WBC N WBC N WBC N
+7 0.2 0 0.1 0 0.1 0 0.1 0
+10 0.2 0 0.1 0 0.1 0 0.1 0
+14 0.3 0.15 0.2 0 0.3 0.21 0.1 0.01
+21 0.5 0.25 0.1 0 0.2 0.02 0.5 0.33
+28 0.6 0.2 0.1 0 0.1 0 2.7 1.8
+35 0.2 0 - - - - 1.9 1.1
+42 - - - - - - 4.1 3.69
+56 - - - - - - 2.6 1.9
+74 - - - - - - - -
Case 6.
In September 1990, a 4-year-old boy with severe aplastic 
anaemia received an allogeneic BMT from an HLA matched 
unrelated male donor. He was initially conditioned with 
cyclophosphamide, TLI, 600 cGy in 3 fractions and TBI,
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14.4 Gy in 8 fractions. The donor marrow was T-cell 
depleted with CD6 and CD8 monoclonal antibodies as GVHD 
prophylaxis. Additional post-transplant immunosuppression 
was administered using CSA. Post-transplant, his 
peripheral white count began to regenerate around day 14, 
however this increase was only transient and by day 21 his 
count had fallen again in keeping with graft rejection. 
Despite this he remained clinically well. Exactly one 
month after his first transplant he was given a second 
infusion of marrow from the same donor. Prior to this he 
received further conditioning, this time with ALG and 
cyclophosphamide. The donor marrow was again T-cell 
depleted and CSA administered in the post-transplant 
period as GVHD prophylaxis, on this occasion his 
peripheral counts regenerated promptly, with a neutrophil 
count of 1 x 109/1 by day 23 post-BMT. Around this time he 
also developed signs of acute GVHD. His clinical condition 
deteriorated over the next few weeks and he subsequently 
died 68 days after his second transplant of CMV 
pneumonitis.
5.2.2 PREPARATION OF SAMPLES.
Peripheral blood and bone marrow samples were taken at 
various times post-transplant. All samples were collected 
in anti-coagulant, either lithium-heparin or EDTA. In 
samples with adequate WBC counts, usually > 0.3 x 109/1,
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DNA extraction was performed as previously described, 
using small volumes where required to minimize the loss of 
material (See Chapter 2).
When the WBC count was noted to be particularly low,
usually < 0.3 x 109/1, or when only a very small WBC
pellet was obtained following initial separation, it was
considered unlikely that DMA would be obtained from the
sample and in this situation a crude white cell lysate was 
prepared instead.
In order to prepare a white cell lysate, the red cells 
were first lysed with an appropriate volume of red cell 
lysis buffer and a white cell pellet obtained by 
centrifugation (See Chapter 2). The pelleted material was 
first washed with PBS to remove excess lysis buffer and 
then resuspended in 30 /il of TE which was transferred to 
an Eppendorf tube. This cell suspension was boiled for 10 
min in order to lyse the white cells and then placed on 
ice for a further 10 min. In order to remove cellular 
debris the samples were re-centrifuged at 3000 g for 10 
min, following which the supernatant lysates were 
transferred to fresh Eppendorf tubes. These lysates could 
then be used immediately or stored at -2 0°C until 
required.
5.2.3 PCR REACTIONS.
The PCR reactions were carried out using the thermostable
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enzyme Tag polymerase and oligonucleotide primers flanking 
the hypervariable region lying 3' to the apolipoprotein-B 
gene on the short arm of chromosome 2 • At least two 
different sets of primers exist for amplification of this 
region (228,229). The primers chosen for use in this study 
were found in preliminary experiments to be less 
frequently associated with the production of non-specific 
sequences and were therefore felt to be more reliable 
(Table 5.3).
Table 5.3. Apolipoprotein B primer sequences
51 CAC A6C AAA ACC TCT A6A ACA 3' - Sense 
5' GTT CCT CAG GAT CAA AGT ATG TAC 3'- Antisense
Each PCR reaction was set up in a 500 pi reaction tube 
with Cetus PCR Core Reagents - 10 pi of lOx PCR reaction 
buffer, 200 pHol/1 each of dATP, dCTP, dGTP and dTTP and 
2 ^Mol/1 MgCl2 (Cetus, Norwalk, CT, USA) plus 500 ng of 
each oligonucleotide primer and either 10-20 pi of cell 
lysate or 0.5-1 pq of DNA. Distilled H20 was added to a 
final volume of 99.5 pi. The samples were overlaid with 
2 00 pi of mineral oil to reduce evaporation.
As PCR is sensitive to minor degrees of contamination a
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number of precautions were taken in order to avoid this 
problem. These measures included aliquoting fresh 
reagents prior to use and the preparation of premixed 
reagent aliquots in order to reduce the number of 
transfers from each individual reagent. In addition, all 
volumes were pipetted with positive displacement pipettes 
in order to prevent contamination due to carry-over from 
previous samples.
The reactions were initially heated at 99°C for 5 min and 
then cooled briefly on ice prior to the addition of 2.5 U 
of Taq DNA Polymerase (Cetus, Norwalk, CT, USA) • The use 
of Cetus AmpliTag and PCR Core Reagents was found on 
testing to result in a higher yield than other available 
Taq polymerase enzymes (Figure 5.2). Following the 
addition of enzyme the samples were amplified using a 
programmable thermal reactor (Hybaid, Middlesex, UK) 
according to the following programme: 94°C for 1 min 
(denaturation), 55°C for 1 min (annealing), 72°C for 4 min 
(extension) for a total of 30 cycles, followed by a final 
extension step at 72°C for 10 min.
5.2.4 VISUALIZATION OF PCR PRODUCTS.
Once the amplification program was complete, the resulting 
PCR products were analysed by direct inspection of 
ethidium bromide stained gels. High percentage, 2.5 - 3%,
agarose gels were found to provide adequate product
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Figure 5.2
COMPARISON OF 2 DIFFERENT Taq POLYMERASE ENZYMES
PCR products obtained with 2 different Taq polymerase 
enzymes. Lanes 1-3, on the right, are samples which which 
have been amplified with Cetus AmpliTag and Cetus core 
reagents; lanes 1-3, on the left, have been amplified 
using an alternative Tag polymerase. The use of Cetus 
AmpliTag and Cetus core reagents was associated with a 
higher yield of PCR products. The picture is a negative 
image of an ethidium bromide stained gel.
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separation and it was therefore not necessary to use 
polyacrylamide gels.
Following a brief (10 s) centrifugation, to remove excess 
condensation from the top of each tube, 25 pi of each PCR
reaction product was removed and loaded onto a 2.5 or 3%
TBE agarose gel containing ethidium bromide (0.5 pg/m1). 
Care was taken to use a separate set of positive 
displacement pipettes from those routinely used to set up 
the PCR reactions and to deal with the PCR products in a 
separate area of the laboratory.
Electrophoresis was carried out in lx TBE at 100 V for
6-8 h. The resulting bands, which lie between 570-900 bp,
were then visualized directly by placing the ethidium 
stained gel on a UV (320 nm) transilluminator. Permanent 
records were obtained by photographing the gels with 
Polaroid type 55, positive/negative sheet film (Polaroid, 
Corporation, Mass., USA.).
5.3 RESULTS.
5.3.1 HETEROZYGOSITY STUDIES.
DNA from 33 unrelated patients was analysed by PCR prior 
to BMT in order to examine heterozygosity at this locus. 
Following PCR amplification, 2 6/33 patients were shown to 
have a heterozygous band pattern. The calculated index of 
heterozygosity in this group of unrelated individuals was
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therefore 0.79.
5.3.2 INFORMATIVE MARKER STUDIES.
When each of these 33 pre-BMT patients was then analysed 
with their respective donors, 24/33 (73%) of cases were 
found to be informative at this locus (Figure 5.3).
5.3.3 MIXING EXPERIMENTS.
Using the system of direct visualization of PCR products 
on an ethidium bromide stained agarose gel, the threshold 
level for detection of a minor cell population was 5-10%, 
when using 0.5 pg of DNA as starting material. The 
intensity of the visualized bands was found to relate to 
the relative proportions of cells in the mixture, thus 
providing a semi-quantitative analysis.
5.3.4 PCR DOCUMENTATION OF ENGRAFTMENT DESPITE SLOW 
REGENERATION.
Two of the cases examined here (cases 1 and 3), 
demonstrated rather slow regeneration of peripheral blood 
counts in the early post-transplant period. Both cases 
showed a complete absence of neutrophil regeneration at 
day 21 post-transplant and also had very hypocellular bone 
marrow samples at this time. Despite the extremely low
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Figure 5.3
PCR AMPLIFICATION PRODUCTS FROM A SERIES OF 
DONOR/RECIPIENT PAIRS
1 2 3 4 5 6 7 8 9  10 11
PCR products from 5 pre-BMT patients and their respective 
donors. 1 = mw markers (EcoRI/Hindlll cleaved lambda DNA); 
2 & 3, 4 & 5, 6 & 7, 8 & 9 = informative donor/recipient
pairs; 10 & 11 = an uninformative donor/recipient pair. 
The picture is a negative image of an ethidium bromide 
stained gel.
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peripheral blood counts, PCR analysis was technically 
possible and informative (Figures 5.4 and 5.5). In b»oth 
cases donor cells were detected in peripheral blood and 
bone marrow samples, confirming that engraftment with 
donor marrow was taking place despite the peripheral 
pancytopenia. In these two cases the results were tihus 
predictive of subsequent complete regeneration.
In case 1 it was not possible to say whether residual 
host cells ie. MXC existed, as the recipient shared the 
lower fragment with his donor. In case 3, however, the 
recipient bands were specific and no residual cells were 
noted in the samples analysed.
5.3.5 PCR DOCUMENTATION OF GRAFT REJECTION.
In the other four cases examined, PCR analysis was used to 
document the occurrence of host mediated graft rejection. 
In cases 2, 4 and 6 (BMT1), rejection occurred as a
delayed or secondary event, following an initial transient 
period of engraftment. In case 2, after the first BMT, 
analysis of a bone marrow sample on day 14 (Figure 5.6) 
showed a mixed chimeric picture with predominance of donor 
cells over host cells. By day 40 the bone marrow continued 
to show a mixed chimeric picture, but this time with a 
predominance of host cells. This reversal in the relative 
proportion of host cells was indicative of the ongoing 
host mediated graft rejection. PCR analysis of the
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peripheral blood samples from days 21 and 35, showed 
virtually no evidence of donor cells and would therefore 
appear to have been more predictive of the ultimate 
failure of the graft.
Similarly in case 4, analysis of a bone marrow sample 
from day 21 showed a mixed chimeric pattern (Figure 5.7), 
followed by conversion to a recipient specific pattern at 
the point of rejection. Thus in both cases, transient 
engraftment was associated with MXC, while graft rejection 
was associated with a resurgence of host cells.
In case 5, regeneration of peripheral counts did not 
occur at any stage and PCR analysis of peripheral blood 
and bone marrow samples at various time points failed to 
detect the presence of any donor cells (Figures 5.8).
5.3.6 PCR DOCUMENTATION OF ENGRAFTMENT FOLLOWING INITIAL 
GRAFT REJECTION.
Following graft rejection, two of the cases examined 
(cases 2 and 6), underwent further conditioning and 
received second allogeneic transplants. In both cases PCR 
analysis confirmed the presence of complete engraftment 
after the second transplant (Figure 5.9).
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Figure 5.4
PCR PRODUCTS FROM CASE 1
■
*
1 = mw markers (£coRI/HindIII cleaved lambda DNA), 2 =
recipient BM pre-BMT, 3 = donor BM, 4 = recipient BM from 
day 21 post-BMT, 5 = recipient PB from day 21 post-BMT. 
The samples analysed by PCR on day 21 post-BMT show the 
presence of the donor specific band pattern, despite the 
absence of an increase in the PB count. The picture is a 
negative image of an ethidium bromide stained gel.
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Figure 5.5
PCR PRODUCTS FROM CASE 3
t o ■
t o t o
/  -  T
1 2 3 4 5 6 7
1 & 7 = mw markers (EcoRI/Hindlll cleaved lambda DNA), 2 = 
recipient BM pre-BMT, 3 = donor BM, 4 = recipient PB from 
day 21 post-BMT, 5 = recipient BM from day 21 post-BMT, 6 
= recipient PB from day 35 post-BMT. Both the day 21 and 
35 samples show complete conversion to the donor band 
pattern with no evidence of host cells. The picture is a 
negative image of an ethidium bromide stained gel.
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Figure 5.6
PCR PRODUCTS FROM CASE 2
2 3 4 5 6 7 8
1 & 8 = mw markers (EcoRI/Hindlll cleaved lambda DNA), 2 = 
recipient BM pre-BMT, 3 = donor BM, 4 = recipient BM from 
day 14 post-BMTl, 5 = recipient PB from day 21 post-BMTl, 
6 = recipient BM from day 40 post-BMTl, 7 = recipient BM
from day 21 post-BMT2. The day 14 and day 4 0 post-BMTl BM 
samples both show MXC, with reversal of the relative 
proportions of recipient and donor cells by day 4 0 in 
keeping with graft rejection. Virtually all the cells in 
the day 21 post-BMTl PB sample are recipient in origin. 
The day 21 post-BMT2 sample shows complete engraftment.
210
Figure 5.7
PCR PRODUCTS FROM CASE 4.
R = recipient BM pre-BMT, D = donor BM, 1 = recipient PB 
from day 21 post-BMT, 2 = recipient BM from day 35 
post-BMT. The day 21 sample shows MXC, which has converted 
to a recipient specific pattern by day 35 in keeping with 
graft rejection. The picture is a negative image of an 
ethidium bromide stained gel.
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Figure 5.8
PCR PRODUCTS FROM CASE 5
1 = mw markers (EcoRI/Hindlll cleaved lambda DNA); 2 =
recipient BM pre-BMT; 3 = donor BM; 4 & 5 = PB and BM
from day 21 post-BMT; 6 = PB from day 28 post-BMT. All the 
post-BMT samples show the recipient band pattern, 
indicating failure of engraftment. The picture is a 
negative image of an ethidium bromide stained gel.
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Figure 5.9
PCR PRODUCTS FROM CASE 6
1 = recipient DMA pre-BMT; 2 = donor DNA; 3 = BM from day
28 post-BMTl showing the recipient band pattern, in
keeping with graft rejection. The picture is a negative
image of an ethidium bromide stained gel.
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5.4 DISCUSSION.
The study of engraftment kinetics during the very early 
post-transplant period has, until recently, been very
limited. One important reason for this is the small number
of cells which are available for analysis at this time.
RFLP analysis by Southern blotting for example, is an 
extremely useful technique for monitoring host and donor 
cell populations, but will be limited in the early
post-transplant period, due to a requirement for at least 
106 cells. PCR amplification of specific DNA sequences, 
provides a method for overcoming the problems of 
inadequate cell numbers. Not only does PCR analysis 
require very little starting material, there is also no 
absolute requirement for highly purified, intact DNA, as 
there is for Southern blotting. The other major advantage 
which PCR analysis has over Southern blotting is that it 
can be completed in a considerably shorter period of time 
and is much less labour intensive.
A number of polymorphic sequences can now be successfully 
amplified using PCR technology. In this study the 
polymorphic VNTR sequence located 31 to the 
apolipoprotein B gene on chromosome 2, was evaluated as a 
marker of early engraftment. This relatively small VNTR 
sequence can be successfully amplified under standard PCR 
conditions. The resulting products which range in size 
from 570-900 bp can be adequately resolved on a high
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percentage, ethidium bromide stained, agarose gel. It has 
previously been documented that at least 12 different 
alleles can be defined in this way.
In this study the apolipoprotein B VNTR sequence was 
found to be highly polymorphic, with an index of 
heterozygosity of 0.79 in 33 unrelated pre-BMT patients. 
The majority of these patients were from the West of 
Scotland area. When these pre-BMT patients were PCR typed 
with their respective donors, 73% were found to be 
informative at this locus and would therefore have been 
suitable for engraftment studies.
The method of PCR product detection used in this study, 
i.e. direct visualization of ethidium bromide stained 
gels, was originally selected to permit the achievement of 
results in the shortest possible period of time. Thus the 
time required for the analysis can be as short as 12 h. 
This method does, however, limit the sensitivity for 
detection of a minor cell population i.e. MXC, to around 
5-10%. It is likely, however, that this sensitivity level 
could be improved by adding a radioactive detection 
system. This question of the sensitivity of PCR-VNTR 
analysis will be considered in more detail in the next 
chapter•
In the majority of allogeneic transplants engraftment 
occurs promptly in association with the regeneration of 
peripheral blood counts and an increase in bone marrow 
cellularity. In a group of thirty-five patients
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transplanted in Glasgow, the mean time to reach a 
neutrophil count of 0.5 x 109/1 was 2 0 days (± 1 SEM) and 
to reach 1.0 x 109/1 was 28 days (± l SEM). The six cases 
studied here, however, demonstrate the problems which may 
arise in the early post-transplant from delayed 
engraftment and graft rejection.
Both of these situations are associated with marked and 
in some cases prolonged pancytopenia making analysis of 
individual cell populations extremely difficult. The use 
of PCR typing of the apolipoprotein B locus in these 
cases, provided detailed information on the status of 
engraftment during these periods of pancytopenia. In many 
cases this information was clinically useful and 
particularly in a clinical context, the speed in which 
results can be achieved makes the technique rather 
attractive.
It is anticipated that PCR technology such as this, will 
permit the detailed study of engraftment kinetics in a 
number of different situations and will also for the first 
time allow the analysis of individual lineages subsets 
which has again been limited up until the present time due 
to small cell numbers.
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CHAPTER 6
PCR ANALYSIS OF A Y-SPECIFIC DNA SEQUENCE FOR THE 
DETECTION OF MIXED CHIMERISM
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6.1 INTRODUCTION.
The PCR technique, originally described by Saiki in 1985, 
is recognized as having been one of the most important 
advances in molecular genetics. Its ability to produce a 
selective and up to 107 fold enrichment of a specific 
target DNA sequence, has led to an ever increasing list of 
applications, many of which have had important clinical 
consequences. In addition to facilitating the analysis of 
small amounts of material, e.g. from chorionic villi in 
pre-natal diagnosis (230, 231). PCR also permits the
detection of low levels of specific DNA sequences, i.e. a 
sequence only present in a small number of cells within 
the total cell population being examined. In the field of 
haemato-oncology, this latter feature has stimulated 
considerable interest in using the technique to monitor 
minimal residual disease (MRD) in patients with malignant 
conditions, who by conventional monitoring techniques 
appear to be in a state of complete remission.
Both CML and the follicular non-Hodgkin's lymphomas are 
examples of diseases which are strongly associated with 
particular chromosomal translocations, t(9,22) in CML and 
t (14,18) in follicular lymphomas. If these translocations 
are documented at diagnosis, they can subsequently be 
analysed by PCR once a stage of apparent remission has 
been reached in order to look for evidence of MRD 
(232-234). in this situation the sensitivity of the PCR
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technique has proved to be significantly greater than that 
of other available methods, allowing the detection of a 
single abnormal cell in a population of 106 normal cells.
In CML, the abnormal DNA sequence resulting from the 
t(9,22) translocation is extensive in size and it is 
therefore necessary to amplify from the abnormal mRNA 
sequence instead. This involves the addition of a reverse 
transcriptase step, to obtain cDNA for subsequent
amplification. Using this technique to look for bcr-abl
mRNA transcripts in patients with CML following allogeneic
transplantation, it has become apparent that residual 
bcr-abl positive cells are a frequent occurrence, even 
when patients are in a state of apparent haematological 
and cytogenetic complete remission. The exact clinical 
significance of these findings currently awaits the 
results of further prospective studies. However, it 
appears that the detection of mRNA sequences by PCR early 
in the post-transplant period need not be a poor 
prognostic feature, as patients do not always subsequently 
relapse and indeed results may still become negative 
during longer follow-up.
In the context of monitoring engraftment and chimerism 
after allogeneic BMT, the ability of PCR to amplify 
specific polymorphic sequences has permitted the 
identification of individual host and donor cell
populations. The technique has been applied to the
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analysis of small numbers of cells in the post-transplant 
period and has facilitated the examination of early 
engraftment kinetics and graft rejection incidents. This 
system has been extensively documented in the previous 
chapter (Chapter 5)• Somewhat analogous to the detection 
of MRD, it was envisaged that PCR would also provide a
more sensitive method for the detection of residual normal 
host cells i.e. MXC, following transplantation and this 
has recently been investigated by several different groups 
(235-238).
The polymorphic regions used to monitor host and donor 
cells by PCR, are in general based either on VNTR 
sequences e.g. the apolipoprotein B locus, or on 
dinucleotide repeat sequences (microsatellites) and an 
increasing number of these simple repeat sequences have 
been described during the last two or three years. In 
reconstruction mixing experiments, however, even with 
sensitive radioactive PCR product detection systems, the 
threshold for detection of a minor cell population has 
generally been documented at only 1%. Recently, Lawler 
reported the ability to reach a sensitivity level of
0.1%, but this was possible with just two out of a panel 
of seven microsatellites examined (238) . The higher 
sensitivity of some microsatellite sequences presumably 
reflects differences in size, since small sequences will
be amplified more efficiently than larger ones. Overall
therefore, the sensitivity level is not dramatically
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better than that of Southern blotting, although 
technically the procedure is rapid, more convenient to 
perform and at least partly automated.
As far as sensitivity is concerned, the limiting factor 
with this type of PCR analysis, in the context of MXC, is 
the presence of both sets of polymorphic alleles, which 
will thus both be amplified in the same reaction 
regardless of the cell of origin. The analysis therefore 
becomes relative rather than absolute, since minor 
proportions of residual host DNA sequences will be 
amplified in competition with an excess of donor DNA. This 
contrasts with the situation in CML, where the bcr-abl 
mRNA sequence of interest is amplified against a negative 
background. In this situation the sensitivity is absolute 
and inevitably much higher. As already mentioned mixing 
experiments using serial dilutions of leukaemic cell DNA 
with DNA from normal cells have shown that PCR can 
reliably detect the target DNA sequence at a 1:106 level.
In a similar type of analysis to that of the bcr-abl mRNA 
sequence in CML, the amplification of a Y-specific 
sequence aimed at detecting small amounts of male DNA in a 
female i.e. negative background should also be associated 
with a high degree of sensitivity. This system would 
therefore seem well suited to the examination of residual 
male cells i.e. MXC in male patients who have received 
transplants from female donors.
In this study MXC was evaluated in a small number of male
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recipients of female bone marrow, at various times 
post-transplant using PCR analysis of a highly repetitive 
region specific to the Y-chromosome. The results of PCR 
analysis were compared with those obtained using 
conventional cytogenetic techniques. The sensitivity of 
the analysis was initially established in reconstruction 
mixing experiments using DNA from known cell mixtures 
containing low levels of male cells.
In view of the anticipated high sensitivity of this 
particular type of analysis a number of additional 
precautions were taken in order to avoid the problems of 
false positive results due to cross-contamination (239)•
6.2 PATIENTS AND METHODS.
6.2.1 PATIENTS.
A total of 8 male patients who had received allogeneic 
bone marrow transplants from HLA matched, MLC non-reactive 
female sibling donors were examined at various intervals 
post-BMT. Their primary diseases are shown in Table 6.1.
Table 6.1. Primary disease
ALL 5
CML 3
222
All patients were adults and were conditioned with 
cyclophosphamide and TBI as described in Chapter 4• 
Patients with CML received additional cytoreduction with 
either busulphan or an anthracycline. In each case the 
donor marrow was T-cell depleted with CD6 and CD8 
monoclonal antibodies as the sole method of GVHD 
prophylaxis. All 8 patients engrafted promptly and only 
one (case 6) developed significant, ie. > grade I, acute 
GVHD in the post-transplant period.
6.2.2 PREPARATION OF SAMPLES.
DNA extraction from whole blood, MNC and granulocyte 
fractions was performed as described in Chapter 3.
In samples where the white blood cell count was noted to 
be particularly low, crude white cell lysates were 
prepared as described in Chapter 5.
DNA samples extracted from a panel of male/female MNC 
mixtures at known cell concentrations were used as 
described in Chapter 3. In addition, in view of the 
anticipated high sensitivity, samples with lower dilutions 
of male DNA were also prepared. This was done by diluting 
male MNCs with female MNCs down to a concentration of 
10~6.
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6.2.3 PCR REACTIONS.
The PCR reactions were set up using standard conditions 
with Cetus Tag polymerase (AmpliTag) and PCR core reagents 
as described in Chapter 5.
The Y-specific primers Yl.l and Yl.2 (Table 6.2) amplify 
an 149 bp sequence, which is part of a highly repetitive 
(800-1500 copies) sequence situated on the Y-chromosome•
Table 6.2. Oligonucleotide primer sequences
Y: Yl.l 5'- TCCACTTTATTCCAGGCCTGTCC - 3*
Yl.2 51- TTGAATGGAATGGGAACGAATGG - 3'
XJbals 7.1 51 - CACGAGCTCTCCATCTGAACATG - 3'
7.10 51- GGGCTGCAGGGGGGGGGGACAACAG - 3'
An initial series of experiments was carried out utilizing 
only the Y-specific primers, in this situation female DNA 
(or mixtures of female DNA with male DNA at an 
undetectable level) resulted in a completely blank signal. 
Subsequently however, in order to avoid the potential 
problem of false negative results due to an overall
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failure of DNA amplification, a set of control primers was 
introduced to co-amplify with the Y-specific primers.
The primers used for this purpose, 7.1 and 7.10 (Table 
6.2), amplify a 96 bp Xjbal target sequence, which is an 
informative factor VIII polymorphism on the X chromosome. 
This X chromosome sequence will amplify from both male 
and female DNA samples thus making it a suitable control.
In view of the extremely high sensitivity of the analysis, 
a number of additional precautions to those already 
outlined in Chapter 5 were introduced in order to reduce 
the possibility of false positive results due to 
cross-contamination. These included the complete isolation 
of PCR products in a separate area of the laboratory from 
where the reactions were set up and the extensive use of 
control samples, including positive and negative male 
samples as well as controls containing low levels of male 
DNA and controls in which DNA had been omitted. The 
reactions were also always set up by myself, so that 
operator induced contamination should not have been a 
problem.
All reactions were amplified according to the following 
programme: 94°C for 30 s (denaturation), 65°C for 90 s
(annealing and extension) for a total of 30 cycles, 
followed by a final extension step at 65°C for 5 min.
Following amplification, the resulting PCR products were
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analysed by direct inspection of ethidium bromide stained 
gels. As with the apolipoprotein B region adequate product 
resolution was possible using a high percentage (2.5%) 
agarose gel (See Chapter 5).
6.3 RESULTS.
6.3.1 MIXING EXPERIMENTS.
In reconstruction mixing experiments it was found that 
amplification of this highly repetitive region on the 
Y-chromosome facilitated the detection of a minor 
population of male cells in a male/female MNC mixture 
down to a level of 10~5-10~6 male cells (Figure 6.1). When 
the Xbal, X chromosome specific, control primers were used 
together with the Y primers to simultaneously amplify the 
Y and Xbal target sequences, there appeared to be little 
reduction in sensitivity, with the threshold for detection 
of male cells recorded at 10“5.
In this latter situation it was also noted that once the 
level of male DNA in a sample mixture reached a certain 
level, amplification of the highly repetitive Y-sequence 
was so excessive as to virtually exclude the amplification 
of the Xbal sequence. This is presumably due to the highly 
repetitive nature of the Y-sequence which will facilitate 
extremely rapid accumulation of amplified Y-sequences as 
compared with amplification of the single copy Xbal
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Figure 6.l
MIXING EXPERIMENTS - Y PRIMERS ALONE
The DNA has been amplified using the primers Yl.l and Yl.2 
only. 1 = mw markers (EcoRI/Hindlll cleaved lambda DNA); 2 
& 3 = 100% male DNA, the amplification produces an 149 bp 
band; 4 - 8 = serial dilutions of male DNA in female DNA: 
10"2, 10”3, 10”4, 10"5, 10“6 respectively; 9 & 10 = 100%
female DNA, there is an absence of amplification products 
with the female samples.
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Figure 6.2
MIXING EXPERIMENTS Y AND Xbal PRIMERS
1 2 3 4 5 6 7
The DNA has been amplified using both the Yl.l and Yl.2 
and the Xbal primers 7.1 and 7.2. The larger band is the 
Y-specific band (14 9 bp), the lower band is the Xbal band 
(96 bp). l = 100% female DNA; 2 = 100% male DNA; 3-6 =
serial dilutions of male DNA in female DNA: 10“2, 10“3,
10“4, 10"5 respectively; 7 = mw markers (EcoRI/Hindlll
cleaved lambda DNA), the 120 bp marker is just visible.
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sequence. Similarly in samples containing 100% male DNA, 
amplification of the Xbal sequence was not apparent 
(Figure 6.2).
6.3.2 DETECTION OF MXC IN M/F TRANSPLANTS.
The results of simultaneous cytogenetic and PCR analysis 
of bone marrow samples taken at various times 
post-transplant in 8 male recipients of female marrow are 
shown in Table 6.3.
Apart from cases 5 and 8, who as indicated relapsed during 
the period of the study, all other cases have remained in 
continuous complete remission for at least 6 months 
following the last analysis.
These results indicate a much higher incidence of apparent 
MXC using the highly sensitive PCR assay as compared with 
the results achieved from routine cytogenetic analysis 
(Figures 6.3, 6.4 & 6.5). In all patients it was possible 
using the PCR technique to demonstrate residual host cells 
in the post-transplant period. In two patients (cases 3 &
6) the level of male cells appeared to decline with time 
and in case 6 appeared completely negative by 6 months 
post-BMT. It is of interest to note that case 6 was the 
only patient in this group who experienced acute GVHD of 
> grade I.
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Table 6.3. Detection of MXC: cytogenetic and PCR analysis.
Case Diagnosis Time
Post-BMT
46XY
Cytogenetic
Y-sequence
PCR
1 ALL 6 MO - +
12 MO - +
2 ALL 1 MO - +
6 MO - +
12 Mo + +
18 MO - +
3 ALL 12 Mo - +
24 MO - +
36 Mo - +/-
4 ALL 12 MO + +
24 MO - +
36 MO + +
5 ALL 6 Mo - +
12 Mo - +
17 MO (Rel) + +
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Table 6.3 (Continued).
Case Diagnosis Time
Post-BMT
46XY
Cytogenetic
Y-sequence
PCR
6 CML 3 MO +
6 Mo - -
7 CML 12 Mo - +
24 MO - +
36 Mo - +
8 CML 1 Mo - +
3 Mo - +
15 Mo + +
23 Mo (Rel) + +
(Mo = months, Rel = relapse)
All 8 cases were also examined by Southern blot analysis, 
using the repetitive Y-pecific probe - 6M6Y7, as described 
in Chapter 3. In cases 1, 3, 6 and 7 the results of 
Southern blotting were also consistently negative for the 
detection of residual male cells. In case 5 Southern blot 
analysis was negative until the time of leukaemic relapse.
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Figure 6.3
PCR PRODUCTS FROM CASE 1
1 2 3 45 6 7 8
DNA has been amplified with the primers Yl.l and Yl.2 
alone. 1 & 8 = mw markers (£coRI/Hinc?III cleaved lambda 
DNA); 2 & 3 = 100% female DNA; 4 & 5 = 100% male DNA; 6 &
7 = DNA extracted from bone marrow samples taken 6 and 12 
months post-BMT respectively. There is evidence of 
residual male DNA in both post-transplant samples.
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Figure 6.4
PCR PRODUCTS FROM CASE 2
DNA has been amplified simultaneously with the primers 
Yl.l, Yl.2, Xjbal 7.1 and Xbal 7.2. 1 & 10 = mw markers 
(£coRI/HindIII cleaved lambda DNA); 8 & 9 = 100% female
DNA; 2 & 7 = 10”1 dilution of male DNA in female DNA; 5 &
6 = BM from 6 months post-BMT; 3 & 4 = BM from 12 months
post-BMT. There is evidence of residual male DNA in both 
the 6 and 12 month samples, the relative proportion of 
female DNA appears greater in the 12 month sample.
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Figure 6.5
PCR PRODUCTS FROM CASE 8
DNA has been amplified simultaneously with the primers 
Yl.l, Yl.2, Xbal 7.1 and Xbal 7.2. 6 = mw markers
(2?coRI/tfi.ndIII cleaved lambda DNA) ; 5 = 100% female DNA; 4 
= 100% male DNA; 3 = BM from 1 month post-BMT; 2 = BM from 
3 months post-BMT; 1 = BM from 15 months post-BMT. There 
is an apparent decline in the relative proportion of 
female cells associated with a relative increase in male 
cells. The final sample coincides with the occurrence of a 
cytogenetic relapse.
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In cases 3 and 7, MNC and granulocyte fractions from 
peripheral blood samples were also analysed by PCR on two 
separate occasions. In these two cases, although both 
fractions were clearly positive, the male signal was noted 
to be considerably stronger in the MNC fraction suggesting 
that a relatively greater proportion of male cells was 
present in this fraction.
6.4 DISCUSSION.
One of the major advantages of the PCR technique has been 
its extreme sensitivity, enabling the detection of small 
numbers of cells containing a specific marker DNA sequence 
within a population of cells which lack this marker. Thus 
in leukaemia for example, it has been possible to detect 
minor contamination with residual abnormal leukaemic cells 
during a phase of apparent complete remission.
In the context of detecting MXC following allogeneic BMT, 
it has been possible to utilize this high degree of 
sensitivity to identify residual host cells. A useful 
scheme for such an analysis has been the amplification of 
a Y-specific sequence to detect residual male cells, in 
male recipients of female marrow. Although obviously 
limited in terms of the proportion of transplant 
recipients who can be analysed in this way, the scheme 
nevertheless, is capable of providing useful biological 
information regarding the transplant procedure in general.
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In artificial mixing experiments, using MNC mixtures 
containing small numbers of male cells in a background of 
female cells, it has been possible to detect male cells 
down to a level of 10”5-10"6. These results are in keeping 
with the sensitivity levels achieved in experiments 
looking for residual bcr-abl mRNA sequences in patients 
with CML. The fact that this level of sensitivity is 
possible without the requirement of a radioactive PCR 
product detection system, probably in part reflects the 
highly repetitive nature of this particular Y-specific 
sequence, which will thus accumulate rapidly during the 
amplification process. Such a sensitive analysis obviously 
offers a major improvement over the more conventional 
techniques of cytogenetics and Southern blotting.
When this PCR technique is applied to the analysis of 
actual patient samples, it is apparent that residual host 
cells can be detected in the majority of patients 
following allogeneic BMT. From the data presented in this 
study, there appears to be a tendency for the results to 
become negative with time in some cases, but the patient 
numbers are small and the duration of follow up remains 
relatively short. It is perhaps interesting to note that 
in this group of patients the only one in whom the PCR 
analysis became negative relatively early in the 
post-transplant period was also the only patient in the 
group with > grade I GVHD. This might indicate a potential 
contribution from GVHD to the removal of residual host
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cells.
Having apparently established the presence of a high 
degree of PCR positivity in this set of post-transplant 
samples, it is crucial to go on and consider the nature of 
the cells which are being detected. Firstly, with such a 
sensitive technique it is important to exclude the 
possibility of contamination leading to false positive 
results. The problem of false positivity with PCR has been 
highlighted in other studies and has led to the 
publication of a number of recommendations regarding 
laboratory practice in this area (239)• In the present 
study every attempt has been made to follow these 
recommendations and together with the use of multiple 
control samples, set up and run in parallel with each set 
of PCR reactions, it has been possible to be reasonably 
confident that false positivity has not been a problem.
Having hopefully minimised if not completely eliminated 
the problem of invalid results, a number of questions 
remain to be answered regarding the nature of the PCR 
detected host cells:
i. Are the host cells detected by this PCR assay normal 
haemopoietic cells or residual abnormal leukaemic cells ?
ii. If the host cells detected in this assay represent 
normal haemopoiesis, are they actively repopulating 
elements or simply cells which have survived the
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cytoreductive conditioning regimen eg. long lived T and B 
lymphoid cells ?
iii. Is it possible that the PCR technique is actually 
detecting non-haemopoietic host cells e.g. marrow stromal 
cells which will inevitably be of host origin ?
At the present time it is not possible to answer any of 
the above questions with any degree of certainty. 
Regarding (i), it is now well established in patients 
transplanted for CML that residual leukaemic cells may be 
detected by PCR for long periods post-transplant, 
especially in the context of T cell depleted BMT. Such 
leukaemic cells will inevitably be detected in any assay 
system of an equivalent sensitivity which aims to detect 
cells of host origin. It would therefore require a more 
sophisticated type of quantitative and qualitative 
analysis to differentiate normal and abnormal cells within 
the same sample. Compared with CML, the situation 
regarding residual disease following transplantation for 
acute leukaemia is less well defined, especially in AML 
where in general disease specific markers are lacking.
Whether or not small numbers of residual host cells 
detected by PCR are actually actively repopulating 
elements is also a difficult question. Since it is well 
known that certain lymphoid subsets are extremely long 
lived, if such cells were to survive cytoreduction even in
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small numbers, they could conceivably remain detectable 
for a prolonged period. The finding in this study of two 
cases in which it was possible to demonstrate a more 
strongly positive signal in the MNC fraction (consisting 
predominantly of lymphoid cells) as compared to the 
granulocyte fraction lends support to this concept.
If however, the PCR technique is truly detecting actively 
repopulating normal host haemopoietic elements, arising 
from the stem cell compartment, then it may be possible to 
speculate that all patients undergoing allogeneic BMT are 
to some extent mixed chimeras in the post-transplant 
period. What may exist however, is considerable 
inter-patient (and possibly also intra-patient) variation 
in the actual level of MXC. Thus in patients where MXC is 
detected by cytogenetic analysis or by Southern blotting, 
it implies a considerably greater degree of host 
haemopoiesis than in a patient where MXC is detected by 
PCR alone. In the future therefore, studies examining MXC 
may have to look more closely at the quantification of 
residual host cells rather than simply detecting their 
presence or absence by a particular technique.
In conclusion, regarding the application of the PCR 
technique to the study of MXC, it appears somewhat ironic 
that as in studies looking at MRD, the quest for the 
ultimate tool in terms of sensitivity has left a whole new 
set of issues unresolved.
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CONCLUDING COMMENTS.
1. In patients undergoing T-cell depleted BMT, it has been 
possible, using a pre-transplant conditioning regimen 
incorporating high dose TBI (14.3 GY Midline dose), to 
demonstrate a reduction in the overall incidence of MXC as 
compared with other reported series.
2. In the context of T-cell depleted BMT, a comparison 
between two different TBI regimens has revealed a 
significant difference in the incidence of mixed 
haemopoietic chimerism, suggesting that, in terms of 
marrow ablation, relatively small changes in the TBI dose 
may be biologically significant.
3. Using serial analysis of individual patients, it 
appears that the chimeric status of haemopoiesis is 
established early in the post-transplant period and 
thereafter remains relatively stable with time. However, 
chimeric status has been noted to vary between individual 
haemopoietic lineages; the reasons for this latter finding 
are poorly understood at the present time.
4. During long term follow up, mixed haemopoietic 
chimerism has not been found to be predictive of 
subsequent leukaemic relapse, nor of impaired leukaemia- 
free survival and in fact patients with mixed chimerism in
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this study were noted to have a tendency towards improved 
overall survival.
5. The analysis of a polymorphic region such as that found 
adjacent to the apolipoprotein locus on chromosome 2, 
using PCR technology, has been shown to provide an 
extremely useful method for monitoring early engraftment 
and graft rejection episodes, despite the profound 
pancytopenia which exists during these events.
6. Using a sensitive PCR analysis of a highly repetitive 
region on the Y-chromosome to examine male recipients of 
female marrow, it has been possible to detect mixed 
haemopoietic chimerism in a much higher percentage of 
patients than is found with conventional techniques; the 
significance of this finding awaits the results of further 
studies.
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APPENDIX.
Considerable variation exists in the published literature 
in the terminology used to describe the chimeric status of 
haemopoiesis following allogeneic BMT. Great care must 
therefore be taken to define the terminology employed in 
this area in order to avoid ambiguity and confusion.
Based on the definition of a chimera proposed by 
Anderson and Billingham (140), all successful recipients 
of allogeneic BMT will exhibit chimerism since they will 
all possess cells derived from two different zygotic
lineages, ie. host derived cells and donor derived cells. 
In this situation the donor derived cells will obviously 
be restricted to cells which are haemopoietic in origin. 
The terms "mixed haemopoietic chimerism" and "full
chimerism" go on to further define the type of chimerism 
present within the haemopoietic compartment itself.
In this thesis "mixed haemopoietic chimerism" refers
to the co-existence in the post-transplant period of both
host and donor haemopoietic cells. This is now generally 
accepted as the standard term to describe this phenomenon. 
"Full chimerism", on the other hand, refers to a situation 
in which all haemopoietic cells in the post-transplant 
period are derived from the donor. This can also be 
referred to as "donor chimerism".
In addition, it is important to stress that these 
terms only apply to the post-transplant detection of 
normal host haemopoietic cells. Where residual host cells
are abnormal leukaemic cells, this will represent 
leukaemic relapse or where such cells are present only in 
very small numbers, a state of minimal residual disease.
Taking into account these definitions the term "triple 
chimerism", as applied to post-transplant haemopoiesis 
(page 154), appears to be somewhat ambiguous. Its use in 
this context seems to indicate the presence of
haemopoietic cells derived from three different zygotic 
lineages. However, both in this thesis and in the paper by 
Becher et al (186), "triple chimerism" refers to a
situation in which, in the post-transplant period, a 
patient who has been transplanted for CML, has three 
different haemopoietic clones, derived from only two 
different zygotic lineages. Two of these clones are 
derived from the host, one clone consisting of normal 
haemopoietic cells with the other consisting of abnormal 
(Ph' positive) leukaemic cells . The third clone comprises 
a normal donor cell line. The dynamics of leukaemic
relapse in patients transplanted for CML often permits 
these clones to co-exist in an equilibrium for a prolonged 
period of time.
In this thesis therefore the term "triple chimerism" 
does not indicate the presence of cells derived from three 
different zygotic lineages but refers to the co-existence 
of mixed chimerism with leukaemic relapse or with minimal 
residual disease. "Triple chimerism" should not therefore 
be thought of as indicating the presence of a "third 
party" cell line which is neither host or donor derived.
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